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Abstract
The role of the Hippo pathway in etiology and
progression of pancreato-biliary tumors and clear cell
renal cell carcinoma
Schütte, Ute Theodora Gesina
In the quest for the discovery of novel targets for cancer therapy, aberrantly reactivated
embryonic signaling pathways have proven to be a rich mine and recent years have seen
the introduction of the hedgehog-inhibitor cyclopamine into clinical practice. Dysfunctional
signaling via the growth inhibitory embryonic signaling pathway clustered around the Hippo
kinase and aberrant expression of its main target Yes-associated protein (YAP) is likewise
emerging to be involved in maintenance and progression of various human cancers.
The purpose of this dissertation is to identify the incidence, functional relevance and mech-
anistic significance of aberrant Hippo signaling in etiology and progression of different solid
tumor entities that vary in their biology as well as tissue of origin, but share an unfavorable
clinical prognosis and the dire need for novel therapeutic approaches. Specifically cancers
of the pancreato-biliary tract, more precisely pancreatic ductal adenocarcinoma (PDAC) and
cholangiocarcinoma (CCC), as well as clear cell renal cell carcinoma (ccRCC) have been an-
alyzed in the course of this dissertation. For these tumor entities initial evidence of aberrant
Hippo signaling has been published.
In a first step, aberrant expression of the transcriptional co-activator YAP, which constitutes
the principal target of the growth-inhibitory Hippo-pathway, was confirmed in human tumor
tissue samples by immunohistochemistry. Nuclear YAP expression correlated with nodal sta-
dium in PDAC and was also more frequent in ccRCC patients with tumor-positive lymph nodes.
A common feature in all three tumor entities were solitary, fibroblast-like cells residing inside
vi
the tumor adjacent stroma that were highlighted by robust nuclear YAP-staining, suggesting
that YAP might be a mediator of tumor-stroma crosstalk.
In a second step, the role of aberrant YAP activity in tumor cell lines was examined by
shRNA-mediated knockdown of the protein in selected, highly YAP-expressing cell lines. Phe-
notypic consequences of the knockdown included inhibition of cell proliferation as measured by
the MTS-assay as well as impairment of colony formation in vitro for PDAC, CCC and ccRCC
cell lines and decreased tumorigenicity in vivo for ccRCC cells in tumor xenograft experiments.
However, shRNA-mediated YAP knockdown impaired in vitro cancer cell migration only in
ccRCC cell lines.
In a third and final step, the transcriptomic output of YAP in the three different tumor
entities was compared by gene expression analysis of YAP-knockdown vs. mock transfected
cancer cell lines. Although the phenotype of YAP-knockdown cells was functionally similar
in PDAC, CCC and ccRCC cell lines, the transcriptional output of the Hippo-YAP axis as
determined by transcriptomic profiling appeared to be fundamentally different and seemed to be
highly tissue context-dependent. In fact, certain pathways were activated by YAP-knockdown
in one cell line while they were inhibited in another (e.g. MAPK in PK9 v. MZ1774 cells). As
no single, clearcut mechanism of YAP-mediated tumorigenicity could be observed, mechanistic
considerations were made for each of the three tumor entities individually and feature CTGF
and Wnt-signaling for pancreatic cancer as well as c-Myc and endothelins in ccRCC. The
observation of solitary cells that exhibit robust nuclear YAP-expression was common in all three
tumor entities analyzed, suggesting a role of Hippo-YAP signaling in tumor-stroma crosstalk
which is certainly a highly interesting starting point for future research.
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1. Introduction
1.1. The Hippo pathway in development and disease
1.1.1. Evolutionary and physiological significance of the Hippo
pathway
The Hippo pathway was named after the Drosophila hippo kinase that was initially dis-
covered using genetic mosaic screening [63]. These techniques were developed to identify
genes involved in regulating cell fate and cell proliferation in the fruit fly and provide use-
ful tools to study the effects of genetic mutations that are otherwise embryonically lethal
and can function as guiding experiments in the search for novel oncogenic pathways [12].
Drosophila clones expressing a mutated hippo protein displayed severely overgrown heads
and eyes that were folded and darker than their wild type counterparts. This distinct
phenotype inspired the name of the protein and, eventually the pathway around it [58].
The Hippo pathway is now considered to be a highly evolutionary conserved regulator
of tissue growth and cell fate. Since it was first discovered, it has emerged as an integrator
of signals from a vast network of proteins and is now considered an important regulator
of key cellular processes, including organ size regulation, cell proliferation and survival as
well as stem cell regulation [64].
The pathway is composed of a core kinase cascade that results in phosphorylation of
the transcriptional co-activator yorkie (i.e. YAP and its paralogue TAZ in mammals).
This phosphorylation promotes the cytoplasmic retention of this growth-promoting co-
transcription factor by 14-3-3 proteins. Multiple upstream signals feed into the core
signaling cascade and also the transcriptional output of yorkie/YAP/TAZ is dependent on
tissue context and cell type and can vary greatly. In the following part, the members of the
mammalian core signaling pathway, important upstream signals as well as transcriptional
programs controlled by YAP and TAZ are reviewed and current understanding about the
role of the Hippo pathway in neoplasia is recapitulated.
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Figure 1.1.: Schematic overview of the core signaling cascade in mammals. Phospho-
rylation of YAP by the core signaling cassette leads to cytoplasmic retention of the transcriptional
co-activator by 14-3-3 proteins. This marks YAP for ubiquitin-mediated proteolysis.
1.1.2. The core signaling cassette
The core signaling cassette of the Hippo signaling pathway is comprised of a set of highly
evolutionary conserved kinases (see table 1.1 on page 3). In mammals two related ser-
ine/threonine kinases, mammalian STE20-like protein kinase 1 (MST1, also known as
STK4) and MST2 (also known as STK3) as well as large tumor suppressor 1 (LATS1)
and LATS2, form the main part of the core cassette, together with their adaptor pro-
teins Salvador homologue 1 (SAV1), MOB kinase activator 1A (MOB1A) and MOB1B.
LATS1/2 in association with MOB1A/MOB1B phosphorylates the homologous oncopro-
teins Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding
motif (TAZ), creating binding sites for 14-3-3 proteins and promoting their cytoplasmic
retention and ubiquitin-mediated proteolysis [64]. Both YAP and TAZ are transcriptional
co-activators that promote tissue growth and cell viability by regulating transcriptional
activity in association with TEAD or SMAD transcription factors. Figure 1.1 provides a
graphic overview of the interaction of the core pathway members.
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Table 1.1.: Members of the Drosophila Hippo pathway and their mammalian counterparts
Drosophila gene Mammalian orthologue Reference
hippo MST1/MST2 [63]
salvador SAV1 [158]
warts LATS1/2 [76, 158]
mats MOB1A/MOB1B
yorkie YAP1, TAZ [70]
scalloped TEAD1-4 [93]
1.1.3. Multiple inputs into the Hippo Pathway
Multiple upstream branches feed into the Hippo pathway to control YAP/TAZ activity
although not all upstream signals control YAP/TAZ by activation of the core signaling
pathway. Some proteins form physical complexes with the transcriptional co-activators
and sequester them at cell-cell junctions far away from the transcriptional machinery in
the nucleus.
There is evidence of an evolutionary shift between Drosophila and mammalian sys-
tems regarding upstream input into Hippo signaling. While giant atypical cadherins like
Fat and Dachsous are well-characterized upstream members of the Hippo network in
Drosophila, they lack crucial domains in mammals and therefore do not interact with
pathway members in the mammalian system [14].
Several tissue level processes have been linked to Hippo pathway activation in devel-
opment and disease and will be briefly discussed below. Although the upstream Hippo
signaling network comprises many proteins, the last molecular link between the cell sur-
face and pathway activation or inhibition is in many cases still missing and conclusions
rely on empirical evidence. Figure 1.2 on page 6 provides an overview over the current
knowledge about the Hippo signaling network in mammalian cells.
Apicobasal cell polarity proteins
Apicobasal cell polarity proteins (ABCP) are responsible for the definition and mainte-
nance of functionally distinct membrane surfaces in epithelial tissues. In mice, the ABCP
protein Scribble can bind members of the Hippo core cassette and might thus promote
LATS-dependent YAP phosphorylation [26]. Mislocalization and aberrant expression of
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ABCP proteins has been observed in some cancers and could explain YAP/TAZ hyper-
activity in human neoplasia [64, 71].
Mechanotransduction
Hippo pathway activation is dependent on the mechanical properties of the cellular mi-
croenvironment and has been shown to be sensitive to signals from the actin cytoskeleton
in drosophila and mammals (reviewed in [64]). While stretching of cultured mammalian
cancer cells leads to decreased Hippo pathway activity and nuclear YAP localization,
compression of cells results in Hippo activation and YAP exclusion from the nucleus [37].
Although the detailed molecular mechanism is not yet fully understood, this finding has
important consequences for the role of Hippo signaling in neoplasia: due to alterations of
tissue architecture like changes in the extracellular matrix and infiltration of stromal and
immune cells, tumor tissue has altered mechanical properties that increase tissue rigidity
and might lead to YAP hyper-activation [37]. Recent studies have found that not only
neoplastic cells but also cancer associated fibroblasts in breast cancer depend on YAP-
signaling to promote malignant features of a tumor such as matrix-stiffening, cancer cell
invasion and angiogenesis [21].
Cell-cell adhesion molecules
There is experimental evidence that compromised function of cell-cell adhesion molecules
can lead to YAP/TAZ hyper-activation. Epithelial cells are connected to each other
via protein complexes anchored in adherens junctions (intercellular junctions) and tight
junctions (intercellular junctions in the apical regions of epithelial cells). Many proteins
involved in the formation of these junctions have been shown to "handcuff" YAP and TAZ
and to sequester them at cell junctions [64]. Notably Crumbs, angiomotins (AMOT), α-
catenin and E-cadherin bind YAP/TAZ and physiologically suppress their activity [139].
Contact inhibition
The phenomenon that adherent cells cease to proliferate when they come into physical
contact with their neighbors is defined as "contact inhibition". Loss of this characteristic
is one trait of oncogenically transformed cells in vitro [68]. Overexpression of YAP and
loss of upstream members of Hippo signaling, such as neurofibromin 2 (NF2), can induce
non-transformed cells to overcome contact inhibition [182]. Although the molecular mech-
anisms remain to be elucidated and the in vivo relevance of this finding is unclear, it has
4
1. Introduction
been shown many times that the sub-cellular localization of YAP and TAZ is influenced
by contact inhibition in vitro [63, 182].
Interaction with other signaling pathways
Pro-apoptotic stimuli, e.g. staurosporine treatment, have been shown to up-regulate
MST1 activity [160] and the same is true for DNA damage [61]. Oncogenic stress signals,
for example constitutively active Ras-signaling, physiologically also increase MST activity
and Hippo-mediated apoptosis [81]. Furthermore, the Hippo pathway has been shown to
integrate signals from several pathways that are known to carry oncogenic mutations,
for example the Wnt-, TGF-β-BMP-, Hedgehog-, Notch-, insulin- and mTOR-signaling
pathways [72].
G-protein coupled receptors
Recent work identified G-protein-coupled receptor (GPCR) signaling as one upstream
regulator of the Hippo pathway [178]. Serum-borne Lysophosphatic acid (LPA) and Sph-
ingosine 1-phosphate (S1P) activate G12/13-coupled receptors which leads to the inhibition
of LATS1/2 and consecutive derepression of YAP and TAZ. Gs-coupled receptors have
the opposite effect and ultimately lead to YAP inhibition [178]. This is very interesting
in light of recent results from a cell-based screening of small molecules in search of Hippo
pathway stimulators that found dobutamine, an agonist for Gs-coupled β1-adrenoceptors,
as an effective inhibitor of YAP-dependent gene transcription [6]. GPCR signaling is fre-
quently disturbed in cancer and accessible to small molecular therapies, which makes this
a promising field for YAP directed cancer therapies [64].
1.2. Transcriptional Output of the Hippo pathway
The transcriptional output of the Hippo-regulated transcriptional co-activators YAP and
TAZ are about as diverse as the upstream input feeding into the core signaling cassette.
The transcriptional program is highly context and cell-type dependent and may result in
growth suppression, mediation of stress-induced apoptosis, or the regulation of cell-fate
decisions [58]. This is of course partly due to the fact that the transcriptional co-activators
YAP and TAZ can partner with multiple different transcription factors.
The oncogenically relevant transcriptional responses of YAP seem to be regulated in
coalition with the TEAD-family of transcription factors, which have been shown to control
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Figure 1.2.: Schematic overview of the Hippo signaling network in humans. Figure
reprinted from [64] with permission from Macmillan Publishers Ltd.
transcriptional programs in Epithelial-mesenchymal transition (EMT), oncogenic trans-
formation, inhibition of apoptosis as well as contact inhibition [58]. Curiously, YAP can
also pair with p73 to elicit pro-apoptotic effects, a process that is equally dependent on
core pathway members as the anti-apoptotic response initiated by the YAP-TEAD com-
plex [156]. This can only be explained by cell-type and tissue context dependent input
into the Hippo pathway, which underlines again how little is known about the precise
mechanisms underlying its regulation. Another partner of YAP is the SMAD-family of
transcription factors, and YAP can drive transcription downstream of the BMP pathway
[1].
Recent findings excitingly revealed YAP as an important regulator of cell-density de-
pendent microRNA (miRNA) biogenesis [111]. At low cell density, nuclear YAP binds
and sequesters p72, which functions as a regulatory component of the miRNA processing
machinery. At high cell density, Hippo-mediated cytoplasmic retention of YAP facili-
tates miRNA processing. Hence, YAP hyperactivity can result in widespread miRNA
downregulation which is commonly found in a majority of human cancers [111, 177].
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1.3. The Hippo pathway and cancer
Although YAP is frequently overexpressed in various human cancer tissues and promotes
tumor cell properties, such as proliferation and resistance to apoptosis in epithelial cells,
the explanation for Hippo pathway perturbation remains elusive. In the following part,
influence of YAP on cancer cell properties as well as examples for Hippo pathway dereg-
ulation in cancer will be reviewed.
1.3.1. Influence on cancer cell properties
Proliferation
One of the most important features of cancer cells is their limitless replicative potential
[62]. Dysfunctional Hippo signaling and resulting unrestrained YAP/TAZ activity have
been linked to excess proliferation in murine models and human cancer tissues, as strik-
ingly demonstrated in the murine liver [34]. This is at least partly due to evasion of p53-
and Retinoblastoma (RB)-mediated senescence which constitute major tumor suppressor
checkpoints [64].
Survival
The Hippo-YAP axis is further involved in another area of malignant transformation:
evasion of apoptosis. YAP overexpression leads to inhibition of TNF- and Fas-induced
apoptosis in the murine liver [34]. In cancer cell lines, resistance against chemotherapy-
induced apoptosis as well as programmed cell death resulting from loss of cellular contact
to the extracellular matrix (i.e. anoikis) have been observed by several groups [122, 184],
providing a potential YAP-overexpressing subpopulation of tumor cells with the necessary
features to relapse early after chemotherapy.
Maintenance of a stem cell-like phenotype
The cancer stem-cell hypothesis proposes subpopulations of tumor cells that assume cel-
lular properties normally only associated with the regenerative cell compartment, for
example a marked resistance towards chemotherapeutic drugs and the loss of mature dif-
ferentiation markers. Both YAP and TAZ are enriched in multiple types of stem cells
[69, 99] and YAP is physiologically expressed in the stem- and progenitor-cell compart-
ments of various tissues and overexpression promotes expansion of this cell pool that can
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culminate in tumorigenesis (e.g. hepatic oval cells, [95]). YAP overexpression therefore
might contribute to neoplastic transformation by the establishment or maintenance of
stem cell like properties.
Invasion and metastasis
Metastasis is defined as a multistep process that requires cancer cells to undergo EMT,
to dissociate from the primary tumor and cross over into the blood or lymph stream,
to resist anoikis during dissemination, and finally to establish a filial tumor colony at
the distant site [64]. There are numerous papers that link dysfunctional Hippo signaling
and YAP hyperactivity to tumor progression and metastasis. In one of the first papers
that examined the role of the Hippo-YAP axis in cancer, Overholtzer et al. showed that
YAP overexpression promotes EMT and suppresses anoikis in non-transformed mammary
epithelial cells [122]. Loss of members of the growth-inhibitory Hippo pathway as well as
YAP/TAZ overexpression was found to be more frequently associated with high-grade,
metastatic malignancy in animal models (development of highly metastatic osteosarcomas
in Nf2+/--mice, [106]) as well as human breast [24, 26] and prostate cancer [184].
1.3.2. Direct and indirect disruption of Hippo signaling in human
cancer
Hippo pathway deregulation and consequent nuclear accumulation of its target YAP have
been observed in many human tumor tissues. Nuclear YAP expression is detectable in
about 62% of hepatocellular carcinomas [175], 36% of all lung adenocarcinomas [154] and
even more frequent in non small cell lung cancer with 66.3% [172]. In those cancers,
nuclear YAP expression is prognostically relevant and associated with shorter overall
survival. In ovarian cancer, high nuclear YAP staining coupled with low cytoplasmic
YAP immunoreactivity was found to be an independent prognostic marker for survival
(hazard ratio of 7.8) and associated with a 50% decrease in 5-year overall survival rates as
compared to patients with high nuclear/ high cytoplasmic, low nuclear/ high cytoplasmic,
or low nuclear/ low cytoplasmic YAP staining patterns [60].
Despite overwhelming evidence of prognostically relevant Hippo pathway perturbation
in multiple cancer tissues, the current understanding about the underlying cause is in-
complete. Members of the Hippo signaling axis, especially of the core signaling cassette
are infrequently mutated in human cancers. In contrast to other oncogenic signaling
pathways and with the exception of neurofibromin 2 (NF2 ), no germline mutations of
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Hippo pathway members have so far been linked to hereditary cancer syndromes and
also somatic mutations appear to be relatively rare [64]. Amplification of the YAP gene
and consecutive overexpression of YAP has been reported in various tumors [122, 180].
Deletions of SAV1 as an example of upstream members of the Hippo pathway have been
reported in clear cell renal cell carcinoma [105] but a more common scenario seems to be
epigenetic silencing of Hippo core pathway members.
Due to this multitude of possible inputs into the Hippo signaling pathway and its
interaction with various other signaling pathways, it is very likely that Hippo signaling is
indirectly disrupted. Cross-talk has been reported between the Hippo pathway and Wnt-,
TGF-β-BMP-, Hedgehog-, Notch-, insulin- or mTOR-signaling [72], all of which represent
signaling pathways frequently found to be aberrantly activated by oncogenic mutations
in cancer [75, 167].
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1.4. Pathogenesis and molecular biology of tumor
entities analyzed
1.4.1. Pancreatic ductal adenocarcinoma
Epidemiology
Cancers of the pancreas in the vast majority of cases (>95%) arise from the exocrine
compartment of the organ [3], and typically present as solid ductal adenocarcinomas with
a dense stroma. Less than 5% of all pancreatic neoplasms are cystic lesions [92]. Pancreatic
ductal adenocarcinoma (PDAC) accounts for over 90% of all pancreatic cancers and is
one of the most fatal malignant tumor as of to date. It is usually diagnosed at advanced,
already metastatic stages and almost invariably leads to death within few months after
diagnosis. This dire prognosis is reflected in the current cancer statistics published by
the American Cancer Society for 2013 [3]. In the United States, PDAC represents the
10th most common cancer diagnosis in men and the 9th most common cancer diagnosis
in women with an estimated 45,220 new cases per year. Of these, an estimated 38,460
patients will succumb to their disease within the same year. PDAC is accountable for
7% of all cancer deaths, thus representing the 4th most common cause of cancer-related
mortality in men and women alike. It is about 30% more common in men than in women
and incidence and death rates increase with age, showing a steep increase after the age of
fifty. The incidence rates have increased slightly but steadily over the last 10 years (2000-
2009) in the United States [3], while the overall prognosis remained poor, despite recent
advances in understanding the molecular pathology of the disease and the availability of
novel treatment options.
Pancreatic cancer is now generally recognized as a genetic disease not arising de novo but
originating from histologically well-defined non-invasive precursor lesions (e.g. Pancreatic
Intraepithelial Neoplasia, PanIN). Progression of PanINs to invasive carcinoma is believed
to be a multistep process resulting in accumulation of inherited and acquired mutations
in cancer-related genes. Histopathologic progression towards pancreatic cancer is closely
mirrored by genetic progression [104]. This paradigm correlates well with the increase of
incidence and mortality rates with age as well as with attributed risk factors of PDAC.
Two major modifiable risk factors have been identified in smoking and obesity, each
increasing the lifetime risk of developing PDAC by about 20% [3].
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Table 1.2.: Syndromes associated with the formation of PDAC
Syndrome Affected gene Comments
Hereditary
breast/ovarian cancer
BRCA2 ca. 5%-17% of inherited pancreatic can-
cers harbor BRCA2 mutations
Familial atypical multi-
ple mole melanoma syn-
drome (FAMMMS)
CDKN2A/p16 mutation increases the lifetime risk about
13-22-fold
Peutz-Jeghers Syndrome
(PJS)
STK11/LKB1 11%-36% chance of developing PDAC dur-
ing lifetime
Hereditary pancreatitis PRSS1 mutation increases the lifetime risk about
70-fold, about 40%-55% will develop
PDAC during lifetime
BRCA2 : breast cancer 2, early onset, CDKN2A/p16 : cyclin-dependent kinase
inhibitor 2A, STK11/LKB1 : serine/threonine kinase 11, PRSS1 : protease,
serine, 1 (trypsin 1)
Since the pathomechanistic basis of PDAC is genetic, there are not surprisingly inherited
genetic features that considerably increase the lifetime risk of PDAC. A family history of
pancreatic cancer increases the general risk of PDAC by twofold, seven- nine-fold if one
1st degree relative is afflicted, 17-32-fold if three or more 1st degree relatives have been
diagnosed [3]. It is estimated that 5%-10% of all PDAC cases are inherited and arise
either on the background of a known cancer syndrome or in association with hereditary
pancreatitis or cystic fibrosis, or are referred to as familial pancreatic cancers without
association with a known syndrome [134]. Table 1.2 provides an overview of genetic
syndromes that predispose to development of pancreatic cancer and lists their respective
underlying genetic mutations [3, 134].
It is now known that most of the above-mentioned syndromes do not predominantly
result in pancreatic but rather in other forms of cancer. The majority of inherited pancre-
atic cancer cases is not associated with a known clinical syndrome, and familial pancreatic
cancer kindreds have been reported to harbor clearly defined mutations in other genes, for
example palladin [130]. These points illustrate that there is a wide spectrum of genetic
alterations in a given pancreatic cancer lesion and a study of 99 human pancreatic tumors
identified well over 3,000 genomic aberrations in total [11]. There are, however, methods
that provide a way to spot order among the chaos. In a study published by Jones and
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Figure 1.3.: Pancreatic carcinogenesis is a multistep process. Figure reprinted from
[103] with permission from Macmillan Publishers Ltd.
colleagues in 2008, 24 pancreatic cancers were analyzed by next generation sequencing
methods and although the individual mutations observed were manifold and marked by
considerable inter-individual variations, the group identified twelve core signaling path-
ways that were almost uniformly affected across all PDAC samples analyzed [75]. Some
of the most common genetic alterations affecting these pathways are discussed in more
detail in the following section.
Molecular pathology
The pathogenesis of cancer is based on a variety of genetic changes culminating in inva-
sive disease [167]. In line with this view, pancreatic cancer is today regarded as a genetic
disease, which arises from morphologically and genetically clearly defined precursor le-
sions through stepwise accumulation of genetic alterations [44]. These precursor lesions
comprise Pancreatic intraepithelial neoplasia (PanIN), which can be subclassified into
PanIN-1, PanIN-2, and PanIN-3 lesions depending on the degree of cytologic and archi-
tectural atypia, intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic
neoplasms (MCN). PDAC may develop from any type of these precursor lesions with
PanIN being the most common origin.
12
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Mutations of genomic DNA within oncogenes and tumor suppressor genes are involved
as well as epigenetic changes and aberrations of transcriptional patterns. Genetic changes
may also affect caretaker genes like genes of the Fanconi’s anemia DNA repair pathway
that normally function to minimize genetic alterations during DNA replication thus lead-
ing to accumulation of additional genetic mutations and facilitating progression towards
invasive carcinoma. Mutations of mitochondrial DNA are also very frequently observed
in PDAC and non-malignant precursor lesions [43]. The hallmark-mutations of oncogenes
and tumor-suppressor genes that are acquired along the pathogenic cascade of pancreatic
cancer development follow here.
KRAS Activating point mutations of the oncogene KRAS occur in almost 90% of all
PDAC cases. Most commonly they affect codon 12, 13 or 61 and result in abrogation of
the intrinsic GTPase activity of the RAS-protein, which leads to constitutive activation
of the intracellular signaling cascade [43]. Acquisition of constitutively active KRAS is
among the first genetic changes in PDAC and is already present in nonmalignant precursor
lesions. About 30% of PanIN-1 lesions harbor an activating point mutation of the KRAS
gene [114].
CMYC, AKT2, EGFR Other oncogenes involved in the molecular pathogenesis of pan-
creatic cancer are CMYC, AKT2, and EGFR. Although mutations of those oncogenes are
less frequent, they represent potential therapeutic targets and experimental evaluation is
currently underway [43]. CMYC is amplified and subsequently overexpressed in 50-60% of
pancreatic cancers while amplifications of AKT2 are detected in less than 5% of cases [43].
Nevertheless, the Akt signaling pathway is activated in 30 to 40% of pancreatic cancers
indicating additional activating mechanisms and underscoring the potential therapeutical
relevance of Akt-targeting [133]. Constitutive EGFR pathway activation by amplification
of the EGFR gene or by other mechanisms have likewise been described in pancreatic
cancer [43].
CDKN2A/p16 The CDKN2A/p16 gene is located on the short arm of chromosome 9
(9p) and encodes the cell-cycle regulator protein p16INK4A, which exerts function via the
p16/Rb pathway and inhibits cell cycle progression through the G1-S checkpoint. In over
90% of PDAC it is inactivated by either homozygous deletion (approx. 40% of cases),
intragenic mutation (40%) or epigenetically by hypermethylation of its promoter (10-15%)
[5]. The loss of function mutation of the CDKN2A gene is thought to be an early event
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during the multistep process towards invasive carcinoma and can already be observed in
30% of PanIN-1, 55% of PanIN-2, and 71% of PanIN-3 lesions, respectively [140].
DPC4/SMAD4/MADH4 Deleted in pancreatic carcinoma 4 (DPC4/SMAD4/MADH4)
is located on chromosome 18q21 and loss of function mutations can be observed in ap-
prox. 55% of all PDAC cases while they occur only very rarely in other malignancies [43].
Inactivation is mediated by mutation of one allele with concomitant loss of the second
allele (25% of cases) or homozygous mutation (30% of cases) resulting in reduced growth
inhibition and increased proliferation via impaired TGF-β signaling. Loss of DPC4 con-
stitutes a rather late event in pancreatic cancer development and is usually only observed
in a minority of PanIN-3 lesions [174].
TP53 The oncogene TP53 on chromosome 17p usually induces cell cycle arrest and
apoptosis in response to DNA damage and is inactivated due to intragenic mutation
with loss of the second allele in 50-75% of pancreatic cancers. Loss of function of TP53
facilitates the acquisition of additional genetic mutations and is considered to be a late
event in pancreatic cancer development as nuclear accumulation of mutated TP53 can
only be observed in advanced PanIN-3 lesions [174].
1.4.2. Biliary tract carcinoma
Epidemiology of biliary tract cancers
The structure of the biliary tract can be compared to a tree: the trunk is formed by the
common bile duct with the ampulla of Vater opening into the duodenum at its bottom.
The trunk then branches out into the cystic duct with the attached gallbladder, and
further up turns into the common hepatic duct which then parts into the large hepatic
bile ducts. Those large intrahepatic bile ducts split twig-like into a network of small
intrahepatic bile ducts that form the canopy of the biliary tree. Invasive carcinomas
can arise in all parts of the biliary tree and include cancers of the gallbladder as well as
cancers of the intrahepatic and extrahepatic bile ducts. Although they are often grouped
together, differences in epidemiology and pathobiology warrant their classification into
two separate entities.
Gallbladder carcinoma Carcinoma of the gallbladder develops from the epithelial lin-
ing of the organ and represents the most frequent malignant tumor of the biliary tract.
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It arises more frequently in women and displays a heterogeneous geographic distribution
with higher incidence rates in Mexico and South America as compared to Western coun-
tries [92]. Very often (60% to 90% of cases), gallbladder carcinoma develops on the basis of
cholelithiasis and it is suspected that recurring trauma and chronic inflammation inflicted
by gallstones contribute to the development of gallbladder carcinoma. Carcinoma of the
gallbladder is often discovered incidentally during surgery for removal of gallstones and
the presenting symptoms are often indistinguishable from those of cholelithiasis. Conse-
quentially, diagnosis is generally very late and tumors are often not resectable, leading to
a very low 5-year overall survival rate of 5% [92].
Cholangiocarcinoma Cholangiocarcinoma (CCC) is the second most common hepatic
malignancy after hepatocellular carcinoma (HCC). Cancers of the hepatobiliary tract
account for 13% of cancer-related deaths worldwide and about 10-20% of these are at-
tributable to cholangiocarcinoma [13]. While HCC is thought to arise from hepatocytes,
cholangiocarcinomas are defined as hepatobiliary cancers with features of cholangiocyte
differentiation, although the cell of origin is a matter of some debate, as will become
apparent below [132]. Based on their anatomic location, CCC are classified into three
subtypes that are distinct in epidemiology, etiology and pathogenesis. They are: firstly
intrahepatic cholangiocarcinoma, secondly perihilar cholangiocarcinoma, also referred to
as "Klatskin-Tumor", and finally distal cholangiocarcinoma. The second-order bile ducts
serve as a demarcation between intrahepatic and perihilar cholangiocarcinoma while the
cystic duct separates perihilar from distal cholangiocarcinomas [132]. The latter two have
been grouped together as extrahepatic cholangiocarcinomas but differences in frequency,
pathobiology and management have led to the understanding that they are two separate
entities [78]. Perihilar CCC is the most common subtype (50%-60%), followed by distal
CCC (about 20%) and intrahepatic CCC (up to 20%). A small subset of 5% consists of
tumors with multiple foci [78].
Not unlike PDAC, CCC is diagnosed usually at late, unresectable stages and the prog-
nosis is generally grim with 5-year-survival rates ranging at around 10% which is slightly
improved after attempted curative resection to 20%-40% [107]. Mean survival times post-
surgery range from 6 to 18 months, regardless whether aggressive resection or palliative
surgery is performed [92]. CCC has a slight male predominance and develops later in life,
with the median age at diagnosis in Western countries being >65 years [13]. For reasons
yet unknown, incidence and mortality rates of intrahepatic CCC have been increasing
worldwide, while those of extrahepatic CCC have remained stable [132].
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Although most cases of CCC are sporadic, some risk factors have been established. The
geographic occurrence of these factors varies greatly and explains the geographic variabil-
ity of incidence rates of CCC, which are the highest in Southeast Asia (113 per 100,000 in
Thailand in contrast to 0.1 per 100,000 in Australia for intrahepatic CCC) [132]. The main
risk factor for the development of CCC seems to be chronic biliary inflammation, although
the underlying cause varies geographically as well. In Asian countries infections with the
hepatobiliary flukes Opisthorchis viverrini and Clonorchis sinensis and hepatholithiasis
are more prevalent and predispose for the development of CCC, while in Western coun-
tries primary sclerosing cholangitis, a chronic disease of suspected autoimmune genesis, is
the primary predisposing condition and is associated with a 5%-10% lifetime prevalence
of CCC [132]. Further risk factors include infection with hepatitis B or hepatitis C virus
and liver cirrhosis.
Pathobiology
Cell of origin Distal and perihilar CCC are thought to arise from cholangiocytes that
line the larger intrahepatic as well as the extrahepatic bile ducts and form the biliary
epithelium. Cholangiocytes are mucin-producing cuboidal cells that contribute to bile
secretion – a task mainly performed by hepatocytes – via net release of bicarbonate and
water. Intrahepatic CCC on the other hand may not have a single lineage and there is
evidence that they develop from either biliary epithelial cells or hepatic progenitor cells
(oval cells) [132]. It has also been proposed that CCC could arise from transdifferentiated
hepatocytes that have reverse-developed into liver cancer stem cells which in turn can give
rise to hepatocellular or cholangiocellular carcinoma [67]. The multiple-lineage hypothesis
is supported by the fact that the histologic presentation of CCC and particularly intrahep-
atic CCC is diverse and rare subtypes include combined hepatocellular/cholangiocellular
carcinomas [132].
Role of biliary inflammation Although the majority of biliary carcinomas are sporadic,
the known risk factors and predisposing conditions all involve chronic biliary inflamma-
tion, making inflammatory processes a likely contributing factor to biliary carcinogenesis.
Inflammation produces a wide array of mediators like cytokines, growth factors and ki-
nases that can influence cellular processes crucial in carcinogenesis including regulation of
the cell-cycle and cell proliferation, senescence and apoptosis. Key mediators involved in
biliary carcinogenesis have been identified and characterized. Inducible nitric oxide syn-
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thase (iNOS) is activated by inflammatory mediators leading to oxidative DNA damage
while DNA repair enzymes are inhibited [73]. The cytokine interleukin-6 (IL-6) is secreted
by CCC cells as well as tumor-associated immune cells and increases the expression of the
antiapoptotic protein myeloid cell leukemia sequence 1 (MCL1) via constitutive activa-
tion of the signal transducer and activator of transcription (STAT) pathway and activates
STAT3 in a janus kinase (JAK)-dependent manner [132].
Cholestasis and bile acids contribute to the inflammatory environment by activating
growth factor signaling like epidermal growth factor receptor (EGFR) and increasing the
expression of cyclooxygenase-2 (COX2). Bile contains a high concentration of oxysterols
which are products of the oxidative degradation of cholesterol and function as endogenous
ligands for the hedgehog signaling pathway. Oxysterols have likewise been implicated to
foster biliary carcinogenesis [132].
Development via precursor lesions As seen for a lot of epithelial tumor entities such
as colon carcinoma, prostate cancer or PDAC (as discussed above), there has been in-
creasing evidence in recent years that the development of cancers of the biliary tract is
equally most accurately described by a multistage progression model that includes the
formation of precursor lesions in healthy biliary epithelium which will eventually give rise
to invasive carcinoma. Precancerous changes in the gallbladder and the biliary tract are
likewise characterized by increasing degrees of atypia of the tissue architecture that are
accompanied by molecular changes affecting tumor suppressor and oncogenes although
the knowledge about the molecular signature of precursor lesions of the biliary system
is merely fragmentary to date. In line with their classification as two separate entities,
there are histologically and molecularly distinct precursor lesions of invasive gallbladder
and cholangiocarcinoma [65].
There are two major types of precancerous lesions that may develop into invasive cholan-
giocarcinoma: biliary intraepithelial neoplasia (BilIN) and intraductal papillary neoplasms
of the bile duct (IPNB). BilINs are only microscopically detectable, flat and do not form
masses which is why they are usually asymptomatic. The lesions are characterized his-
tologically by columnar epithelial cells that exhibit multilayering of abnormal nuclei as
well as the formation of desmoplastic stroma. The degree of cellular atypia increase from
low-grade BilINs (BilIN1-2) towards high-grade BilIN3 and carcinoma in situ. IPNBs
are papillary lesions that form masses inside the bile ducts, eventually becoming macro-
scopically visible and causing biliary obstruction which makes them clinically detectable.
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IPNBs are thought to give rise to about 10%-15% of bile duct tumors and occur in pre-
dominantly in extrahepatic, sometimes in large intrahepatic bile ducts [82].
Similarly, there are BilINs of the gallbladder that share microscopic characteristics
with their counterparts in the bile ducts and arise in the cholecystic mucosa. They are
often found next to invasive carcinomas and are mostly detected at cholecystectomies. The
presence of BilIN3 lesions is a strong indicator of invasive carcinoma of the gallbladder.
Intracholecystic papillary-tubular neoplasms of the gallbladder are preinvasive dysplastic
epithelial lesions that form exophytic mucosal tumors. They typically form solitary masses
larger than 1 cm in diameter and can likewise produce clinical symptoms that may lead
to an early detection with more favorable outcome for the patient [82].
Molecular pathology The evaluation of the molecular pathology is ongoing and the
molecular cascade of biliary carcinogenesis is considerably less well defined than in PDAC.
Nevertheless the association of morphological changes with a mutational spectrum of
oncogenes and tumor suppressor genes has been demonstrated in several studies. The
most important genes are discussed here. It will become apparent that there is con-
siderable overlap between the mutational spectrum of PDAC and CCC. Activation of
KRAS is found in subsets of both CCC and gallbladder carcinoma. While activation of
the oncogene is observed in 40%-50% of intrahepatic CCCs and occurs in about 30% of
gallbladder carcinomas, it is less frequent in extrahepatic CCCs (10%-15%). Mutations
in v-raf murine sarcoma viral oncogene homolog B1 (BRAF), an important downstream
mediator of oncogenic KRAS signaling were observed in an additional 30% (gallbladder
carcinomas) or 20% (intrahepatic CCC), respectively. Of note, those mutations occurred
mutually exclusive, suggesting the activation of the Ras/Raf/MAPK signaling axis as a
key event in biliary carcinogenesis [65].
The spectrum of tumor suppressor gene mutations seen in biliary tract carcinomas
largely mirrors that of other GI malignancies like PDAC and includes loss of function
of CDKN2A, TP53 (tumor protein p53), and SMAD4. The cell-cycle regulator pro-
tein CDKN2A/p16 is frequently mutated in biliary tract cancers by mechanisms such
as promotor hypermethylation, homozygous deletion, and inactivating point mutations.
Frequencies as high as 88% have been reported for intrahepatic CCC and range around
50% for both extrahepatic CCC and gallbladder carcinoma [65]. Inactivation of TP53
has been reported to occur in cancers of the biliary tree with frequencies of 30%-40%,
regardless of the site of origin. A mouse model of CCC combining the expression of con-
stitutively active Kras with the inactivation of p53 in hepatic precursor cells has recently
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been published. These animals develop precancerous lesions that mimic human BilINs
which progress into invasive carcinoma of CCC or mixed (HCC/CCC) histology [119].
Inactivation of SMAD4 has been reported for CCC, although frequencies vary greatly
with 15%-50% for extrahepatic and 10%-15% for intrahepatic CCC [65].
Desmoplastic reaction and cancer associated fibroblasts Like PDAC, intrahepatic
and perihilar CCCs are characterized by an intense desmoplastic reaction which surrounds
the relatively sparse tumor cells with a dense, fibroblast-rich stroma. The stroma in fact
comprises most of the tumor mass and it is suspected that it promotes tumor progression
by cross-talk between cancer cells and stromal components, such as cancer-associated
fibroblasts, which have been studied in the setting of biliary tract carcinoma. Although
the cellular origin of cancer-associated fibroblasts remains to be elucidated – hypotheses
include hepatic stellate cells, portal fibroblasts or bone marrow-derived precursor cells as
candidates – they have been shown to stimulate production of the extracellular matrix
by secretion of growth factors like connective tissue growth factor (CTGF), transforming
growth factor-β (TGF-β), platelet derived growth factor (PDGF) and insulin-like growth
factor binding proteins (IGFBPs) [132].
1.4.3. Renal cell carcinoma
Epidemiology of renal cell carcinoma
Renal cell carcinoma (RCC) represents the majority (80%-85%) of all primary malignant
tumors of the kidney and is thought to arise from the renal tubular epithelium. RCC
accounts for about 2-3% of all malignant diseases in adults with ccRCC being the most
common histological subtype that represents 70-80% of all cases [131]. Worldwide, in-
cidence registers at 209,000 cases per annum while the annual mortality rate is around
102,000. A steady increase in incidence and mortality rates for all stages of RCC has been
reported for the last 20 years [131]. RCC is a cancer of the elderly and most patients
are diagnosed in the sixth or seventh decade of their lives. There is a noticeable male
predominance with men being affected about twice as often as women [92]. While patients
with organ-confined disease profit greatly from curative partial or radical nephrectomy
with 5-year survival rates as high as 85%, the prognosis of metastatic renal cancer remains
poor with 5-year survival rates of less than 10% despite the emergence of novel targeted
therapies such as antiangiogenic drugs and mTOR inhibitors during the past decade [2].
About 20%-30% of patients present with metastatic disease and an additional 20%-30%
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relapse after attempted curative surgery, illustrating the need for a better understanding
of the pathobiology of RCC for the development of novel therapeutic options [2].
The vast majority of renal cell carcinomas are sporadic, nevertheless certain factors
increasing the lifetime risk have been identified. Modifiable risk factors include active
and passive cigarette smoking, which increases the risk of developing RCC about 2-3
fold, obesity, exposure to cadmium and hypertension [92, 131]. RCC seems to be more
common in patients with chronic renal conditions such as end-stage renal disease, acquired
renal cystic disease or tuberous sclerosis [131]. In fact, the risk of developing RCC is
increased by approximately 30-fold in patients who develop acquired polycystic disease
as a complication of chronic dialysis [92].
About 2%-3% of RCC cases present in the context of an inherited cancer syndrome (see
Table 1.3 on page 21). Of these, the study of von Hippel-Lindau syndrome has provided
valuable insight into the pathogenesis of ccRCC. The function of the protein encoded by
the affected VHL gene is similarly lost in a large number of sporadic ccRCC cases and VHL
mutation seems to be one of the major underlying events driving ccRCC pathogenesis.
Pathobiology
Subtypes Today, RCC is not considered to be one homogeneous entity, but rather a
collection of different tumor types that are derived from distinct parts of the nephron.
About 70%-80% of cases present as ccRCC which are usually solitary, unilateral, highly
vascularized masses, and are histologically characterized by cells with clear cytoplasm
that resemble plant cells due to storage of high amounts of lipids and glycogen, embedded
in scarce surrounding stroma [92]. The tumor margins tend to be clearly defined but
projections into the surrounding parenchyma as well as formation of filial nodules occur,
which illustrates the aggressive nature of this invasive carcinoma. Vascular invasion via
the renal vein is very frequent, at late stages reaching as far as the inferior vena cava [92].
Papillary RCC comprises 10%-15% of all RCC cases and is characterized by a papillary
growth pattern and tumors with multiple foci that often affect both kidneys at the same
time. Both clear cell and papillary RCC are thought to arise from the cells of the proximal
tubule of the nephron [20]. A third subtype is comprised of chromophobe RCCs which
account for 3%-5% of all RCC cases and are derived from the intercalated cells of the
collecting duct [92].
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Table 1.3.: Cancer syndromes predisposing for RCC, modified from [2] with permission from
S. Karger AG.
Syndrome Affected gene &
chromosomal
location
Clinical manifestations
von Hippel-Lindau
syndrome
VHL
3p25-26
ccRCC, CNS haemangioblastoma,
phaeochromocytoma
Hereditary papillary
renal carcinoma
cMET
7q31
papillary RCC
Hereditary leiomy-
omatosis and RCC
FH
1q42
papillary RCC, leiomyomas of skin or
uterus, uterine leiomyosarcomas
Birt-Hogg-Dubé FLCN
17p11
Oncocytoma, chromophobe RCC, hy-
brid oncocytic tumor (less frequently,
clear cell or papillary RCC), cutaneous fi-
brofolliculomas
Familial RCC asso-
ciated with constitu-
tional chromosome 3
translocation
FHIT and others
3p and 3q
Clear cell RCC
VHL: von Hippel-Lindau, cMET : met proto-oncogene, FH : fumarate hydratase,
FLCN : folliculin, FHIT : fragile histidine triad
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The scope of the study presented in this dissertation is limited to ccRCC as the most
frequent subtype of RCC, which is why I will focus on the molecular features of this entity
in the following part.
VHL and hypoxia-related genes The genetics and molecular pathology of ccRCC are
unique and distinct from other solid cancers. While known cancer genes like the RAS -
family, BRAF, TP53, RB and CDKN2A are largely not part of the mutational spectrum,
the vast majority of ccRCCs harbor inactivating mutations in the VHL gene, which in turn
does not play a large role in most other tumor entities [31]. VHL encodes the substrate
region of an E3-ubiquitin ligase complex that marks the α-subunit of hypoxia-inducible
factor (HIF) transcription factors for degradation. HIF1α or HIF2α associate with HIF1β
to form a heterodimeric transcription factor. The heterodimer binds to hypoxia-responsive
elements in the regulatory regions of genes and induces the transcription of hypoxia-
inducible genes that regulate angiogenesis, metabolism and pH control, among others.
The polyubiquitination mediated by the VHL gene product depends on the hydroxylation
of conserved protein residues of the HIF1/2α proteins in the presence of oxygen. In
conditions of hypoxia these residues remain unhydroxylated prohibiting the ligation of
ubiquitin, thus permitting HIF to activate the hypoxia pathway [20]. VHL lies within a
43-Mb region on chromosome 3p that is monoallelically deleted in approximately 90% of
ccRCC tumors. The remaining copy is lost by mutation in about 55% of sporadic ccRCC
and the gene is inactivated by promotor hypermethylation in an additional 10% of cases
[31]. Inactivation of VHL seems to be an important and early event in renal carcinogenesis
as it can be observed even in the smallest renal tumor masses [20]. There seem to exist
two distinct subtypes of ccRCC characterized by the expression of genes associated with
cellular hypoxia: Dalgliesh and colleagues reported upregulation of hypoxia-associated
genes in 75 out of 91 ccRCC cases, most of which also carried a VHL-inactivating mutation
[31]. This group proposed a classification into hypoxic and non-hypoxic tumors and
reported a distinct mutational and gene expression signature for the two classes [31].
One can further subdivide ccRCC tumors according to the expression profile of the HIF
isoforms. Tumors either express HIF1α and HIF2α simultaneously or HIF2α alone. The
associated molecular signature is distinct. Tumors expressing both isoforms reportedly
exhibit activation of the Akt/mTOR and MAPK pathways and show higher response rates
towards antiangiogenetic therapies [20]. Tumors expressing only HIF2α meanwhile are as-
sociated more frequently with amplification in the region chromosome 8q24 encompassing
the MYC gene which is concomitantly overexpressed.
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Figure 1.4.: VHL and HIF in the context of targeted therapy. Figure reprinted from
[131] with permission from Elsevier.
Inactivation of histone modifying genes Although the loss of VHL gene function is
undoubtedly an important and early event in renal carcinogenesis, there are certainly
other factors involved as well: despite continued efforts, targeted deletion of VHL in the
murine kidney has not led to an experimental animal model that faithfully recapitulates
human carcinogenesis [125]. Interestingly, the region of LOH on chromosome 3p further
comprises three other genes frequently mutated in ccRCC: polybromo-1 (PBRM1, mu-
tated in 50%), BRCA1-associated protein-1 (BAP1, mutated in 15%) and SET domain
containing 2 (SETD2, mutated in 15%). Of these, mutations in PBRM1 and BAP1 tend
to be mutually exclusive [125]. Pena-Llopis and colleagues outlined a model for ccRCC de-
velopment which proposes VHL mutation as an early event that is followed by a loss of 3p.
The group proposes subsequent mutations in the remaining alleles of PBRM1 or BAP1,
respectively, as a divide between distinct molecular subtypes of ccRCC [125]. Intrigu-
ingly, the histone H3 lysine 36 methyltransferase SETD2 was independently identified to
harbor inactivating mutations in a subgroup of ccRCC in a large study sequencing 3,544
protein-coding genes of 101 ccRCC cases alongside two other histone modifying genes,
JARID1C and UTX [31]. Mutations within the chromatin remodeling landscape might
therefore represent another crucial part in the puzzle of ccRCC-carcinogenesis.
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Hippo pathway deregulation in ccRCC The same large systematic sequencing study
by Dalgliesh et al. revealed a subgroup of ccRCC tumors within the non-hypoxic class
that display somatic truncating mutations in the NF2 gene. In contrast to the histone-
modifying genes JARID1C and SETD2, none of the NF2 -mutant ccRCC samples har-
bored a VHL mutation [31]. NF2 is a member of the Hippo pathway upstream of the
core kinase cassette. To this date it is the only pathway member that is a recognized
cancer gene in the catalogue of somatic mutations in cancer (COSMIC) and that can be
considered a bona fide tumor suppressor gene homozygously mutated in about 2% ccRCC
cases [64]. Germline-mutations of NF2 predispose for neurofibromatosis II, a hereditary
cancer syndrome associated with the development of acoustic neuromas, meningiomas
and schwannomas [31]. Targeted knockout of NF2 in the proximal convoluted epithelium
of Villin-Cre;NF2flox/flox-mice leads to the formation of intratubular neoplasia within 3
months which progresses to invasive carcinoma in 6-10 month old mice [112]. This model
can therefore be considered the first to faithfully depict human renal carcinogenesis, albeit
only for a subset of ccRCC tumors.
In addition to mutational events concerning Hippo pathway members, downregulation
of the core pathway member SAV1 and consecutive nuclear accumulation of YAP has been
reported for a significant subgroup of ccRCC tumors [105]. Of note, copynumber loss on
chromosome 14q22, i.e. in the region of the SAV1 gene, has been previously described in
high-grade ccRCC by different groups [49, 105, 176].
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1.5. Question addressed in this dissertation
Dysfunctional Hippo signaling and nuclear YAP hyperactivity can be observed in many
human tumor tissues. The first question addressed in this dissertation is whether YAP is
differentially expressed in human tumor tissue samples in the three entities PDAC, biliary
cancer and ccRCC and whether nuclear YAP expression correlates with clinico-pathologic
parameters in these tissues.
In a second step, the role of aberrant YAP activity in tumor cell lines is examined
by shRNA-mediated knockdown of the protein in selected, highly YAP expressing cell
lines. Phenotypic consequences of the knockdown are examined by a wide range of cell-
based in vitro and in vivo assays and results among the three different tumor entities
are compared. One of the lead questions, especially regarding the high tissue-context
dependency, is whether there is a common phenotype across different types of cancer.
In a third and final step, the transcriptomic output of YAP in the three different tumor
entities is compared by gene expression analysis of YAP-knockdown vs. mock trans-
fected cancer cell lines. Hypothetically, the transformative transcriptional output of YAP
should display some overlaps in different cancer cells but should also reflect differences
in cell types. From the gene expression data, mechanistic considerations for the role of
YAP activity in etiology and progression of PDAC, biliary cancers and ccRCC will be
attempted.
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2.1. Equipment
Table 2.1.: Equipment
Appliance/ tool Manufacturer
Air displacement pipettes (0.1-2.5 µl; 0.5-
10.0 µl; 2-20 µl; 10-100 µl; 20-200 µl; 100-
1000 µl)
Eppendorf AG, Hamburg, Germany
Air displacement pipettes (0.5-10 µl; 20-
200 µl; 100-1000 µl)
Biohit mLINE, Sartorius Biohit Liquid
Handling Oy, Helsinki, Finland
Autoclave (tissue culture) Systec GmbH, Wettenberg, Germany
Balance Sartorius TE601, Sartorius AG, Göttin-
gen, Germany
Blotting unit Mini TransBlot Cell, BIO-RAD Laborato-
ries, Hercules, California, USA
Casting unit BIO-RAD Laboratories, Hercules, Cali-
fornia, USA
Cell counter Scepter 2.0 handheld automated cell
counter, Merck Millipore, Billerica, Mas-
sachusetts, USA
Cell culture centrifuge Centrifuge 5810R, Eppendorf AG, Ham-
burg, Germany
Cell culture incubator Sanyo MCO18-AIC, Panasonic Health-
care, Osaka, Japan
Digital calipers Milomex, Pulloxhill, United Kingdom
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Table 2.1.: Equipment (continued)
Appliance/ tool Manufacturer
Electrophoresis chamber (horizontal) PEQLAB 40-1214 and 40-0708, PEQLAB
Biotechnologie GmbH, Erlangen, Ger-
many
Electrophoresis power supply Consort EV 202, Sigma-Aldrich, St.
Louis, Missouri, USA
Electrophoresis unit (vertical) Mini PROTEAN Tetra Cell, BIO-RAD
Laboratories, Hercules, California, USA
Freezer (-20 ºC) Siemens, München, Germany
Freezer (-80 ºC) Forma 905 -86C ULT Freezer, Thermo
Fisher Scientific, Waltham, Mas-
sachusetts, USA
Gel documentation system ChemiDocTM BIO-RAD Laboratories,
Hercules, California, USA
Ice machine Scotsman AF 20, Scotsman Ice Systems,
Vernon Hills, Illinois, USA
Illumina iScan Applied Biosystems, Darmstadt, Ger-
many
Inverted microscope Nikon Eclipse TS100, Nikon Instruments
Europe B.V., Düsseldorf, Germany
Laminar flow hood, biosafety level II MSC Advantage (1,8m), Thermo Fisher
Scientific, Waltham, Massachusetts, USA
Magnetic stirrer ARE Heating Magnetic Stirrer, VELP
Scientifica, Usmate, Italy
Microcentrifuge Centrifuge 5430R, Eppendorf AG, Ham-
burg, Germany
Microscope with camera, upright Nikon H 550S, Nikon Instruments Europe
B.V., Düsseldorf, Germany
Microwave Panasonic NN-E245WB, Panasonic, Os-
aka, Japan
Mini centrifuge miniSpin plus, Eppendorf AG, Hamburg,
Germany
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Table 2.1.: Equipment (continued)
Appliance/ tool Manufacturer
Mini centrifuge MiniStar Silverline, VWR, Radnor, Penn-
sylvania, Germany
Mr. Frosty Nalgene, Thermo Fisher Scientific,
Waltham, Massachusetts, USA
Orbital shaker Rotamax 120, Heidolph Instruments
GmbH, Schwabach, Germany
pH Meter S20 SevenEasyTM pH, Mettler-Toledo
GmbH, Gießen, Germany
Pipette controller for serological pipettes PIPETBOY acu, INTEGRA Biosciences
AG, Zizers, Switzerland
Precision balance Extend ED124S, Sartorius AG, Göttin-
gen, Germany
Probe sonicator Branson SLPe 4C15, Branson Ultrasonics,
Danbury, Connecticut, USA
Realtime PCR machine Realplex2 Mastercycler epgradient S, Ep-
pendorf AG, Hamburg, Germany
Refrigerator (+4ºC) Siemens, München, Germany
Rotating tube shaker (1.5 ml) Intelli-Mixer RM-2M, ELMI Ltd., Riga,
Latvia
Shaker incubator Certomat IS, B. Braun Biotech Interna-
tional, Melsungen, Germany
Spectrophotometer NanoDrop ND-1000 (PeqLab, Erlangen,
Germany)
Suction pump Membranpumpe MP060E, ilmvac GmbH,
Ilmenau, Germany
Thermocycler Mastercycler pro, Eppendorf AG, Ham-
burg, Germany
Thermomix Thermomixer comfort, Eppendorf AG,
Hamburg, Germany
Tube rotator Roller mixer SRT9, Bibby Scientific Lim-
ited, Staffordshire, United Kingdom
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Table 2.1.: Equipment (continued)
Appliance/ tool Manufacturer
Ultra deep freezer (-150 ºC) SANYO MDF-C2156VAN, Panasonic
Healthcare, Osaka, Japan
Vortex 2_X3 VELP Scientifica, Usmate, Italy
Waterbath WNB22, Memmert GmbH, Schwabach,
Germany
2.2. Consumables
Table 2.2.: Consumables
Item Manufacturer
6 well tissue culture plates Sarstedt AG, Nümbrecht, Germany
24 well tissue culture plates Sarstedt AG, Nümbrecht, Germany
96 well tissue culture plates, flat bottom Corning Inc., Corning, New York, USA
transwell 24 well plates BD Biosciences, San Jose, California,
USA
Sterile pipettes (5 ml, 10 ml, 25 ml, 50 ml) Greiner Bio-One GmbH, Frickenhausen,
Germany
Sterile conical centrifuge tubes, PP (15
ml, 50 ml)
Greiner Bio-One GmbH, Frickenhausen
1,5 ml microcentrifuge tubes Sarstedt AG, Nümbrecht
Sterile filtered pipette tips (10 µl, 20 µl,
200 µl, 1000 µl)
Nerbe plus GmbH, Winsen/Luhe, Ger-
many
Pipette tips (1-10 µl, 2-200 µl, 100-1000
µl)
Nerbe plus GmbH, Winsen/Luhe, Ger-
many
8,0 µm cell culture inserts BD Biosciences, San Jose, California,
USA
Tissue culture flasks, (25 cm2, 75 cm2, 175
cm2)
Sarstedt AG, Nümbrecht, Germany
Tissue culture plates, 150 mm Sarstedt AG, Nümbrecht, Germany
Cell scraper, 1.7 mm blade Sarstedt AG, Nümbrecht, Germany
Cryo tubes, 2.0 mm, PP, sterile Sarstedt AG, Nümbrecht, Germany
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Table 2.2.: Consumables (continued)
Item Manufacturer
Scepter Sensors, 60 µm Merck Millipore, Billerica, Massachusetts,
USA
Microscopic slides Engelbrecht Medizin- und Labortechnik,
Edermünde, Germany
Cover slips Engelbrecht Medizin- und Labortechnik,
Edermünde, Germany
Pasteur pipettes, glass Brand GmbH, Wertheim, Germany
Nuclease-free microcentrifuge tubes (0.2
ml, 0.5 ml 1.5 ml)
Nerbe plus GmbH, Winsen/Luhe
Syringes (2 ml, 20 ml) Becton, Dickinson and Company, Franklin
Lakes, New Jersey, USA
Syringe filters, 0.45 µm pore size Filtropur S 0.45, PES-Membran, Sarstedt
AG, Nümbrecht, Germany
Syringe filters, 0.22 µm pore size Filtropur S 0.2, PES-Membran, Sarstedt
AG, Nümbrecht, Germany
2.3. Chemicals and reagents
2.3.1. Reagents
Table 2.3.: Chemicals and reagents
Product Manufacturer
2-propanol AppliChem, Darmstadt, Germany
4-iodophenylboronic acid (4-IPBA) Sigma-Aldrich, St. Louis, Missouri, USA
Acetic acid, glacial Merck, Darmstadt, Germany
Agarose, standard Carl Roth, Karlsruhe, Germany
Agarose, 4%, sterile Life Technologies, Carlsbad, California,
USA
AKASOLV Aqua Care Dr. Kilic AKADIA-CHEMIE, Mannheim,
Germany
Ammonium persulfate (APS) Carl Roth, Karlsruhe, Germany
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Table 2.3.: Chemicals and reagents (continued)
Product Manufacturer
β-mercaptoethanol Sigma-Aldrich, St. Louis, Missouri, USA
Bovine serum albumin, fraction V, molec-
ular biology grade
Carl Roth, Karlsruhe, Germany
Citric acid, anhydrous AppliChem, Darmstadt, Germany
Crystal violet Sigma-Aldrich, St. Louis, Missouri, USA
Cytoseal 60 Thermo Fisher Scientific, Waltham, Mas-
sachusetts, USA
Dimethyl sulfoxide (DMSO), cell culture
grade
Sigma-Aldrich, St. Louis, Missouri, USA
Disodium ethylenediaminetetraacetate
(Na2(EDTA)) dihydrate
Sigma-Aldrich, St. Louis, Missouri, USA
Ethanol, 70%, denatured Otto Fischar, Saarbrücken, Germany
Ethanol, anhydrous, molecular biology
grade
AppliChem, Darmstadt, Germany
Ethidium bromide solution (10 mg/ml) Sigma-Aldrich, St. Louis, Missouri, USA
Formaldehyde, 37%, analytical grade Merck, Darmstadt, Germany
Formalin, 4% Otto Fischar, Saarbrücken, Germany
Fugene 6 Roche Applied Science, Penzberg, Ger-
many
Glycerol Merck, Darmstadt, Germany
Glycine, synthetical quality Carl Roth, Karlsruhe, Germany
Hematoxylin solution, Harris modified Sigma-Aldrich, St. Louis, Missouri, USA
Hydrochloric acid Carl Roth, Karlsruhe, Germany
Igepal CA 630 Sigma-Aldrich, St. Louis, Missouri, USA
Luminol Sigma-Aldrich, St. Louis, Missouri, USA
Matrigel BD Biosciences, Franklin Lakes, New Jer-
sey, USA
Methanol, analytical grade AppliChem, Darmstadt, Germany
Nonfat dry milk Carl Roth, Karlsruhe, Germany
Nuclease-free water Life Technologies, Carlsbad, California,
USA
Phosphatase inhibitor cocktail 2 Sigma-Aldrich, St. Louis, Missouri, USA
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Table 2.3.: Chemicals and reagents (continued)
Product Manufacturer
Phosphatase inhibitor cocktail 3 Sigma-Aldrich, St. Louis, Missouri, USA
Ponceau S solution Sigma-Aldrich, St. Louis, Missouri, USA
Protease inhibitor cocktail Sigma-Aldrich, St. Louis, Missouri, USA
RotiLoad, 4 × loading dye Carl Roth, Karlsruhe, Germany
Rotiphorese NF-Acrylamide/ bis solution,
30% (29:1)
Carl Roth, Karlsruhe, Germany
Sodium dodecyl sulfate (SDS), molecular
biology grade
AppliChem, Darmstadt, Germany
Sodium acetate trihydrate Merck, Darmstadt, Germany
Sodium chloride, analytical grade AppliChem, Darmstadt, Germany
Sodium hydrogen carbonate (NaHCO3) Merck, Darmstadt, Germany
Sodium hydroxide, pellets Sigma-Aldrich, St. Louis, Missouri, USA
Sodium hydroxide solution, 5 N Carl Roth, Karlsruhe, Germany
Sodium deoxycholate Sigma-Aldrich, St. Louis, Missouri, USA
TEMED (N,N,N’,N’-Tetramethylene-
ethylenediamine)
Carl Roth, Karlsruhe, Germany
TRITON X-100 Sigma-Aldrich, St. Louis, Missouri, USA
Trizma base Sigma-Aldrich, St. Louis, Missouri, USA
Xylenes, histological grade AppliChem, Darmstadt, Germany
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2.3.2. Ready-made kits
Table 2.4.: Ready-made kits
Product Manufacturer
BCA Assay Thermo Fisher Scientific, Waltham, Mas-
sachusetts, USA
CellTiter 96 AQueous One Solution Cell
Proliferation Assay
Promega, Fitchburg, Wisconsin, USA
HumanHT-12v4.0 Expression Bead Ar-
rays
Illumina, San Diego, California, USA
Illumina Total Prep RNA Amplification
Kit
Illumina, San Diego, California, USA
LB Amp Ready Mix Fermentas by Thermo Fisher Scientific,
Waltham, Massachusetts, USA
LB Liquid Amp Ready Media Fermentas by Thermo Fisher Scientific,
Waltham, Massachusetts, USA
PureYield Plasmid Midiprep Promega, Fitchburg, Wisconsin, USA
QiaPrep Spin Miniprep Qiagen, Hilden, Germany
Qiashredder Qiagen, Hilden, Germany
RNase free DNase I Set Qiagen, Hilden, Germany
RNeasy Mini Kit Qiagen, Hilden, Germany
2.3.3. Biochemicals and enzymes
Table 2.5.: Biochemicals and enzymes
Product Manufacturer
dNTP Set, 100 mM Solutions Fermentas by Thermo Fisher Scientific,
Waltham, Massachusetts, USA
DreamTaq Green DNA Polymerase Fermentas by Thermo Fisher Scientific,
Waltham, Massachusetts, USA
FastDigest BamHI Fermentas by Thermo Fisher Scientific,
Waltham, Massachusetts, USA
High Capacity cDNA Reverse Transcrip-
tion Kit
Life Technologies, Carlsbad, California,
USA
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Table 2.5.: Biochemicals and enzymes (continued)
Product Manufacturer
Protein A agarose Sigma-Aldrich, St. Louis, Missouri, USA
Protein G plus agarose Santa Cruz Biotechnology, Santa Cruz,
California, USA
RiboLock RNase Inhibitor Fermentas by Thermo Fisher Scientific,
Waltham, Massachusetts, USA
Sonicated salmon sperm DNA Applichem, Darmstadt, Germany
SYBR Premix Ex Taq™ (Tli RNase H
Plus)
TaKaRa Bio Europe, Saint-Germain-en-
Laye, France
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2.4. Antibodies
Table 2.6.: Primary Antibodies
Primary antibodies for Immunohistochemistry
Antigen Clone/ catalogue no. Manufacturer
Cytokeratin mouse monoclonal, clones
AE1/AE3/ M3515
Dako, Glostrup, Denmark
EDN2 rabbit polyclonal/
NBP1-87942
Novus Biologicals, Littleton, Colorado,
USA
SAV1 mouse monoclonal, clone
3B2/ H00060485-M02
Abnova, Taipei City, Taiwan
YAP rabbit polyclonal/ 4912 Cell Signaling Technology, Danvers,
Massachusetts, USA
pYAP rabbit polyclonal/ 4911 Cell Signaling Technology, Danvers,
Massachusetts, USA
Primary antibodies for Western blot
Antigen Clone/ catalogue no. Manufacturer
GAPDH rabbit monoclonal, clone
14C10/ 2118
Cell Signaling Technology, Danvers,
Massachusetts, USA
LKB1 mouse monoclonal, clone
Ley 37/G6/ sc-32245
Santa Cruz Biotechnology, Santa
Cruz, California, USA
SAV1 mouse monoclonal, clone
3B2/ H00060485-M02
Abnova, Taipei City, Taiwan
TEF-1/TEAD1 mouse monoclonal, clone
H-4/ sc-376113
Santa Cruz Biotechnology, Santa
Cruz, California, USA
TEF4/TEAD2 rabbit polyclonal/ sc-67115 Santa Cruz Biotechnology, Santa
Cruz, California, USA
VGLL1 rabbit polyclonal/ ab48921 Abcam, Cambridge, United Kingdom
YAP rabbit polyclonal/ sc-15407 Santa Cruz Biotechnology, Santa
Cruz, California, USA
YAP rabbit polyclonal/ 4912 Cell Signaling Technology, Danvers,
Massachusetts, USA
pYAP rabbit polyclonal/ 4911 Cell Signaling Technology, Danvers,
Massachusetts, USA
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Primary antibodies for Chromatin Immunoprecipitation
Antigen Clone/ catalogue no. Manufacturer
Acetyl Histone
H3
rabbit polyclonal/ 06-599B Merck Millipore, Billerica,
Massachusetts, USA
normal rabbit
IgG
rabbit polyclonal/ PP64B Merck Millipore, Billerica,
Massachusetts, USA
normal mouse
IgG
mouse monoclonal, clone
3B2/ sc-69786
Santa Cruz Biotechnology, Santa
Cruz, California, USA
TEF-1/TEAD1 mouse monoclonal, clone
H-4/ sc-376113X
Santa Cruz Biotechnology, Santa
Cruz, California, USA
TEF4/TEAD2 rabbit polyclonal/
sc-67115X
Santa Cruz Biotechnology, Santa
Cruz, California, USA
YAP mouse monoclonal, clone
G-6/ sc-376830X
Santa Cruz Biotechnology, Santa
Cruz, California, USA
Table 2.7.: Secondary Antibodies
Secondary antibodies for Western blot
Antigen Clone/ catalogue
no.
Manufacturer
Rabbit IgG goat polyclonal,
HRP-coupled/ 7074
Cell Signaling Technology, Danvers,
Massachusetts, USA
Mouse IgG horse polyclonal,
HRP-coupled/ 7076
Cell Signaling Technology, Danvers,
Massachusetts, USA
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2.5. Plasmids
For the generation of stable knockdowns, clones expressing sequences for short hairpin
RNAs directed against mRNA of YAP1 were ordered from The RNAi Consortium (TRC)
Lentiviral shRNA Library, available at Open Biosystems, a branch of Thermo Scientific
Inc.. Two clones showing the best knockdown efficiency in preliminary experiments were
selected from a set of five and used in the experiments for this dissertation.
Table 2.8.: Plasmids
shRNA-plasmids
Name Mature antisense shRNA-sequence Source,
Reference
pLKO.1 Clone
TRCN0000107268
"YAPshRNA#4"
AAA GGA TCT GAG CTA TTG GTC Open Biosystems
by Thermo
Scientific, [161]
pLKO.1 Clone
TRCN0000107269
"YAPshRNA#5"
AAG GAT CTG AGC TAT TGG TCG Open Biosystems
by Thermo
Scientific, [161]
pLKO.1 empty vector Open Biosystems
by Thermo
Scientific, [161]
Packaging plasmids
Name Purpose Source,
Reference
pCMV-VSV-G carries sequence of the VSV-G protein for
pseudotyping of lentiviral particles
Addgene plasmid
no. 8454, [155]
pCMV-dR8.2 packaging plasmid for construction of
replication-deficient lentiviral particles
Addgene plasmid
no. 8455, [155]
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2.6. Oligonucleotides
Sequences for oligonucleotides were retrieved from published literature where indicated.
Primer sequences for RT-qPCR were retrieved from PrimerBank (http://pga.mgh.har-
vard.edu/primerbank/index.html) [152, 153, 170, 171]. Primers for ChIP-qPCR were
designed using Primer3 [87, 164] and blasted against the reference assembly of the human
genome provided by the GeneBank of the National Institute of Health, Bethesda, Mary-
land, USA (http://ncbi.nlm.nih.gov) to check for unintentional products on off-target
sequences. Parameters on Primer3 were set to meet the requirements of primers for RT-
qPCR experiments (length of oligonucleotides: 18-22 bp, product length: <150 bp, Tm:
58-62 ºC)
All primers were ordered at a synthesis scale of 25 nmoles from Life Technologies (Carls-
bad, California, USA). Oligonucleotides were desalted and shipped freeze-dried at room
temperature. They were reconstituted with nuclease-free water to obtain a 100 µM stock
solution (stored at -20 ºC) which was further diluted 1:10 into working solutions kept at
4 ºC. Concentration in PCR reactions was 0.5 µM unless indicated otherwise.
Table 2.9.: Oligonucleotides
Primer Sequence 5’ – 3’
Primers for PCR
Myco C GGG AGC AAA CAG GAT TAG ATA CCC
T
[165]
Myco D TGC ACC ATC TGT CAC TCT GTT AAC
CTC
[165]
Primers for RT-qPCR
CD74 sense CCG GCT GGA CAA ACT GAC A
CD74 antisense GGT GCA TCA CAT GGT CCT CTG
CDH6 sense AGA ACT TAC CGC TAC TTC TTG C
CDH6 antisense TGC CCA CAT ACT GAT AAT CGG A
CDK6 sense CCA GAT GGC TCT AAC CTC AGT
CDK6 antisense AAC TTC CAC GAA AAA GAG GCT T
CTGF sense AAA AGT GCA TCC GTA CTC CCA
CTGF antisense CCG TCG GTA CAT ACT CCA CAG
CYR61 sense GGT CAA AGT TAC CGG GCA GT
CYR61 antisense GGA GGC ATC GAA TCC CAG C
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Table 2.9.: Oligonucleotides(continued)
Primer Sequence 5’ – 3’
DUSP10 sense TGA AGC ACA CTC GGA TGA CC
DUSP10 antisense CCT CGA ACT CTA GCA ACT GCC
EDN1 sense AGA GTG TGT CTA CTT CTG CCA
EDN1 antisense CTT CCA AGT CCA TAC GGA ACA A
EDN2 sense CGT CCT CAT CTC ATG CCC AAG
EDN2 antisense AGG CCG TAA GGA GCT GTC T
F3 sense GGC GCT TCA GGC ACT ACA A
F3 antisense TTG ATT GAC GGG TTT GGG TTC
FOLR1 sense GCT CAG CGG ATG ACA ACA CA
FOLR1 antisense CCT GGC CCA TGC AAT CCT T
GADD45 sense TGC TGT GAC AAC GAC ATC AAC
GADD45 antisense GTG AGG GTT CGT GAC CAG G
GAPDH sense TGC ACC ACC AAC TGC TTA GC
GAPDH antisense GGC ATG GAC TGT GGT CAT GAG
IGFBP3 sense AGA GCA CAG ATA CCC AGA ACT
IGFBP3 antisense GGT GAT TCA GTG TGT CTT CCA TT
IGFBP5 sense TGA CCG CAA AGG ATT CTA CAA G
IGFBP5 antisense CGT CAA CGT ACT CCA TGC CT
KLF6 sense GGC AAC AGA CCT GCC TAG AG
KLF6 antisense CTC CCG AGC CAG AAT GAT TTT
MYC sense GTC AAG AGG CGA ACA CAC AAC
MYC antisense TTG GAC GGA CAG GAT GTA TGC
NDRG1 sense CTC CTG CAA GAG TTT GAT GTC C
NDRG1 antisense AGA GCC ATG TAA AGT CTC GAT GT
PLAC8 sense GTG TGA CTG TTT CAG CGA CTG
PLAC8 antisense CTG CAA CTT GAC ACC CAA GG
S100P sense AAG GAT GCC GTG GAT AAA TTG C
S100P antisense ACA CGA TGA ACT CAC TGA AGT C
SNX4 sense GAG TCA GAG CTA GAG TAG CAG AT
SNX4 antisense ATG GCA CTC CAT TCA CTG AAA A
TAGLN sense CCG TGG AGA TCC CAA CTG G
TAGLN antisense CCA TCT GAA GGC CAA TGA CAT
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Table 2.9.: Oligonucleotides(continued)
Primer Sequence 5’ – 3’
THBS1 sense AGA CTC CGC ATC GCA AAG G
THBS1 antisense TCA CCA CGT TGT TGT CAA GGG
VGLL1 sense TCA GAG TGA AGG TGT GAT GCT
VGLL1 antisense GCA CGG TTT GTG ACA GGT ACT
YAP1 sense TAG CCC TGC GTA GCC AGT TA
YAP1 antisense TCA TGC TTA GTC CAC TGT CTG T
Primers for ChIP-qPCR
GAPDH sense TAC TAG CGG TTT TAC GGG CG [108]
GAPDH antisense TCG AAC AGG AGG AGC AGA GAG CGA [108]
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2.7. Cell culture supplies
2.7.1. Cell culture reagents
Table 2.10.: Cell culture reagents
Basic media
DMEM, high glucose (4,5 g/l), stable
glutamine
PAA Laboratories, Pasching, Austria
DMEM, low glucose (1 g/l), stable
glutamine
Life Technologies, Carlsbad, California,
USA
M3 BaseA medium, with antibiotics Incell, San Antonio, Texas, USA
OptiMEM I Life Technologies, Carlsbad, California,
USA
RPMI 1640, stable glutamine PAA Laboratories, Pasching, Austria
Supplements
Reagent Manufacturer
recombinant human Endothelial Growth
Factor (EGF)
ReliaTech, Wolfenbüttel, Germany
Fetal calf serum (FCS), standard, heat
inactivated
PAA Laboratories, Pasching, Austria
MEM vitamin solution, 100 × Sigma-Aldrich, St. Louis, Missouri, USA
MEM Non-essential amino acids, 100 × PAA Laboratories, Pasching, Austria
Sodium pyruvate, 100 mM PAA Laboratories, Pasching, Austria
Antibiotics
Gentamycin 50 mg/ml, CELLPURE Carl Roth, Karlsruhe, Germany
Penicillin/Streptomycin, 10,000 I.U./ml
and 10,000 µg/ml
PAA Laboratories, Pasching, Austria
Plasmocin, 25 mg/ml Invivogen, San Diego, California, USA
Puromycin, 10 mg/ml Life Technologies, Carlsbad, California,
USA
Buffers and solutions
DPBS without Ca2+ or Mg2+ PAA Laboratories, Pasching, Austria
Trypsin-EDTA, 0.05 %/ 0.02 % in PBS PAA Laboratories, Pasching, Austria
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2.7.2. Cell culture media
Table 2.11.: Cell culture media
293FT medium
DMEM, high glucose (4,5 g/l), stable
glutamine
500 ml
FCS, heat inactivated 50 ml
MEM Non-essential amino acids 5.5 ml
Sodium pyruvate, 100 mM 5.5 ml
Penicillin/Streptomycin, 10,000 I.U./ml
and 10,000 µg/ml
5.5 ml
Plasmocin 25 mg/ml 100 µl
DMEM full medium
DMEM, high glucose (4,5 g/l), stable
glutamine
500 ml
FCS, heat inactivated 50 ml
Penicillin/Streptomycin, 10,000 I.U./ml
and 10,000 µg/ml
5.5 ml
Plasmocin 25 mg/ml 100 µl
HPNE medium
DMEM, low glucose (1 g/l), stable
glutamine
375 ml
M3 BaseA medium, with antibiotics 125 ml
FCS, heat inactivated 25 ml
Gentamycin 50 mg/ml 250 µl
rh EGF 10 µg/ml
Penicillin/Streptomycin, 10,000 I.U./ml
and 10,000 µg/ml
5.5 ml
Plasmocin 25 mg/ml 100 µl
RPMI full medium
RPMI 1640, stable glutamine 500 ml
FCS, heat inactivated 50 ml
Penicillin/Streptomycin, 10,000 I.U./ml
and 10,000 µg/ml
5.5 ml
Plasmocin 25 mg/ml 100 µl
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PL medium
DMEM, high glucose (4,5 g/l), stable
glutamine
500 ml
FCS, heat inactivated 50 ml
MEM vitamin solution 5.5 ml
MEM Non-essential amino acids 5.5 ml
Sodium pyruvate, 100 mM 5.5 ml
Penicillin/Streptomycin, 10,000 I.U./ml
and 10,000 µg/ml
5.5 ml
Plasmocin 25 mg/ml 100 µl
Cell lines transduced with lentivirus were selected by adding the appropriate, prede-
termined concentration of puromycin to the regular full cell culture medium. Selected
puromycin-resistant polyclonal cell lines were kept continuously in selection medium.
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2.7.3. Cell lines
Pancreatic cancer cell lines
Table 2.12.: PDAC cell lines
Cell line Catalogue No./
Reference
Source
AsPC-1 ATCC-CRL-1682 American Type Culture Collection,
Manassas, Virginia, USA
Description: AsPC-1 is an adherent cell line derived from malignant ascites of a
62-year-old Caucasian woman with pancreatic adenocarcinoma.
BxPC-3 ATCC-CRL-1687 American Type Culture Collection,
Manassas, Virginia, USA
Description: BxPC-3 is an adherent cell line derived from a pancreatic tumor of
a 61-year-old Caucasian woman with pancreatic adenocarcinoma.
Capan-1 ATCC-HTB-79 American Type Culture Collection,
Manassas, Virginia, USA
Description: Capan-1 is an adherent cell line derived from the liver metastasis
of a 40-year-old Caucasian man with pancreatic adenocarcinoma.
CFPAC ATCC-CRL-1918 American Type Culture Collection,
Manassas, Virginia, USA
Description: CFPAC is an adherent cell line derived from the liver metastasis of a
26-year-old Caucasian man with pancreatic ductal adenocarcinoma
and cystic fibrosis.
E3LZ10.07
(syn. A10.7)
[30],
[39]
Kindly provided by Prof. Dr. Anirban
Maitra, Johns Hopkins University,
Baltimore, Maryland, USA
Description: E3LZ10.07 is an adherent cell line derived from the liver metastasis
of a 60-year-old man with pancreatic ductal adenocarcinoma.
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Table 2.12.: PDAC cell lines (continued)
Cell line Catalogue No./
Reference
Source
L3.6pl [18] Kindly provided by Prof. Dr. Anirban
Maitra, Johns Hopkins University,
Baltimore, Maryland, USA
Description: L3.6pl is a highly metastatic adherent cell line derived via sev-
eral cycles of in vivo-selection of the human pancreatic adenocarci-
noma cell line COLO357 in nude mice. COLO357 cells were derived
from the lymph-node metastasis of a 77-year-old African-American
woman with pancreatic ductal adenocarcinoma [110].
MIAPaCa-2 ATCC-CRL-1420 American Type Culture Collection,
Manassas, Virginia, USA
Description: MIAPaCa-2 is an adherent cell line derived from the pancreatic
tumor of a 65-year-old Caucasian man with pancreatic cancer.
PANC-1 ATCC-CRL-1469 American Type Culture Collection,
Manassas, Virginia, USA
Description: PANC-1 is an adherent cell line derived from the pancreatic ductal
tumor of a 56-year-old Caucasian man with pancreatic epithelioid
carcinoma.
Panc 1.98
(syn. Pa20C)
[30] Kindly provided by Prof. Dr. Anirban
Maitra, Johns Hopkins University,
Baltimore, Maryland, USA
Description: Panc 1.98 is an adherent cell line derived from the primary pancre-
atic tumor of a 69-year-old man with pancreatic ductal adenocar-
cinoma.
Panc 10.05 ATCC-CRL-2547 American Type Culture Collection,
Manassas, Virginia, USA
Description: Panc 10.05 is an adherent cell line derived from the pancreatic tu-
mor of an adult Caucasian man with pancreatic adenocarcinoma.
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Table 2.12.: PDAC cell lines (continued)
Cell line Catalogue No./
Reference
Source
PK9 [83] Kindly provided by Prof. Dr. Anirban
Maitra, Johns Hopkins University,
Baltimore, Maryland, USA
Description: PK9 is an adherent cell line derived from a tumor of the head of
the pancreas of a patient with moderately differentiated tubular
adenocarcinoma of the pancreas.
Su86.86 ATCC-CRL-1837 American Type Culture Collection,
Manassas, Virginia, USA
Description: Su86.86 is an adherent cell line derived from the liver metastasis of
a 57-year-old Caucasian woman with pancreatic ductal adenocarci-
noma.
SW 1990 ATCC-CRL-2172 American Type Culture Collection,
Manassas, Virginia, USA
Description: SW 1990 is an adherent cell line derived from the splenic metastasis
of a 56-year-old Caucasian man with pancreatic adenocarcinoma.
All human pancreatic cancer cell lines were cultured in PL medium, see 2.11. Lentivirally
transduced Panc 10.05 or PK9 cells were selected in PL medium containing 3.0 µg/ml
puromycin and maintained continuously in selection medium.
Cholangiocellular carcinoma cell lines
Table 2.13.: CCC cell lines
Cell line Catalogue No./
Reference
Source
G-415 [88] Kindly provided by Prof. Dr. Anirban
Maitra, Johns Hopkins University,
Baltimore, Maryland, USA
Description: G-415 is an adherent cell line derived from malignant ascites of a
68-year-old man with gallbladder adenocarcinoma.
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Table 2.13.: CCC cell lines (continued)
Cell line Catalogue No./
Reference
Source
GBD-1 [147],
[98]
Kindly provided by Prof. Dr. Anirban
Maitra, Johns Hopkins University,
Baltimore, Maryland, USA
Description: GBD-1 is an adherent cell line derived from a lymph-node metasta-
sis of a 58-year-old man with poorly differentiated adenocarcinoma
of the gallbladder.
HuCCT-1 [109] Kindly provided by Prof. Dr. Anirban
Maitra, Johns Hopkins University,
Baltimore, Maryland, USA
Description: HuCCT-1 is an adherent cell line derived from malignant ascites
of a 56-year-old man with moderately differentiated intrahepatic
cholangiocellular carcinoma.
Nec [40],
[41]
Kindly provided by Prof. Dr. Ulrich
Spengler, Rheinische
Friedrich-Wilhelms-Universität, Bonn,
Germany
Description: Nec is an adherent cell line derived via in vivo-selection of the
human cholangiocellular adenocarcinoma cell line ETK-1 by serial
transplantation in nude mice. ETK-1 cells were derived from the
malignant ascites of a 64-year-old Japanese patient with intrahep-
atic cholangiocellular carcinoma [40].
RBE [40],
[41]
Kindly provided by Prof. Dr. Ulrich
Spengler, Rheinische
Friedrich-Wilhelms-Universität, Bonn,
Germany
Description: RBE is an adherent cell line derived from the malignant ascites of
a 64-year-old Japanese woman with intrahepatic cholangiocellular
carcinoma.
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Table 2.13.: CCC cell lines (continued)
Cell line Catalogue No./
Reference
Source
SNU308 [91] Korean Cell Line Bank, Seoul National
University College of Medicine, Seoul,
Korea
Description: SNU308 is an adherent cell line derived from the primary tumor of
a Korean patient with moderately differentiated adenocarcinoma of
the gallbladder.
SNU478 [91] Korean Cell Line Bank, Seoul National
University College of Medicine, Seoul,
Korea
Description: SNU478 is an adherent cell line derived from the primary tumor of
a Korean patient with poorly differentiated adenocarcinoma of the
ampulla of Vater.
TFK-1 ACC-344 and
[136]
Leibniz Institute-DSMZ German
Collection of Microorganisms and Cell
Cultures, Braunschweig, Germany
Description: TFK-1 is an adherent cell line derived from the primary tumor
of a 63-year-old male patient with extrahepatic cholangiocellular
carcinoma.
All human biliary cancer cell lines were cultured in RPMI full medium, see 2.11. Lentivi-
rally transduced Nec or G-415 cells were selected in RPMI full medium containing 3.0
µg/ml puromycin and maintained continuously in selection medium.
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Renal cell carcinoma cell lines
Table 2.14.: RCC cell lines
Cell line Catalogue No./
Reference
Source
A498 ATCC-HTB-44 American Type Culture Collection,
Manassas, Virginia, USA
Description: A498 is an adherent cell line derived from the primary tumor of a
52-year-old female patient with renal cell carcinoma.
ACHN ATCC-CRL-1611 American Type Culture Collection,
Manassas, Virginia, USA
Description: ACHN is an adherent cell line derived from the malignant pleu-
ral effusion of a 22-year-old Caucasian male patient with widely
metastatic renal adenocarcinoma.
Caki-2 ATCC-HTB-47 American Type Culture Collection,
Manassas, Virginia, USA
Description: Caki-2 is an adherent cell line derived from the primary tumor
of a 69-year-old Caucasian male patient with clear cell renal cell
carcinoma.
MZ1774 [143] Kindly provided by Prof. Dr. Peter
Brossart, Rheinische
Friedrich-Wilhelms-Universität, Bonn,
Germany
Description: MZ1774 is an adherent cell line derived from the primary tumor of
a patient with renal cell carcinoma.
B1 [163] Kindly provided by Prof. Dr. Ingo
Schmidt-Wolf, Rheinische
Friedrich-Wilhelms-Universität, Bonn,
Germany
Description: B1 is an adherent cell line derived from the primary tumor of a
patient with renal cell carcinoma.
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Table 2.14.: RCC cell lines (continued)
Cell line Catalogue No./
Reference
Source
B3 [163] Kindly provided by Prof. Dr. Ingo
Schmidt-Wolf, Rheinische
Friedrich-Wilhelms-Universität, Bonn,
Germany
Description: B3 is an adherent cell line derived from the primary tumor of a
patient with renal cell carcinoma.
RCC177 [148] Kindly provided by Prof. Dr. Ingo
Schmidt-Wolf, Rheinische
Friedrich-Wilhelms-Universität, Bonn,
Germany
Description: RCC177 is an adherent cell line derived from the primary tumor of
a patient with renal cell carcinoma.
Human RCC cell lines A498, Caki-2, MZ1774, B1, B3, and RCC177 were cultured in
RPMI full medium (see 2.11) while ACHN was maintained in DMEM full medium (see
2.11) Lentivirally transduced A498, MZ1774 or ACHN cells were selected in RPMI or
DMEM full medium containing 3.0 µg/ml puromycin and continuously maintained in
selection medium.
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Other cell lines
Table 2.15.: Other cell lines
Cell line Catalogue No./
Reference
Source
293FT R700-07 Life Technologies, Carlsbad, California,
USA
Description: The 293FT Cell Line is derived from the 293F Cell Line and stably
expresses the SV40 large T antigen from the pCMVSPORT6TAg.neo
plasmid. Expression of the SV40 large T antigen is controlled by
the human cytomegalo-virus (CMV) promoter and is high-level and
constitutive. Studies have demonstrated maximal virus production
in human 293 cells expressing SV40 large T antigen [115], making
the 293FT cell line a suitable host for generating lentiviral constructs.
The parental 293 cell line is a permanent line established from primary
embryonal human kidney transformed with sheared human adenovirus
type 5 DNA [50]. 293FT cells were used in this study as a host cell
line to generate lentiviral particles.
hTERT-
HPNE
ATCC-CRL-4023 American Type Culture Collection,
Manassas, Virginia, USA
Description: The hTERT-HPNE cell line was developed from normal human pan-
creatic ductal cells of a healthy 52-year-old male donor by transduc-
tion with a retroviral expression vector (pBABEpuro) containing the
hTERT gene. The infected cells became positive for telomerase, failed
to senesce, and continued to proliferate. HPNE cells were found to
have properties of the intermediary cells formed during acinar-to-
ductal metaplasia, which included their undifferentiated phenotype,
expression of Nestin and, evidence of active Notch signaling. HPNE
cells were used as a normal control cell line alongside malignant PDAC
cell lines.
293FT cells were maintained in 293FT medium (2.11) as per instructions provided by the
distributor. Human pancreatic nestin-expressing (HPNE) cells were cultured as previously
described by Lee et al. [94], see 2.11.
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2.8. Experimental animals
2.8.1. CD1nu/nu-mice
Nude mice were first discovered in 1962, when a spontaneous mutation in the FOXN1
gene caused the hairless "nude" phenotype [46]. This mutation also causes the absence
of a functional thymus, therefore the animals cannot generate mature T-cells and are
unable to mount most immune responses adequately. This immune-defect makes them
suitable hosts for tumor-xenograft studies because they fail to mount an adequate immune
response against foreign tissue and therefore tolerate and maintain growing human cancer
cells.
The CD1nu/nu strain was developed from the transfer of the nude gene from Crl:NU-
Foxn1nu to a CD-1 mouse through a series of crosses and backcrosses beginning in 1979
at Charles River, Wilmington, MA.
For xenograft experiments, six-week-old, male CD1nu/nu mice were ordered from Charles
River, Wilmington, Massachusetts, USA and kept in the laboratory animal facility of the
University of Bonn („Haus für Experimentelle Therapie“ HET) in specific pathogen free
(SPF) conditions. The animals were provided with food and water ad libitum.
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2.9. Solutions and buffers
Stock Solutions
Table 2.16.: 1 M Tris-HCl, pH 7.4
Component Composition
Trizma base 121.14 g
ultrapure water ad 1.0 l
Dissolve in approximately 800 ml ultra-
pure water, adjust pH to 7.4 with con-
centrated hydrochloric acid. Fill up to
1.0 l with ultrapure water.
Table 2.17.: 1.0 M Tris-HCl, pH 8.0
Component Composition
Trizma base 121.14 g
ultrapure water ad 1.0 l
Dissolve in approximately 800 ml ultra-
pure water, adjust pH to 8.0 with con-
centrated hydrochloric acid. Fill up to
1.0 l with ultrapure water.
Table 2.18.: 0.5 M Tris-HCl, pH 6.7
Component Concentration
Trizma base 60.57 g
ultrapure water ad 1.0 l
Dissolve in approximately 800 ml ultra-
pure water, adjust pH to 6.7 with con-
centrated hydrochloric acid. Fill up to
1.0 l with ultrapure water.
Table 2.19.: 1.5 M Tris-HCl, pH 8.8
Component Concentration
Trizma base 181.71 g
ultrapure water ad 1.0 l
Dissolve in approximately 800 ml ultra-
pure water, adjust pH to 8.8 with con-
centrated hydrochloric acid. Fill up to
1.0 l with ultrapure water.
Table 2.20.: 250 mM EDTA, pH 8
Component Concentration
Na2 EDTA × 2 H2O 23.26 g
ultrapure water ad 250.0 ml
Dissolve in approx. 200 ml ultrapure wa-
ter, adjust pH to 8 with 5 N NaOH. Fill
up to 250.0 ml with ultrapure water.
Table 2.21.: 10% (w/v) SDS
Component Concentration
SDS 10 g
ultrapure water ad 100.0 ml
Dissolve in approx. 80 ml ultrapure wa-
ter. Fill up to 100.0 ml with ultrapure
water.
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Table 2.22.: 250 mM Luminol
Component Amount
Luminol 443 mg
DMSO ad 10.0 ml
Dissolve in DMSO and distribute into
260 µl aliquots. Store aliquots at -20 ºC
Table 2.23.: 90 mM 4-IPBA
Component Amount
4-IPBA 1115 mg
DMSO ad 50.0 ml
Dissolve in DMSO and distribute into
1150 µl aliquots. Store aliquots at -20 ºC
General Buffers and Solutions
Table 2.24.: 0.05% (w/v) Crystal vi-
olet solution
Component Concentration
Crystal violet 250 mg
ultrpure water ad 500.0 ml
Dissolve in approx. 400 ml ultrapure wa-
ter. Fill up to 500.0 ml with ultrapure
water.
Table 2.25.: 10 × citrate buffer, pH
6.0 (IHC)
Component Amount Conc.
Citric acid 19.2 g 100 mM
ultrapure water ad 1.0 l
Dissolve in approx. 800 ml ultrapure wa-
ter, adjust pH to 6.0 with 5 N NaOH fill
up to 1.0 l with ultrapure water.
Table 2.26.: 10 × TBS, pH 8.0
Component Amount Conc.
1 M Tris HCl,
pH 8.0
100.0 ml 100 mM
NaCl 48.15 g 825 mM
ultrapure water ad 1.0 l
Dissolve in approx. 800 ml ultrapure wa-
ter, fill up to 1.0 l with ultrapure water.
Table 2.27.: 10 × TBS, pH 7.4
Component Amount Conc.
1 M Tris HCl,
pH 7.4
100.0 ml 100 mM
NaCl 48.15 g 1.5 M
ultrapure water ad 1.0 l
Dissolve in approx. 800 ml ultrapure wa-
ter, fill up to 1.0 l with ultrapure water.
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Table 2.28.: TBST 0.01%
Component Composition
10 × TBS 100.0 ml
Tween 20 1 ml
ultrapure water ad 1.0 l
Dilute 1:10 with ultrapure water and
add Tween 20.
Table 2.29.: 50 × TAE-buffer
Component Amount conc.
Trizma base 242.0 g 40 mM
Glacial acetic
acid
57.1 ml 20 mM
500 mM EDTA,
pH 8
100 ml 1 mM
ultrapure water ad 1.0 l
Dissolve in approx. 800 ml ultrapure wa-
ter, fill up to 1.0 l with ultrapure water.
Table 2.30.: 10% APS (w/v)
Component Amount
APS 1.0 g
ultrapure water ad 10.0 ml
Dissolve in ultrapure water to a final vol-
ume of 10.0 ml and distribute into 100
µl aliquots and store at -20 ºC
Table 2.31.: PMSF
Component Amount Conc.
PMSF 871 mg 100 mM
Ethanol, anhy-
drous
ad 50.0 ml
Dissolve in anhydrous ethanol to a final
volume of 50.0 ml and store at -20 ºC
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Buffers for Western blot
Table 2.32.: Stacking gel buffer, pH
6.8
Component Amount Conc.
Trizma base 45.4 g M
10 % SDS 13.39 ml
ultrapure water ad 500.0 ml
Dissolve in approx. 400 ml ultrapure wa-
ter, adjust pH to 6.8 with concentrated
hydrochloric acid. Fill up to a final vol-
ume of 500.0 ml with ultrapure water.
Table 2.33.: Separating gel buffer,
pH 8.8
Component Amount Conc.
Trizma base 18.9 g M
10 % SDS 13.39 ml
ultrapure water ad 500.0 ml
Dissolve in approx. 400 ml ultrapure wa-
ter, adjust pH to 6.8 with concentrated
hydrochloric acid. Fill up to a final vol-
ume of 500.0 ml with ultrapure water.
Table 2.34.: 10 × Running buffer
Component Amount Conc.
Trizma base 30 g 250 mM
Glycine 144 g 1.92 M
SDS 10 g 1 % (w/v)
ultrapure water ad 1.0 l
Dissolve in ultrapure water to a final vol-
ume of 1.0 l
Table 2.35.: 10 × Transfer buffer
Component Amount Conc.
Trizma base 30 g 250 mM
Glycine 144 g 1.92 M
ultrapure water ad 1.0 l
Dissolve in ultrapure water to a final vol-
ume of 1.0 l
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Table 2.36.: RIPA lysis buffer
Component Amount conc.
Igepal CA 630 2.5 ml 1%
Sodium deoxy-
cholate
1.25 g 0.5%
10 % SDS 2.5 ml 0.1 %
250 mM EDTA 2.0 ml 2 mM
DPBS ad 250.0 ml
Dissolve in DPBS to a final volume of
250.0 ml
Table 2.37.: ECL solution
Component Amount Conc.
1.5 M Tris-HCl,
pH 8.8
3.3 ml 100 mM
250 mM Lumi-
nol
250 µl 1.25 mM
90 mM 4 IPBA 1111 µl 2 mM
ultrapure water ad 50.0 ml
Dissolve in ultrapure water to a final vol-
ume of 50.0 ml and store at 4 ºC pro-
tected from light. Add 0.5 µl of 30 %
H2O2 freshly to each milliliter of solution
before use.
Table 2.38.: Western blot stripping
buffer
Component Concentration
β-Mercaptoethanol 1.74 ml
10% SDS 50 ml
0.5 M Tris HCl,
pH 6.7
31.3 ml
ultrapure water ad 250.0 ml
Dissolve to a final volume of 250.0 ml in
ultrapure water. Store protected from
light.
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Solutions for Chromatin Immunoprecipitation (ChIP)
All solutions for ChIP were prepared with nuclease-free water.
Table 2.39.: 3M Sodium acetate, pH
5.5
Component Concentration
Sodium acetate ×
3 H2O
3 M
Dissolve and adjust pH to 5.5 with acetic
acid.
Table 2.40.: 1.5M Tris-HCl, pH 8
Component Concentration
Trizma base 1.5 M
Dissolve and adjust pH to 8.0 with con-
centrated hydrochloric acid.
Table 2.41.: 0.5M EDTA, pH 8
Component Concentration
Na2 EDTA × 2 H2O 0.5 M
Dissolve and adjust pH to approx. 8
with 5N NaOH.
Table 2.42.: 10% SDS
Component Concentration
SDS 10% (w/v)
Dissolve in water.
Table 2.43.: 5 M NaCl
Component Concentration
NaCl 5 M
Dissolve and adjust pH to approx. 8
with 5N NaOH.
Table 2.44.: ChIP quencher
Component Concentration
Glycine 2.5 M
Dissolve in water.
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Table 2.45.: ChIP lysis buffer
Component Concentration
SDS 1% (w/v)
Tris-HCl, pH 8 50 mM
EDTA 20 mM
Dissolve and dilute in water.
Table 2.46.: ChIP sonication buffer
Component Concentration
SDS 0.25% (w/v)
NaCl 200 mM
sonicated salmon
sperm DNA
0.1 mg/ml
Dissolve and dilute in water.
Table 2.47.: ChIP dilution buffer
Component Concentration
SDS 0.01% (w/v)
EDTA, pH 8 1.2 mM
Tris HCl, pH 8 16.7 mM
TRITON X-100 1.1% (w/v)
NaCl 167 mM
Dissolve and dilute in water.
Table 2.48.: ChIP wash buffer A
Component Concentration
SDS 0.1%
EDTA, pH 8 2 mM
Tris HCl, pH 8 20 mM
TRITON X-100 1%
NaCl 150 mM
Dissolve and dilute in water.
Table 2.49.: ChIP wash buffer B
Component Concentration
SDS 0.1%
EDTA, pH 8 2 mM
Tris HCl, pH 8 20 mM
TRITON X-100 1%
NaCl 500 mM
Dissolve and dilute in water.
Table 2.50.: ChIP TE buffer
Component Concentration
EDTA, pH 8 1 mM
Tris HCl, pH 8 10 mM
Dissolve and dilute in water.
Table 2.51.: ChIP elution buffer
Component Concentration
SDS 1%
NaHCO3, pH 8 100 mM
Dissolve and dilute in water.
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2.10. Software
Table 2.52.: Software
Name Purpose Source
JabRef reference manager,
v. 2.9.2
Reference management and
bibliography
Open source,
downloaded from
http://jabref.sourceforge.net
GIMP - The GNU Image
Manipulation Program, v.
2.6.6
Image editing Open source, downloaded
from http://www.gimp.org
Image Lab, v. 2.0 build 8 Image acquisition and edit-
ing
Bio-Rad Laboratories, Her-
cules, California, USA
Microsoft© Excel 2008 for
Mac, v. 12.3.6
Data analysis Microsoft Corporation,
Redmond, Washington,
USA
Optima Microplate Reader
Software Package, v.
2.2OR2
Data acquisition BMG Labtech, Ortenberg,
Germany
Pannoramic Viewer, v.
1.15.2
Image analysis 3DHISTECH Kft., Bu-
dapest, Hungary
Prism4 for Macintosh, v.
4.0a
Statistical analysis, graphic
processing
GraphPad Software Inc., La
Jolla, California, USA
SPSS Statistical analysis, data
mining
IBM Deutschland GmbH,
Ehningen, Germany
TextMate, v. 1.5.11 Text editing using LATEX MacroMates Ltd., Limassol,
Cyprus
Realplex, v. 2.2 Data acquisition and analy-
sis
Thomson Reuters, New
York City, New York, USA
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3.1. Cell culture methods
3.1.1. Culturing cell lines from cryoconserved freezebacks
Cryoconserved aliquots of cell lines were taken from storage in ultra-deep freezers and
rapidly defrosted by incubation in a 37 ºC warm waterbath. The liquid cell suspension
was mixed with 9 ml pre-warmed full growth medium and cells were pelleted at 300 × g
and room temperature (RT) for 5 minutes. Cell pellets were resuspended in full growth
medium and cells were seeded into T25 or T75 tissue culture flasks, depending on cell
number and age of freezebacks and subsequently incubated at 37 ºC, 5% CO2, and 90%
relative humidity (rH).
3.1.2. Trypsinization and subculture of cell lines
Adherent cells were grown in a monolayer in T75 tissue culture flasks and cell culture
medium was changed every 2-3 days. Once cells reached 80-90% confluency, the monolayer
was washed twice with 10 ml DPBS without Ca2+ or Mg2+ and incubated with 2 ml of
0.05% Trypsin-EDTA solution for 3-5 minutes at 37 ºC, 5% CO2, and 90% rH. Single cell
suspensions were transferred into sterile 15 ml conical tubes after addition of 8 ml full
growth medium per flask to stop the trypsin-reaction. Cells were pelleted at 300 × g
and RT for 5 minutes and cell pellets were resuspended in 10 ml full growth medium. To
subculture cell lines, 1-2 ml of the cell suspension were seeded into T75 tissue culture flasks
containing 8 or 9 ml of full growth medium to achieve a ratio of 1:5 or 1:10, respectively
and transferred back to the incubator.
3.1.3. Cryoconservation of cell lines
Cells were trypsinized and pelleted after addition of 8 ml full growth medium to stop
the trypsin-reaction. Cells were pelleted at 300 × g and RT for 5 minutes. Cell pellets
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were resuspended in cryomedium to achieve a cell concentration of roughly 2.5 × 106 cells
per ml. Cell suspensions were distributed to cryotubes and transferred inside a freezing
container to the -80 ºC freezer to ensure gradual freezing (-1 ºC/minute). Cryotubes were
subsequently transferred to the -150 ºC freezer for long-term storage.
3.1.4. Cell count using the Scepter automated cell counter
Cells were trypsinized and single cell suspensions were prepared as described above. Small
aliquots of the suspensions were diluted 1:5 or 1:10 in microcentrifuge tubes with full
growth medium or DPBS. Cells were counted using the Scepter 2.0 handheld automated
cell counter with 60 µm sensors according to the manufacturer’s instructions. Cell concen-
trations were adjusted for the dilution factor and cell suspensions were used in downstream
experiments.
3.1.5. Monitoring of cultures for Mycoplasma sp. infection
Apart from employing appropriate aseptic techniques while working with mammalian cell
cultures as well as prophylactic application of an antimycoplasma active agent to the cell
culture media, cells in culture were routinely monitored for infection with Mycoplasma
sp. by screening for contamination with Mycoplasma-DNA present in the cell culture
supernatant via polymerase chain reaction (PCR). The method was developed by van
Kuppeveld et al. [165] and the primers cover the most common strains. An aliquot of
200 µl cell culture medium was removed after incubation with the cells for at least 48 h
and inactivated by incubation at 95 ºC for 10 minutes. 2 µl of this preparation was used
as template for the PCR reaction and both positive and negative controls were included.
Table 3.1.: PCR reaction mix:
Reagents Concentration
PCR Buffer 10 ×
MgCl2 50 mM
dNTP-Mix 10 mM
Primer Mix 1 µM
Template DNA 2 µl per reaction
Nuclease-free water µl per reaction
DreamTaq Polymerase 0.5 U per reaction
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Table 3.2.: PCR program (33 cycles)
Temperature [ºC] Time [s]
94 180
94 30
55 30
72 45
PCR products were analyzed by electrophoresis on a 2 % agarose gel. Only proven
non-contaminated cell lines were used in experiments.
3.2. Molecular biology methods
3.2.1. Generation of shRNA-mediated YAP-knockdowns
Purpose In order to characterize the role of the YAP protein, cell lines expressing
high basal levels of YAP were selected and YAP was stably downregulated by RNA-
interference techniques. The impact of the YAP-downregulation on the phenotype and
the transcriptional program of the cell lines was then analyzed in in vitro and in vivo
experiments.
Heat shock-transformation of ONEShot TOP10/P3 cells and propagation of
plasmids in E.coli
ONEShot TOP10/P3 competent E.coli cells were thawed on ice and 1-10 µl plasmid DNA
(overall amount < 10 µg) was added to the cells. After gentle mixing, cells were incubated
on ice for 30 minutes. A heat shock was performed by immersing the tubes containing
cells and DNA for 30 s in a water bath (42 ºC) and placing them on ice immediately after
this. Cells were incubated in a shaker incubator for 60 minutes at 37 ºC, 225 rpm upon
addition of 250 µl SOC medium per tube. A 100 µl aliquot of the culture was streaked
on LB agar plates containing 50 µg/ml ampicillin and plates were incubated at 37 ºC
overnight. Single colonies were picked and inoculated with 5 ml LB medium containing
50 µg/ml ampicillin overnight at 37 ºC, 225 rpm. Plasmids were extracted from these
pre-cultures and the identity of the plasmids was confirmed by restriction digest and
subsequent gel electrophoresis. An aliquot of the pre-culture was inoculated with 100 ml
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LB medium containing µg/ml ampicillin at a 1:1000 ratio and was placed inside the shaker
incubator at 37 ºC, 225 rpm for overnight incubation. For long-term storage, aliquots of
the pre-culture were mixed with 15% sterile glycerol and shock-frozen in liquid nitrogen.
Extraction of plasmids
Plasmid extraction from 5 ml pre-cultures was performed using the Qiaprep Spin Mini-
prep Kit according to the manufacturer’s instructions. Plasmids from larger culture vol-
umes were extracted using the PureYield Plasmid Midi-prep System and vacuum manifold
as per the manufacturer’s instructions. Concentration and purity of the extracts was de-
termined spectrophotometrically using a NanoDrop UV-spectrophotometer.
Restriction digest of plasmid-DNA
To identify plasmids after colony picking and purification, restriction digest of the plasmid
extracts was performed. The pLKO.1-, pCMV-dR8.74 and VSVg plasmids were digested
using Fast Digest BamHI.
Table 3.3.: Restriction digest reaction mix:
Component Volume [µl]
Nuclease-free water 15
10 × FastDigest Green buffer 2
Template DNA 2
FastDigest BamHI 1
The reaction mix was prepared at room temperature, mixed gently and briefly cen-
trifuged to collect the liquid at the bottom of the tube. The reaction was incubated
at 37 ºC for 5 minutes and thermal inactivation was performed at 80 ºC for 5 minutes.
Fragment size was analyzed via gel electrophoresis on a 2% agarose gel.
Production of lentiviral particles
Lentiviral particles were produced by cotransfection of the pCMV-VSVg, pCMV-dR8.74
and the respective pLKO.1 plasmids into the human embryonic kidney cell line 293FT.
293FT cells were seeded into 24 well plates at a concentration of 50,000 cells/well. After
overnight incubation to ensure adherence of cells, medium was exchanged and Fugene 6
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mediated transfection was performed 4 hours later. First Fugene 6 was mixed with serum-
free OptiMEM medium and incubated at room temperature for 5 minutes and incubation
was continued for additional 20 minutes upon addition of plasmid DNA.
Table 3.4.: Fugene 6 transfection mix:
Component Amounts per well
Fugene 6 6 µl
OptiMEM 15 µl
pCMV-dR8.74 125 ng
pCMV-VSVg 50 ng
pLKO.1 200 ng
Upon completion of incubation, the Fugene-DNA complex was added drop-wise to each
well and plates were returned to the incubator for overnight incubation at 37 ºC, 5%
CO2, and 90% rH. Medium was exchanged the next morning and replaced with 500 µl
fresh medium and plates were returned to the incubator. On the third day, supernatants
containing lentiviral particles were collected, supernatants from multiple wells containing
the same parental plasmids were pooled, and filtered using a syringe filter with 0.45 µm
pore size. Supernatants containing lentiviral particles were aliquoted and stored at -80 ºC
for future use. 500 µl fresh medium was added per well and plates were returned to the
incubator. Harvest of lentiviral supernatants was repeated the following day after which
cells were discarded. All steps were carried out following biosafety level 2 regulations and
consumables waste was destroyed by autoclaving.
Determination of puromycin sensitivity of tumor cell lines Recipient human tumor
cell lines were seeded at a density of 200,000 cells/well into 6 well tissue culture plates.
After overnight incubation to ensure adherence of cells, puromycin containing medium was
added at the following concentrations (2 wells per concentration): 0.0 µg/ml, 0.1 µg/ml,
0.2 µg/ml, 0.4 µg/ml, 0.6 µg/ml, 0.8 µg/ml, 1.0 µg/ml, 1.25 µg/ml, 1.5 µg/ml, 2.0
µg/ml, 2.5 µg/ml, 3.0 µg/ml. Cells were monitored for 10 days and the lowest puromycin
concentration achieving 100% cytotoxicity was chosen for selection of resistant cells upon
lentiviral transduction.
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Lentiviral transduction of tumor cell lines Parental human tumor cell lines were
seeded at a density of 200,000 cells/well and incubated overnight at 37 ºC, 5% CO2,
and 90% rH to ensure adherence of cells. Following exchange of medium on the next
morning, cells were transduced with 500 µl (high titer) or 50 µl (low titer) of lentiviral
supernatant. Plates were returned to the incubator for another 48 hours and medium
was exchanged to medium containing the predetermined concentration of puromycin.
Puromycin selection of resistant tumor cells was performed and cells were cultured in the
presence of puromycin throughout all experiments. Low passage, polyclonal, lentivirally
transduced cell lines were frozen for future use. All steps were carried out following
biosafety level 2 regulations and consumables waste was destroyed by autoclaving.
3.2.2. RNA isolation
RNA extraction from cultured cells
Cells were harvested as per general cell culture protocol and were washed once with DPBS.
Cells were lysed in RLT buffer spiked 1:1000 with β-Mercaptoethanol and the lysate was
homogenized using QiaShredder columns. RNA was extracted using the RNeasy Mini
kit as per the manufacturer’s specifications including an on-column DNA digest step
using Qiagen’s RNase-free DNase I Set. RNA was eluted using 30-50 µl of nuclease-
free water and RNA concentration was measured using the NanoDrop instrument. RNA
concentration was adjusted to 50 ng/µl with nuclease-free water and stored at -80 ºC.
RNA extraction from tissues
Freshly harvested xenograft tumor tissue was snap-frozen in liquid nitrogen and finely
ground using a pre-chilled mortar and pestle. Ground, frozen tissue was transferred into
a chilled microcentrifuge tube and lysed in RLT buffer spiked 1:1000 with β-mercapto-
ethanol and the lysate was homogenized using QiaShredder columns. RNA was extracted
using the RNeasy Mini kit as per the manufacturer’s specifications including an on-column
DNA digest step using Qiagen’s RNase-free DNase I Set. RNA was eluted using 30-50 µl
of nuclease-free water and RNA concentration was measured using the NanoDrop instru-
ment. RNA concentration was adjusted to 50 ng/µl with nuclease-free water and stored
at -80 ºC.
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3.2.3. Transcriptomic profiling
Microarray experiments were carried out on Illumina Bead Arrays by Dr. Per Hoffmann
of the core facility of the Institute of Human Genetics, University Hospital of Bonn. Raw
data was generated and retrieved from the core facility and data analysis was performed
by Dr. Moritz Kebschull of the Department of Periodontology, Operative and Preventive
Dentistry of the University Hospital of Bonn.
Hybridization to Illumina Bead Arrays and data acquisition
An amount of 100 ng total RNA was subjected to a single round of in vitro transcription
and biotin labeling using the Illumina TotalPrep RNA Amplification Kit. The resulting
cRNA was hybridized on HumanHT-12 v4.0 Expression BeadArrays according to the
manufacturers protocols using an automated liquid handling pipeline and scanned on an
iScan System.
Data analysis
Expression data were exported as unnormalized sample and control probe profiles from
the Illumina GenomeStudio software and analyzed using R/ Bioconductor [47] and limma
[151]. Data were quality weighed, backgroundcorrected, quantilenormalized, logtrans-
formed and explored for differentially expressed genes with a Benjamini-Hochberg
false discovery rate (FDR) of 0.05 using Bayesian statistics. Differential regulation of
signaling pathways was performed using the signaling pathway impact analysis algorithm
as described by Tarca et al. [159].
Experimental details and results following the Minimum Information About a Microar-
ray Experiment (MIAME) standards are available at the Gene Expression Omnibus (ac-
cession number GSE50053) [17].
3.2.4. Reverse transcription quantitative Polymerase Chain
Reaction (RT-qPCR)
cDNA generation
RNA was reverse transcribed using random primers and the High Capacity cDNA Reverse
Transcription Kit according to the manufacturer’s specifications.
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RT-qPCR
Reverse transcription quantitative PCR was performed using the SYBR© Premix Ex
Taq™ (Tli RNase H Plus) kit on a Reaplex2 Mastercycler real-time PCR system. Relative
fold levels were determined using the 2(−DeltaDeltaCt) method [101], with GAPDH used as
house-keeping control.
3.3. Cell biology methods
3.3.1. Cell viability assay (MTS-assay)
Principle Determination of cell viability was performed using the 3-(4,5-dimethyl-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)-assay. This colori-
metric method employs the tetrazolium derivative 3-(4,5-dimethyl-2-yl)-5-(3-carboxymeth-
oxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium and phenazine ethosulfate as an electrocoup-
ling reagent. The tetrazolium derivative is reduced by NADPH or NADH produced in
metabolically active cells into a colored formazan product that is soluble in tissue cul-
ture medium [7]. The quantity of the formazan product is determined photometrically at
490 nm and is directly proportional to the number of living cells in culture [27].
Procedure Cells were trypsinized and the cell number was determined as described
above. Cell suspensions were adjusted to c = 10,000 cells/ ml and 200 µl cell suspension
was seeded per well into flat bottom 96 well plates. Following overnight incubation in
full growth medium to ensure adherence of the cells to the surface of the vessel, medium
was exchanged to 100 µl full growth or low serum medium as per experimental layout
and plates were incubated for additional 0, 48 and 96 hours. All experiments were set up
in quadruplicates and results were normalized to the mean cell viability at 0 hours. For
experimental readout at specified time points, 20 µl CellTiter 96 Aqueous One solution
was added to each well and absorbance at 492 nm was determined using a 96 well plate
reader upon incubation of plates at 37 ºC, 5% CO2, and 90% rH for 2 hours.
3.3.2. Replating efficiency assay
Principle The ability to form colonies from single cells is considered a hallmark property
of cancer cells in vitro. The replating efficiency assay assesses the extent of this property.
Single cell suspensions are diluted to 500-1000 cells per milliliter and seeded into normal
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culture vessels at very low densities to prevent cell-cell contact. Cultures are kept for a
defined length of time and the number of colonies formed from single are counted.
Procedure Cells were trypsinized and the cell number was determined as described
above. Cell suspensions were adjusted to c = 500 cells/ ml and 2 ml cell suspension was
seeded per well in full growth medium into 6 well plates. Once colonies became visible,
cells were fixed for with 70% ethanol for 2 minutes and stained with a 0,05% aqueous
solution of crystal violet for 2 minutes. Plates were washed twice with 2 ml DPBS and
stained colonies were air-dried. Images of colonies were acquired by trans-UV illumination
using a gel documentation system and ImageLab software. Colonies were counted and
colony counts were normalized to the mean colony count of mock-transduced cell lines.
3.3.3. Soft-Agar assay
Principle In the process of metastasis, single cancer cells detach from the parental tumor
and the surrounding matrix, translocate into the bloodstream and establish a filial tumor
from a single cell at a distant site. The ability of cells to survive in the absence of a
stable surface to anchor with – extracellular matrix proteins in vivo or tissue culture
treated plastic surfaces in vitro – is termed anchorage-independent growth. The loss of
anchorage-dependency in epithelial cells correlates with the ability to form tumors in
animal models and is considered a strong indicator of malignant transformation [142].
This assay measures the ability of cells to form colonies in a matrix of soft agar that
doesn’t provide a solid phase substrate to attach to.
Procedure Cells were trypsinized and the cell number was determined as described
above. Cell suspensions were adjusted to c = 50,000 cells/ ml. Soft-Agar Assays were set
up in six-well plates with a bottom layer of 1% agarose, an intermediate layer containing
0,6% agarose and 10,000 cells per well, as well as a final layer of medium only. Plates
were incubated for 4 weeks at 37 ºC and medium was exchanged once per week. Upon
termination of the experiment, medium was removed and plates were incubated for two
hours with 2 ml of a 0,05% aqueous solution of crystal violet at 37 ºC, 5% CO2, and 90%
rH. Plates were washed twice with 2 ml DPBS per well and colonies were visualized by
trans-UV illumination using the gel documentation system. Colonies were counted and
colony counts were normalized to the mean colony count of mock-transduced cell lines.
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3.3.4. Boyden chamber assays
Principle Cell migration is defined as the directed movement of cells on a 2D-substrate,
such as basal membrane, extracellular matrix in vivo or the plastic surface of a culture
vessel in vitro [90]. The assay used in this study was first developed by Boyden in 1962
to analyze the migratory capacity of leukocytes in response to chemotactic cues [16]. The
principle relies on two medium-containing chambers separated by a porous membrane.
Importantly, the pores have to be smaller than the migrating cells in order to rule out
passive "drop"-effects and assess only active transmigration. Cells are seeded into the
upper chamber, migrate horizontally towards the next available pore, and transmigrate
vertically into the lower chamber. The assay used in this study relies on the principle
established by Boyden but uses ready-made inserts containing membranes with 8 µm
pores for an easy set-up.
Procedure Boyden Chamber assays were set up in 24-well transwell plates with 8 µm
pore size cell culture inserts. Cells were trypsinized and the cell number was determined
as described above. Cell suspensions were adjusted to c = 50,000 cells/ ml and 1 ml cell
suspension per well was applied into the cell culture insert resting in one well of the plate
on 1 ml of full growth medium. Transwell migration was assessed after 48 and 72 hours
incubation at 37 ºC, 5% CO2, and 90% rH. Cells adherent at the bottom of the filter
were fixed in 70% ethanol and stained with hematoxyllin. Cells were counted in three
randomly selected microscopic fields and means and standard deviations were calculated.
3.3.5. Generation of s.c. xenografts
Principle Human to mouse tumor xenografts are an important means to study tumori-
genicity of certain tumor cell lineages as well as the molecular genetics of human cancer
because they accurately mirror the entire spectrum of genetic alterations of the neoplastic
cell compartments of the human parental tumors. To generate human to mouse tumor
xenografts, patient-derived tumor tissue or human cancer cells are either injected or sur-
gically implanted into immunocompromised mouse strains, usually either athymic Nude
mice, who lack a functional T cell system or Severe Combined Immunodeficient (SCID)
mice, who present with highly impaired T and B cell immune responses. Because of their
respective immune defects, those mice tolerate the xenotransplanted cells and allow the
foreign cells to proliferate. While this model represents a unique platform to study genetic
mutations and aberrations, the xenogenic system naturally fails to appropriately depict
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features of the disease normally conveyed by the tumor microenvironment, especially
effects conferred by the host immune system [141].
Procedure All animal experiments described were approved by the Government of the
State of North Rhine-Westphalia. Mice were maintained according to the guidelines of the
Federation of European Laboratory Animal Science Associations (FELASA). To generate
subcutaneous xenografts, ACHN YAP-knockdown and ACHN mock-transfected cells in
log growth phase were harvested by trypsinization, counted and subsequently injected into
the flanks of five male athymic CD1nu/nu mice, each. 2.5 × 106 cells suspended in a total
volume of 250 µL [full growth medium/ Matrigel (BD Biosciences), 1:1 (v/v), pre-chilled
to 4ºC], were subcutaneously injected into the flanks of 6 to 8 weeks old mice. Starting ten
days after the injection of tumor cells, tumor dimensions were determined twice a week
by use of digital calipers, and tumor volumes (V) were determined as V = 1/2(ab2), with
a being the longest and b the shortest orthogonal tumor diameter. Mice were sacrificed
by incubation with CO2 after six weeks and tumors were harvested and cryopreserved or
formalin-fixed for later analysis.
3.4. Immunological methods
3.4.1. Immunohistochemistry
Tumor tissue samples
All tumor samples were collected from the archives of the Institutes of Pathology of the
Universities of Bonn (PDAC and CCC cases) and Cologne (ccRCC cases). The sam-
ples were formalin fixed and paraffin embedded as part of routine diagnostic procedures.
Clinicopathological data was obtained from case records provided by the Institutes of
Pathology, Universities of Bonn and Cologne, respectively. All tumors were clinically and
pathologically identified as being the primary and only neoplastic lesion and classified
according to WHO guidelines.
Generation of Tissue Micro Arrays (TMA)
Tissue microarrays were constructed from paraffin-embedded tissue blocks of pancreatic
ductal adenocarcinomas and their companion normal tissues as described initially by
Sauter et al. [86]. Three 0.5 mm core needle samples of the preexisting paraffin-embedded
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Figure 3.1.: Generation of Tissue Micro Arrays (TMA) Spots in the recipient block
are targeted using the microdials of the tissue arrayer (a) and a hole is drilled into the recipient
block with the drilling arm of the tissue arrayer (b). Tissue cores are punched using the punching
arm (c) and transferred to the recipient block (d). Tissue cores are inserted seamlessly into the
recipient block (e). Finished TMA (f).
tissues from each tumor and companion normal tissue specimen were obtained and then
re-embedded in an arrayed master block using a manual tissue arrayer. For a description
of the procedure see Figure 3.1.
Immunohistochemistry
Paraffin-embedding of formalin-fixed tissues as well as cutting the paraffin-embedded tis-
sue into sections was performed by the diagnostic laboratories as part of routine diagnostic
procedures by the Institutes of Pathology of the University of Bonn or Cologne. Immuno-
histochemistry was performed at the same place either on a Dako Techmate 500 using
the Dako REAL Detection System, Peroxidase/AEC, Rabbit/Mouse-Kit (Bonn) or on a
LabVision 480S using the Histofine Simple Stain Mouse MAX PO kit (Cologne).
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Table 3.5.: Antibodies and conditions used for Immunohistochemistry
Antibody Dilution Antigen Retrieval
YAP 1:100 Citrate buffer, pH 6; pressure cooker
pYAP 1:500 Citrate buffer, pH 6; pressure cooker
SAV1 1:100 Citrate buffer, pH 6; pressure cooker
EDN2 1:100 Citrate buffer, pH 6; pressure cooker
Cytokeratin 1:200 Citrate buffer, pH 6; pressure cooker
Evaluation of staining intensity Stained slides of TMAs were scanned with a Pan-
noramic 250 slide scanner and staining was reviewed using the "Pannoramic Viewer"-
software. Staining intensity was evaluated individually in a blinded fashion using a four-
tiered scoring system.
Table 3.6.: Scoring system
Staining intensity Score
absent immunoreactivity 0
weak immunoreactivity 1
intermediate immunoreactivity 2
strong immunoreactivity 3
Correlation with clinicopathologic parameters and statistical analysis was performed
using IBM SPSS Statistics 21 for Windows.
3.4.2. Western blot
Protein extraction Cells were trypsinized, pelleted and the cell pellets were washed
with DPBS. Cells were lysed in Radioimmunoprecipitation assay buffer supplemented with
protease and phosphatase inhibitor cocktails (200 µl lysis buffer per T75 tissue culture
flask). In case of cryopreserved tumor tissue, frozen tissue chunks were pulverized in
liquid nitrogen using mortar and pestle and ground tissue was lysed in 200 µl lysis buffer.
Lysates were incubated on ice for 30 minutes and vortexed every 10 minutes. Lysates
were cleared by centrifugation at 20,000 × g, 4 ºC for 30 minutes and supernatants were
collected. Estimation of protein concentration was carried out using the bicinchoninic acid
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(BCA) assay on aliquots that had been diluted with lysis buffer at a ratio of 1:5. Lysates
were aliquoted to avoid multiple freeze-thaw cycles and stored at -80 ºC for long-term
storage.
Gelelectrophoresis and transfer 50 µg of total protein was mixed with loading dye,
loaded on 10% SDS-polyacrylamide gels, and electrophoresed at 100 V until the front had
migrated within the last centimeter of the gel. Separated proteins were transferred onto
nitrocellulose membranes at 250 mA for 52 minutes. Successful transfer was controlled by
performing Ponceau S staining of the membranes. Membranes were blocked in 5% BSA
to prevent unspecific binding.
Probing, reprobing and detection The blots were probed with antibodies against
YAP (Cell Signaling, Danvers, MA) and GAPDH (Cell Signaling) as well as secondary,
HRP-coupled antibodies directed against rabbit or mouse IgG, respectively (Cell Signal-
ing). Detection was performed using a solution of 4-iodophenylboronic acid (4IPBA) and
luminol [53]. Concentration and medium of antibodies used are shown below.
Table 3.7.: Antibodies and conditions used for Western blot
Antibody Dilution Blocking reagent
YAP 1:200 5% BSA in TBS-T
pYAP 1:500 5% BSA in TBS-T
GAPDH 1:1000 5% BSA in TBS-T
goat anti-rabbit IgG-HRP 1:2000 5% BSA in TBS-T
SAV1 1:500 5% NFDM in TBS-T
LKB1 1:500 5% NFDM in TBS-T
MST2 1:5000 5% BSA in TBS-T
3.4.3. Chromatin Immunoprecipitation (ChIP)
Principle
Chromatin Immunoprecipitation (ChIP) was developed as a tool to investigate direct
interactions between proteins and DNA, such as transcription factors, polymerases and
DNA-modifying enzymes. Initially designed to explore interactions between RNA poly-
merase II and transcribed and poised genes in Escherichia coli and Drosophila [48, 121]
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the technique was further developed and adapted for use in mammalian cells [123]. To-
day ChIP is a highly valuable method for the characterization of chromatin-interacting
proteins.
Cells are grown in the desired experimental conditions and growing cells are reversibly
crosslinked using formaldehyde, thus preserving a "snapshot" of protein-chromatin inter-
actions at a given time-point. The chromatin is subsequently extracted and sheared by
sonication to obtain fragments ranging between 200-1000 bp in size. The pre-cleared chro-
matin is immunoprecipitated with the antibody of choice and those chromatin fragments
bound to the antibody are pulled down using protein A/G coupled agarose beads. Cross-
linking is reversed thermically, bound protein is digested and DNA is purified to obtain the
starting material for analysis of those regions of the genome that interact with the protein
of interest. The analysis can be qualitative or quantitative, for example by comparing the
level of enrichment for a putative transcription factor binding site in the promotor region
of a candidate target gene of a given transcription factor in two experimental conditions by
quantitative realtime PCR (qPCR). Using next-generation sequencing technologies, the
eluate of immunoprecipitated DNA-fragments can be mapped onto the reference genome
of a given species and the transcriptional landscape of a transcription factor at a given
timepoint can be analyzed quite conclusively. Figure 3.2 on page 76 provides a stepwise
overview of the technique while a detailed summery of the experimental procedure is given
below.
In this study, ChIP was employed to determine whether the transcriptional coactivator
YAP interacts with the promotor region of specific candidate target genes in clear cell
renal cell carcinoma (ChIP-qPCR).
Cross-link and cell collection
Cells were seeded into 150 mm round tissue culture dishes and grown in a monolayer to
approximately 70% confluency. Fresh 37% formaldehyde was added to a final concentra-
tion of 1% and cells were fixed at room temperature for 8 minutes with gentle agitation.
Residual formaldehyde was quenched by addition of 2.5 M glycine to a final concentration
of 125 mM into the medium and incubation for 5 minutes at room temperature. Upon
completion of incubation, cells were placed on ice and washed twice with ice-cold DPBS.
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Figure 3.2.: Experimental workflow of ChIP, compiled according to [108]
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Lysis and sonication
The monolayer of cells was covered with 1.5 ml of DPBS supplemented with protease- and
phosphatase inhibitor cocktails and cells were removed from the wall of the culture vessel
using a cell scraper. The cell suspension was collected in 15 ml conical tubes and cells were
pelleted for 5 minutes at 3000 rpm and 4 ºC. The cell pellet was resuspended in 500 µl
ChIP lysis buffer and incubated for 10 minutes on ice to break up the cell membrane and
release the nuclei which were collected by centrifugation at 3000 rpm for 5 minutes at
15 ºC. The pellet containing the nuclei was resuspended in 500 µl ChIP sonication buffer
and incubated for 15 minutes on ice. The 15 ml conical tube containing the cell lysates
were fixed using clamps and submerged into iced water. The chromatin was sonicated
using a Branson 450 SLPe probe sonicator to obtain fragments ranging from 200-1000 bp.
Preliminary experiments were performed to determine optimal shearing conditions for the
cell lines analyzed. The precise parameters are given below:
Table 3.8.: Sonication conditions for ChIP
Cell line Concentration Amplitude No. of Duration Duration
(cells/ml) cycles ′ON ′ ′OFF ′
MZ1774 2×107 50% 5 15 s 60 s
PK9 1×107 1st: 65% 1st: 2 10 s 55 s
2nd: 50% 2nd: 3
The correct fragment size distribution of the sheared, cross-linked chromatin was verified
by performing electrophoresis of an aliquot (10 µl) of reverse-cross-linked, sheared DNA
in a 1% agarose gel.
Immunoprecipitation and elution
The sheared, cross-linked chromatin was incubated for two hours at 4 ºC with a mixture of
20 µl protein G PLUS-agarose and 40 µl protein A-agarose that were washed once with 400
µl ChIP dilution buffer in order to minimize unspecific binding to the agarose beads. The
pre-cleared chromatin was removed from the beads and diluted 1:10 with ChIP dilution
buffer. 800 µl diluted chromatin were incubated overnight with the indicated amount of
primary antibody at 4 ºC under continuous rotation. One aliquot of 800 µl was marked
”Input” and conserved at -20 ºC.
77
3. Methods
Table 3.9.: Antibody conditions for ChIP
Antibody Isotype Amount per IP
Acetyl-Histone H3 rabbit polyclonal 10 µg
normal rabbit IgG rabbit polyclonal 10 µg
YAP mouse monoclonal 10 µg
TEF-1 (TEAD1) mouse monoclonal 10 µg
normal mouse IgG mouse monoclonal 10 µg
For all immunoprecipitations using primary antibodies raised in rabbit (i.e. anti-Acetyl-
Histone H3 and rabbit IgG), 40 µl protein A-agarose beads were blocked by incubating
them with 400 µl ChIP dilution buffer supplemented with 0.5 mg/ml BSA and 0.1 mg/ml
salmon sperm DNA overnight at 4 ºC with continuous rotation. All other immunopre-
cipitations using primary antibodies raised in mouse were carried out using pre-blocked
protein G PLUS-agarose. In these cases, 20 µl of protein G PLUS-agarose was put di-
rectly into the samples. In order to pull down those DNA-fragments bound to primary
antibody, pre-blocked protein A- or protein G PLUS-agarose beads were added to the cor-
responding samples and incubated at 4 ºC for two hours with continuous rotation. Upon
completion of incubation the immune-precipitated complexes were washed five times with
400 µl of ChIP wash buffer A, four times with 400 µl of ChIP wash buffer B, and once
with 400 µl of ChIP TE buffer. After washing, the immune-precipitated complexes as
well as 1/10 of the Input-sample were incubated under continuous rotation with 200 µl
ChIP elution buffer for 15 minutes at room temperature. This step was repeated once
and the supernatants of both incubation steps were combined to obtain 400 µl of eluate.
Reversal of cross-links and DNA purification
In order to reverse the protein-DNA cross-links, NaCl was added to a final concentration
of 200 mM and samples were incubated overnight with gentle agitation at 65 ºC. 20 µg
of each Proteinase K and RNase A were added to each sample the next morning and the
mixtures were incubated at 45 ºC for two hours.
Upon completion of incubation DNA was extracted using the phenol/chloroform-method.
One volume of phenol/chloroform/isoamylic alcohol (25:24:1) was added to each sample
and mixed by shaking vigorously for one minute. After centrifugation for 10 minutes at
>20 000×g, the aqueous supernatants containing DNA were transferred to new micro-
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centrifuge tubes and 1/10 volume of 3 M sodium acetate stock and 20 µg of glycogen as
a carrier for the DNA was added to the aqueous phase which was then mixed with 2,5
volumes of absolute ethanol and placed overnight at -20 ºC for precipitation of DNA.
The next morning, the precipitated DNA was pelleted by centrifugation at >20 000×g,
4 ºC for 40 minutes and the pellets were rinsed with ice-cold 70% ethanol (prepared from
absolute ethanol). DNA was again pelleted by centrifugation at >20 000×g, 4 ºC for 25
minutes and the pellets were air-dried upon careful decantation of the supernatant before
they were resuspended in 20 µl of nuclease-free water.
DNA-analysis by ChIP-qPCR
Real Time quantitative PCR was performed using the SYBR® Premix Ex Taq™ (Tli
RNase H Plus) kit on a Reaplex2 Mastercycler real-time PCR System. Relative fold
levels were determined using the 2(−DeltaDeltaCt) method [101], with results normalized to
the normal IgG controls.
3.5. Statistical analysis
Fisher’s exact test and two-tailed Student’s t-tests were done using GraphPad Prism for
Macintosh, version 4.0a. P < 0.05 was regarded to be statistically significant. Unless
indicated otherwise, results are shown as mean ± standard error of the mean (SEM).
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4.1. Nuclear YAP expression is frequent in patients
with PDAC, biliary carcinoma and ccRCC
Deregulation of the Hippo pathway is frequently observed in a wide variety of human
malignancies [64]. Although the effect of this perturbance becomes easily observable in
the form of YAP derepression and consecutive nuclear overexpression by neoplastic cells,
the underlying cause remains elusive and even enigmatic. For several tumor entities
subgroups have been described where nuclear YAP overexpression can be attributed to
the loss-of-function of specific members of the canonical Hippo pathway or other, non-
canonical upstream interaction partners. In almost all of these cases, these loss-of-function
mutations cannot provide a comprehensive explanation for every instance, where nuclear
YAP overexpression is observed [64]. This points to a potentially widespread deregulation
of the upstream signaling network reflecting the extensive array of upstream signals feeding
into the core signaling cassette and the many direct interaction partners of YAP.
In the following chapter, the frequency of Hippo pathway perturbation as measured by
nuclear YAP overexpression is determined using immunohistochemistry on collections of
tumor tissue samples of patients with PDAC, biliary carcinoma and ccRCC. For those
tumor entities there is only limited data on the status of the Hippo-target YAP available so
far. In a second step, hypotheses concerning the potential mechanisms of Hippo pathway
perturbation with regard to specific members of the upstream YAP-interaction partners
(both canonical and non-canonical) are made and tested either by immunohistochemistry
on patient samples or immunoblotting on cell line extracts.
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4.1.1. Analysis of nuclear YAP expression and disruption of Hippo
signaling in PDAC
YAP is frequently overexpressed in PDAC patients
YAP has been shown to be overexpressed in PDAC tissues, although studies have been
limited in scope and only evaluated 20 or 64 patients, respectively [33, 34]. In order
to evaluate the expression status of YAP in PDAC, tissue microarrays were constructed
containing samples of tumor and matched adjacent normal tissue of 145 patients who un-
derwent surgery at the University Hospital of Bonn between 1999 and 2009. Anonymized
clinicopathological data was recovered from case records kept at the archives of the In-
stitute of Pathology at the University Hospital Bonn. Staining was evaluable for the
tumor samples of 143 patients and staining of the adjacent normal tissue was available of
128 patients. As shown in Figure 4.1 on page 82, YAP is frequently strongly expressed
in the nuclei of PDAC patients whereas strong nuclear expression was only occasionally
observed in normal pancreatic ducts. Intriguingly, the hierarchy of the pancreatic duc-
tal architecture is highlighted by a gradient of YAP expression with centroacinar cells
and neoductuli displaying the strongest nuclear and cytoplasmic YAP immunoreactivity,
which then gradually decreases in smaller towards larger pancreatic ducts, where nuclear
YAP expression is hardly detectable (see 4.1 A, C & E).
High nuclear YAP expression correlates with nodal stadium in PDAC patients
Next, correlation of nuclear YAP immunoreactivity with clinicopathological parameters
was examined. Anonymized clinicopathological data concerning tumor grade, stage and
nodal status as well as staining intensities were compiled for each case and fed into SPSS
for statistical analysis. The relationship between nuclear YAP staining intensities and each
parameter was calculated using three different statistical models, the Pearson product-
moment correlation coefficient, Kendall’s tau rank correlation coefficient as well as Spear-
man’s rank correlation coefficient, in order to include both linear and non-parametric
statistical models.
81
4. Results & Discussion
Figure 4.1.: Nuclear overexpression of YAP in PDAC patients. Shown are examples
of YAP immunolabeling of normal ductal epithelium (A, C, E) and neoplastic tissue (B, D, F;
images are shown in 100 × magnification) of three representative cases of PDAC. The first case
exhibits weak to moderate staining (predominantly cytoplasmic) in normal pancreatic ductal
epithelium of larger ducts in tumor-adjacent normal tissue (A) with strong, predominantly nu-
clear staining in corresponding samples of PDAC (B). Weak to negative nuclear or cytoplasmic
YAP immunoreactivity in normal ductal epithelium (C) was associated with moderate to strong
nuclear and cytoplasmic YAP expression in the corresponding tumor samples (D) in a second
exemplary case of PDAC. Thirdly, weak cytoplasmic and negative nuclear staining in normal
ductal epithelium (E) coupled with strong cytoplasmic and weak nuclear immunoreactivity in
corresponding tumor samples (F) were likewise detected, as shown in this third case of PDAC.
Although an inter-individual variation in staining patterns as illustrated by the examples above
was observed, overall statistical analysis of staining intensity in all 143 cases revealed that YAP
shows predominantly nuclear expression in PDAC with moderate to strong staining in approx.
85% of all cases examined (G, n=143) with only approx. 48% of adjacent normal tissue (epithe-
lial cells of larger pancreatic ducts) exhibiting moderate to strong nuclear staining (H), that was
mostly accompanied by equally strong cytoplasmic staining.
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Table 4.1.: Correlation of nuclear YAP expression with clinicopathological parameters in PDAC
patients
Nuclear YAP score Pearson Kendall’s Spearman’s
(tumor cells) Corr.
coeff.
p tau p rho p
0 1 2 3
G 1 0 0 1 0 0,069 0,42 0,062 0,447 0,065 0,447
2 1 9 24 30
3 2 4 32 37
pT I 0 0 1 1 0,089 0,295 0,087 0,277 0,092 0,277
II 1 3 3 3
III 3 9 52 62
IV 0 1 1 1
pN 0 4 5 15 14 0,205 0,024 0,162 0,062 0,171 0,061
1 2 8 32 42
While the nuclear immunoreactivity for YAP in PDAC tumor cells does not correlate
with tumor grade or stage, moderate to high nuclear YAP expression is significantly more
frequent in patients who display lymph node metastases at the time of surgery using the
statistical model of Pearson’s product-moment correlation coefficient (Pearson’s r = 0,205,
p = 0,024), while just failing to meet the criteria of statistical significance in both Kendall’s
tau rank correlation coefficient (Kendall’s tau = 0,162, p = 0,062) and Spearman’s rank
correlation coefficient (Spearman’s rho = 0,171, p = 0,061).
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Analysis of protein expression in a panel of PDAC-cell lines
A panel of 13 pancreatic cancer cell lines as well as the immortalized normal pancreatic
ductal cell line HPNE were subjected to Western blot analysis. Basal YAP-expression was
observed in non-malignant hTERT-HPNE cells and almost all PDAC cell lines examined
with the exception of Capan-1 (Figure 4.2).
Figure 4.2.: Expression of YAP and interaction partners in a panel of PDAC-cell
lines. Displayed are images of two Western blots analyzing two different aliquots of the same
protein extracts of the indicated pancreatic cancer cell lines. GAPDH-expression was used to
confirm loading of equal amounts of total protein.
Protein expression levels varied greatly, ranging from strong signals (PK9, Panc 10.05
and L3.6pl) to barely detectable bands (AsPC-1). Notably, the immortalized normal
pancreatic ductal cell line HPNE displayed high basal levels of YAP, inconsistent with
the histological findings. This might be due to the transformation process needed to
create the immortalized cell line.
The liver kinase B1 (LKB1) is a tumor suppressor which has been implicated in the
pathogenesis of familial pancreatic cancer and is the underlying mutation in Peutz-Jeghers
Syndrome, a hereditary disease predisposing for the formation of pancreatic cancer (refer
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to page 11). Recently, LKB1 has been shown to control phosphorylation and subsequent
degradation of YAP in a mechanism that was independent of the canonical core cassette
[118]. In order to evaluate a potential pathomechanistic relationship in PDAC, the mem-
branes were subsequently probed with antibodies targeting pYAP and LKB1. While there
is no correlation observable across the board, and most cell lines display robust LKB1-
expression, LKB1 is lost in L3.6pl cells. While information on the mutational status of
the LKB1-gene in L3.6pl cells was not available and the cause of the loss of this protein
is speculative, the pYAP/YAP expression ratio appears to be low in L3.6pl cells, which
is consistent with decreased YAP-phosphorylation. The TEAD family of transcription
factors has been described as the principal partner of YAP to elicit its oncogenic, pro-
proliferative and proinvasive properties and there is considerable overlap in promotors
occupied by both YAP and TEAD1 in the breast cancer cell line MCF10A [93, 183].
The expression of the family member TEF-1 (TEAD1) could be detected in all cell lines
examined with the exception of SW1990, although expression levels were variable.
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4.1.2. Analysis of nuclear YAP expression and disruption of Hippo
signaling in CCC patients
Analysis of YAP-protein expression in 14 CCC patients by immunohistochemistry
Formalin fixed and paraffin embedded tumor and adjacent normal tissue of fourteen pa-
tients with biliary carcinoma who had undergone surgery at the University Hospital of
Bonn between 2004 and 2008 were analyzed with regard to YAP expression status by
immunohistochemistry (see Table 4.2 on page 87). As observed in normal pancreatic
tissue, the hierarchy of the branches of the biliary tree is represented by a gradient of
YAP protein expression with small ducts exhibiting strong nuclear immunoreactivity and
larger ducts displaying only weak nuclear staining. Oval cells, which form the precursor
cell department within the liver and are able to differentiate into hepatocytic as well as
cholangiocytic lineages, stain highly positive for YAP as previously described for murine
tissue [95]. Kupffer cells, which form a specialized macrophage cell compartment within
the space of Dissé are equally highlighted by strong YAP expression.
Within the premalignant and malignant cell compartment, cells that had undergone
metaplasia stained positive, while neoplastic cells exhibited a more complex staining pat-
tern. In general, YAP was expressed by the majority of CCC tumors analyzed and
staining intensity seemed to increase with degree of differentiation with highly differenti-
ated tumors exhibiting strong nuclear staining and poorly differentiated tumors exhibiting
weaker nuclear YAP levels (see Figure 4.3 on page 88 and Table 4.2 on 87). Curiously,
tumors with histological features close to those of hepatic precursor or stem cells (oval
cells) stained highly positive for YAP, somewhat contradicting the previous observation.
Cancer associated fibroblasts residing in the tumor adjacent stroma were often found to
contain a marked amount of nuclear YAP (Figure 4.3, B). While it is speculative to re-
port correlations with regard to the small number of tumors examined, YAP highlighted
formations of invasive tumor cells in those cases where perineural invasion or lymph node
metastases were present (patients 3, 4, 5 and 10, see Figure 4.3, E-H). In some cases, the
YAP content of these cells was decidedly elevated as compared to the main tumor (e.g.
patient 10).
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Table 4.2.: Expression of YAP in tumor tissue of biliary cancer patients
Patient Diagnosis Score
Tumor Normal
cytoplasmic nuclear cytoplasmic nuclear
1 perihilar CCC 1 0 1 1
2 extrahepatic CCC 0 2 0 1
3 perihilar CCC 1 1 1 0
4 extrahepatic CCC 1 1 1 2
5 extrahepatic CCC,
highly differentiated
0 0 0 0
6 intrahepatic CCC 1 1 0 1
7 intrahepatic CCC,
stem cell histology
0 2 0 0
8 extrahepatic CCC 1 0 0 2
9 extrahepatic CCC 0 1 0 2
10 intrahepatic CCC 1 2 0 0
11 CCC, stem cell histol-
ogy
1 2 1 1
12 extrahepatic CCC 1 2 1 2
13 intrahepatic CCC,
highly differentiated
0 1 0 2
14 CCC 2 0 2 0
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Figure 4.3.: YAP is highly expressed by tumors of the biliary tract and highlights
invasive tumor cell formations. Nuclear YAP expression is observable in the majority of
CCC tumors analyzed. Shown are HE stainings and YAP immunolabeling of two representative
tumors. Patient 10 exhibited strong YAP-positivity that focused on the nuclei of cancer cells
(A, B), while patient 3 displayed equivocal nuclear and cytoplasmic staining of tumor ducts.
Often, cancer associated fibroblasts that showed very strong nuclear YAP content were found in
the tumor surrounding stroma (B, inset). Formations of invasive tumor cells were highlighted
by a particularly high nuclear YAP content, even if the main tumor displayed weaker staining.
A lymph node metastasis found in the tissue of patient 5 exhibited single invasive, highly YAP
positive cells (E, F) while perineural invasion in the case of patient 4 was marked by bands of
tumor cells with elevated YAP expression levels (G, H). Images are shown in 40 × magnification
with insets in 200 × magnification.
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Analysis of protein expression in a panel of biliary carcinoma cell lines
A panel of eight biliary carcinoma cell lines was subjected to Western blot analysis. High
levels of basal YAP expression was observed across the board and while expression of
pYAP was considerably weaker, even minimal to absent in GBD-1, NEC, SNU478 and
TFK-1, suggesting that YAP is highly active.
Figure 4.4.: Expression of YAP and pYAP in a panel of CCC-cell lines
The potential of high transcriptional YAP activity is corroborated by the expression
of YAP’s principal interaction partner TEF-1 by every single biliary carcinoma cell line
examined. In contrast to the examined panel of PDAC cell-lines, expression levels of
TEF-1 in CCC cell-lines were quite homogenous.
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4.1.3. Analysis of nuclear YAP expression and disruption of Hippo
signaling in RCC patients
Analysis of YAP-protein expression in 31 ccRCC patients by
immunohistochemistry
In order to determine the extent of abnormal YAP activity in ccRCC patients, tissue
samples (tumor and adjacent normal tissue) of 31 patients who had undergone surgery
for renal tumors and were diagnosed with ccRCC at the University Hospital of Cologne
were analyzed for YAP protein expression by immunohistochemistry. YAP expression was
detected in normal as well as neoplastic renal tissue, but displayed marked differences with
regard to the staining pattern.
In non-neoplastic renal parenchyma, strong nuclear YAP expression was observed in
podocytes and differential expression was registered in the proximal and distal compart-
ments of the renal tubules. While the distal segments of the renal tubule consistently
exhibited strong cytoplasmic and nuclear immunolabeling, significantly weaker YAP ex-
pression was observed in the proximal tubules, the putative site of origin of ccRCC (Figure
4.5 A, B). In RCC tissue samples nuclear upregulation of YAP expression was found in 20
of 31 cases (65%, p<0.0001) as compared to the proximal tubules in the adjacent normal
tissue.
Figure 4.5.: Expression of YAP in ccRCC patients. Immunohistochemistry of tumor
tissue of 31 ccRCC patients showed distinct staining of normal renal parenchyma with proximal
tubule cells exhibiting only minimal to weak nuclear staining (A) whereas most tumors showed
moderate to strong nuclear YAP immunoreactivity (B). YAP positivity was stronger at the tumor
margins (C).
There was no apparent correlation of YAP positivity with tumor grade or other clin-
icopathologic parameters, which might be due to the small sample size, with 22 out of
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31 cases being histopathologically classified as grade 2. However, vascular invasion or
lymph node metastases were reported for 9/30 cases and of these, 7 exhibited marked
YAP positivity.
Interestingly, YAP staining intensity was considerably more prominent at the tumor
margins representing the invasive front of the tumor. Additionally, in several patients
that showed high expression levels of YAP, solitary keratin and YAP double-positive
tumor cells invading the surrounding lymphocyte rich stroma were observed, suggesting
a possible role of Hippo signaling in ccRCC tumor cell invasion in vivo (Figure 4.5 (C)
and Figure 4.6 (A-D)).
Figure 4.6.: YAP highlights invading tumor cells. Immunohistochemistry of YAP in
ccRCC tissue highlights single cells invading tumor-adjacent stroma (A, B), that also exhibit
positivity for cytokeratin (C, D).
Salvador/SAV1 is a member of the canonical Hippo pathway and has been reported
to be lost in the ccRCC cell line ACHN in one of the first papers on the function of
the Hippo pathway in drosophila and mammals [158]. Copy number loss of chromosome
14q22.1 where the SAV1 gene is located as well as downregulation of the protein has
been reported for a subset of ccRCC by various groups [105, 176], but it is interesting
to determine to what extent loss of SAV1 correlates with YAP positivity and whether
there are any cases that are double positive, suggesting additional mechanisms of Hippo
pathway perturbation in ccRCC.
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Figure 4.7.: Nuclear YAP localization correlates with loss of SAV1 in ccRCC tu-
mors. Loss of SAV1 immunoreactivity was frequently associated with sequestration of YAP
expression to the nucleus of tumor cells (C, D) whereas retained SAV1 expression results in
mainly cytoplasmic YAP expression (A, B).
Immunohistochemistry revealed strong cytoplasmic SAV1 expression in normal tubu-
lar epithelial cells, but immunolabeling was lost in adjacent neoplastic cells in 16 of 31
cases. Weak or absent SAV1 expression was found to correlate with a predominantly
nuclear staining pattern for YAP whereas sustained SAV1 expression was associated with
a predominantly cytoplasmic or equivocal pattern (p=0.0091; see Table 4.3 and Figure
4.7).
Table 4.3.: Loss of SAV1 immunoreactivity correlates with nuclear localization of YAP.
YAP expression
cytoplasmic nuclear total
SAV1 positive 13 2 15
weak or negative 6 10 16
total 19 12 31
Fisher’s exact test P = 0,0091
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It has to be emphasized that this correlation was only observed between the two specific
parameters of SAV1 positivity and YAP staining pattern, and there are cases, that can
be classified as double positive for YAP and SAV1 (refer to Figure 4.7, D for an exam-
ple) as well as a small subset that shows nuclear YAP localization with sustained SAV1
expression, suggesting additional mechanisms apart from loss of SAV1 that lead to Hippo
pathway perturbation and pathological YAP signaling in ccRCC.
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Expression of YAP and interaction partners in a panel of RCC-cell lines
In a panel of seven ccRCC cell lines, basal YAP expression was found in all cell lines
examined, although expression levels varied greatly, with some cell lines expressing very
high levels of YAP. The phosphorylated form of the transcriptional coactivator constitutes
the inactive form of YAP. Cell lines with high basal levels of total YAP contained minimal
(ACHN) to absent (MZ1774) levels of pYAP pointing towards high transcriptional activity
of YAP. ccRCC cell lines further consistently expressed high levels of TEF-1, the major
interaction partner of YAP, with one exception being MZ1774 where expression levels
were lower.
Figure 4.8.: Expression of YAP, pYAP and TEF-1 in a panel of RCC-cell lines. Basal
expression of YAP was observed in all ccRCC cell lines examined, whereas expression of the
inactive form pYAP was minimal to absent in cell lines expressing high basal levels of YAP. The
transcription factor TEF-1, a major interaction partner of YAP, was found in all ccRCC cell
lines analyzed.
In a second step, the extent of expression of the member of the canonical Hippo path-
way SAV1 was examined in this panel of ccRCC cell lines. As previously described, SAV1
expression was completely lost in ACHN cells, due to a homozygous deletion on chromo-
some 14q13-14q22 [158]. In the examined panel, there was no second case of total loss of
SAV1 expression, although A498, MZ1774, B3 and RCC177 displayed very low levels of
the protein, to some degree consistent with their high levels of YAP expression.
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Figure 4.9.: Expression of the Hippo pathway member SAV1 in a panel of RCC-cell
lines. With the exception of ACHN, all ccRCC cell lines express the member of the canonical
Hippo pathway SAV1, although expression levels in A498, MZ1774, B3 and RCC177 are very
low.
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4.1.4. Summary and Conclusion
Upregulation of nuclear YAP expression is present in a considerable subset of all tumor
entities examined, although frequencies are variable. Nuclear YAP expression correlates
with nodal stadium in PDAC and is more frequent in patients with ccRCC that has
spread to the regional lymph nodes. Contrary to previous studies, there was no correlation
between tumor grade and YAP positivity in PDAC [33]. In CCC, the data on a relatively
small series of 31 cases suggest that elevated YAP levels highlight formations of invading
tumor cells when lymph node metastases or perineural invasion are present, even if the
main tumor is not characterized by particularly high nuclear YAP levels.
In all three cancers, solitary, fibroblast-like cells inside the tumor adjacent stroma that
were highlighted by robust nuclear YAP staining could be observed. In two cases of
ccRCC, these stained likewise positive for cytokeratin and were thus identified as single tu-
mor cells invading the surrounding fibrous tissue, suggesting that aberrant YAP-signaling
might at least in a subset of cases be involved in mediating epithelial-to-mesenchymal
transition as has previously been described for other aberrantly re-activated embryonic
signaling pathways in malignant tumors. This will certainly not be true for all solitary,
highly YAP positive cells residing in the tumor adjacent stroma and it has to be assumed
that the majority are indeed cancer-associated fibroblasts. There is an ongoing debate
about the crosstalk between neoplastic cells and the surrounding stromal compartment
with regard to the extent of the contribution of the tumor microenvironment to tumor
progression and invasion. Notably, both PDAC and cancers of the biliary tract can trig-
ger an intense desmoplastic reaction and the specific types of tumor associated fibroblasts
influencing tumor progression and tumor microenvironment have been described in both
entities (see [4] for a review on the role of pancreatic stellate cells in PDAC and [65] for
the role of hepatic stellate cells and activated fibroblasts in disease progression of bil-
iary cancers). Importantly, YAP directly promotes the transcription and expression of
connective-tissue growth factor (CTGF), a cytokine that has been shown to be crucial for
the formation of the desmoplastic stroma in PDAC [4, 34].
In all cell lines with high YAP activity, a member of the TEAD-family of transcription
factors was simultaneously present providing the prerequisite for YAP to exert its pro-
tumorigenic and pro-invasive properties [93]. Lamar et al. reported enhanced metastatic
potential of breast cancer as well as melanoma cells with increased YAP/TEAD activity;
they concluded that YAP can promote metastasis through its TEAD-interaction domain
[93]. This is significant with regard to the association of high nuclear YAP levels with
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pro-invasive properties such as correlation with nodal status or upregulation in invading
tumor cells, that was observed in all three tumor entities analyzed. However, in light
of a recent paper by Shao et al. showing that YAP can functionally substitute RAS in
cancer cells depending on continued RAS-signaling for survival, the solitary importance
of pro-tumorigenic signaling via the YAP/TEAD complex has to be put in perspective.
YAP rescues cell viability and tumorigenicity in RAS-dependent cancer cell-lines via up-
regulation of immediate early genes such as MYC and FOS as well as EMT-genes that
is independent of TEAD although the actual interaction partner remained elusive [144].
This in turn means that YAP could potentially exert its oncogenic properties in cell-lines
with little to no TEAD expression – as observed in several PDAC cancer cell lines – via
an alternative route.
Based on the experimental data discussed in this thesis, there is no single, universal,
clearcut mechanism apparent that conclusively explains the derepression of YAP in the
three tumor entities analyzed. All currently postulated hypotheses as discussed here can
provide an explanation for a subgroup of cases, but point towards a more widespread
deregulation of upstream members of the Hippo-signaling network. In line with these
observations, conditional knockout of NF2, an upstream activator of the growth inhibitory
Hippo pathway, in the proximal tubular epithelium of Villin-Cre;Nf2(lox/lox) mice leads to
intratubular neoplasia and invasive carcinoma which resembles human RCC in a mouse
model of renal cell carcinoma [112]. Recent reports also linked the renal cilia-associated
proteins NPHP4 and NPHP9 to Hippo-signaling in both oncogenically transformed and
normal kidney epithelial cells. These proteins were found to prevent LATS-dependent
phosphorylation of YAP, thus controlling YAP activation and mediating cell proliferation
[54, 55].
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4.2. YAP-deficient cancer cell lines display
overlapping but distinct phenotypes
Having established the ample occurrence of YAP overexpression in PDAC, CCC and
ccRCC, the next step was to analyze the functional significance of YAP-induced transcrip-
tion for cancer cell properties in vitro and in vivo. An approach using RNA-interference,
more specifically: short hairpin RNAs, was chosen in order to downregulate the YAP
protein and to characterize functional properties of YAP-deficient as compared to non-
modified cell lines.
RNA-interference RNA-interference is a mechanism naturally occurring in all eukary-
otic cells in order to regulate the expression of specific genes in a targeted manner. Double-
stranded RNA inhibits gene expression by targeted destruction of specific mRNAs, a pro-
cess that serves two purposes: firstly, the destruction of potentially harmful nucleotide
sequences, such as viral RNA or transposons. Secondly, the targeted regulation of gene
expression is mediated in part by microRNAs which are endogenously produced and mark
certain mRNAs for degradation. RNA interference can lead to the downregulation of spe-
cific proteins, if mRNA of that protein is targeted and degraded, or similarly, to the
upregulation of protein expression, when mRNA of regulatory structures is targeted and
the production of said protein is disinhibited. This RNA-dependent gene silencing process
is governed by the RNAi pathway in eukaryotic cells, first described by Andrew Fire and
Craig C. Mello [45], who shared the 2006 Nobel Prize in Physiology or Medicine for their
discovery.
Feeding into the RNAi pathway are long double-stranded RNA molecules, originat-
ing either from endogenous primary miRNAs, that are transcribed in the nucleus and
then translocate into the cytoplasm, or from exogenous sources such as viral infections or
laboratory manipulations. Long double-stranded RNA molecules are cleaved by the en-
zyme Dicer into shorter fragments of double-stranded RNA (about 20 bases long) termed
"small interfering" or siRNA. Double-stranded siRNA splits into two strands, the passen-
ger strand, which is swiftly degraded, and the guide or antisense strand, which is bound
by the RNA induced silencing complex (RISC). When the guide strand bound to RISC
pairs with its complementary mRNA, the newly assembled double-strand is cleaved and
degraded by the protein Argonaute, a component of RISC.
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Gene silencing by introduction of short hairpin RNAs The physiologic process of
RNA interference has been developed into widely used tools for molecular biology and
experimental therapeutics. Generally, two routes have been established to introduce RNA
sequences targeting specific mRNAs into cells. siRNA is either directly introduced into
the cytosol by transfection techniques, thus creating a temporary downregulation of the
target mRNA. Alternatively, a sequence coding for short hairpin RNAs (shRNAs) is
introduced into the genome of the cells, mostly by lentiviral transduction, creating a
stable knockdown of the target mRNA and protein. shRNAs mimic miRNA function and
are processed accordingly.
Two major caveats have to be taken into account when designing an shRNA-experiment.
First, there is the possibility that the introduced mature antisense strand of the siRNA
will pair with mRNA of multiple genes in addition to the intended target mRNA thus
creating unspecific "off-target" effects.
Second, double-stranded RNA molecules have the capacity to alert the innate immune
system and elicit the mammalian interferon response thus creating incalculable "off-topic"
effects. It is generally believed that this potential confounding effect plays a major role
particularly with longer double-stranded RNA molecules, but the interactions of siRNA
with the immune system are manifold and "off-topic" effects require appropriate controls
also in classic siRNA or shRNA experiments.
It is therefore indispensable to verify potential effects of shRNA-mediated knockdowns
on in vitro or in vivo properties of cells using at least two different sequences of antisense-
RNA and control against cells transduced with non-silencing controls. Substantial knock-
down needs to be verified on mRNA as well as protein-level. These guidelines where
observed while designing the RNAi experiments presented in this study.
Experimental road map For each of the tumor entities analyzed, two to three cell
lines exhibiting high basal YAP expression levels were chosen and YAP activity was ab-
rogated by shRNA-mediated knockdown. For each of the respective parental cell lines at
least two different shRNA sequences directed against YAP (designated "YAPshRNA#4"
and "YAPshRNA#5") were used and compared to untransduced as well as to mock-
transduced mass clones in order to control for unspecific, off-target effects. After confir-
mation of sufficient YAP-knockdown on the protein level, the phenotype of YAP-deficient
cell lines was characterized employing cell-based in vitro and, where available, in vivo
models.
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4.2.1. PDAC
Downregulation of YAP diminishes proliferation of PDAC cell lines
Two PDAC cell lines with high basal YAP expression levels – PK9, and Panc 10.05 –
were selected and aberrant YAP activity was inhibited by shRNA-mediated knockdown.
Consistent stable knockdown of endogenous YAP was confirmed by Western blot analysis
(Figure 4.10).
Figure 4.10.: Confirmation of consistent stable knockdown. Sufficient shRNA-mediated
YAP-knockdown in PK9 (A) and Panc 10.05 (B) cells is stable and consistent on the protein
level as determined by Western blot.
The first cellular property analyzed was the time-dependent increase of viable cell mass
as determined by the MTS assay. This parameter is used as a reasonably reliable surrogate
for cellular proliferation (see 3.3.1 on 68). In both cell lines, YAP-knockdown led to a
significant time-dependent reduction of net cell growth as compared to mock-transduced
cells (Figure 4.11).
Figure 4.11.: YAP-knockdown decreases proliferation of PDAC cell lines. Knockdown
of endogenous YAP led to a highly significant reduction in viable cell mass after 96 hours for
PK9 (A) and Panc 10.05 cells (B). ** p < 0.01, *** p < 0.001
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YAP-knockdown does not affect migration of PDAC-cell lines
Next, effects of YAP-knockdown on in vitro cell migration was assessed by Boyden Cham-
ber assays. No difference in time-dependent cell migration was detected between mock-
transduced and YAPshRNA-transduced Panc 10.05 and PK9 mass clones (see Figure 4.12
on page 102) All experiments were done in triplicates and repeated twice.
YAP-deficient PDAC cell lines display reduced colony-forming capacity
Anchorage-independent growth and colony formation in soft agar is a widely accepted
in vitro surrogate phenotype of malignantly transformed cells. YAP-knockdown potently
and reproducibly abrogated anchorage-independent growth of PK9 cells in soft agar (mean
reduction of colony counts by 67.80% ± 1,25%, n=4, p<0.0001 for clone #4, and 71.00%
± 3.40%, n=4, p<0.0001 for clone #5, respectively; see Figure 4.13,A).
To determine potential effects of YAP-knockdown on the ability to form colonies from
single PDAC cells, replating efficiency assays were performed using single cell suspensions.
The ability of PK9 YAP-knockdown cells to form colonies from single cells in this setting
was significantly reduced as compared to mock-transduced controls (mean reduction of
colony counts by 70.20% ± 5.73%, n=8, p<0.0001 for clone #4, and 43.40% ± 6.46%,
n=8, p<0.0001 for clone #5, respectively; see Figure 4.13, B). Of interest, the colonies
formed by YAPshRNA knockdown cells were not only less numerous but also smaller in
size as compared to their mock-transduced counterparts, reflecting the extend of YAP-
knockdown as well as reduced in vitro net cell growth as already observed previously in
MTS assays.
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Figure 4.12.: YAP-knockdown does not affect migratory potential of PDAC cell
lines. YAP downregulation did not affect PDAC migration in Boyden chamber assays. Transwell
migration through 8 µm pore filters was assessed after 48 and 72 hours in the cell lines Panc
10.05 (A) and PK9 (B).
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Figure 4.13.: YAP-knockdown decreases anchorage-independent colony formation of
PDAC cell lines. Downregulation of YAP significantly reduced anchorage-independent growth
in soft-agar of the PDAC cell line Panc 10.05 (A). Likewise, colony formation as measured by
replating efficiency assays was reduced in YAP-knockdown cells (B). Representative images and
combined colony counts of two (A) and four (B) independent experiments are shown.
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4.2.2. Biliary cancers
Downregulation of YAP in diminishes proliferation of biliary cancer cell lines
Two biliary cancer cell lines with high basal YAP expression levels – G-415, and Nec
– were picked and aberrant YAP activity was cut off by shRNA-mediated knockdown.
Consistent stable knockdown of endogenous YAP was confirmed by Western blot analysis
(Figure 4.14).
Figure 4.14.: Confirmation of consistent stable knockdown. Sufficient shRNA-mediated
YAP-knockdown in G-415 (A) and Nec (B) cells is stable and consistent on the protein level as
determined by Western blot.
The first cellular property analyzed was the time-dependent increase of viable cell mass
as determined by the MTS assay. This parameter is used as a reasonably reliable surrogate
for cellular proliferation (see 3.3.1 on page 68). In both cell lines, YAP-knockdown led to
a significant time-dependent reduction of net cell growth as compared to mock-transduced
cells (Figure 4.15).
Figure 4.15.: YAP-knockdown decreases proliferation of biliary cancer cell lines.
Knockdown of endogenous YAP led to a highly significant reduction in viable cell mass after 96
hours for G-415 (A) and Nec cells (B). ** p < 0.01, *** p < 0.001
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Figure 4.16.: YAP-knockdown decreases colony formation of biliary cancer cell lines.
Downregulation of YAP significantly reduced colony formation as measured by replating effi-
ciency assays in Nec YAP-knockdown cells. Representative images (A) and combined colony
counts (B) of two independent experiments are shown.
An impact of YAP-knockdown on biliary cancer cell migration as determined by the
Boyden chamber assay could not be determined, as non-transduced, mock-transduced and
shRNA-transduced mass clones of both G415 and Nec cells failed to transmigrate into the
lower chamber in this set-up.
YAP-deficient biliary cancer cell lines display reduced colony-forming potential
To determine potential effects of YAP-knockdown on the ability to form colonies from
single biliary cancer cells, replating efficiency assays were performed using single cell
suspensions. The ability of Nec YAP-knockdown cells to form colonies from single cells
in this setting was significantly reduced as compared to mock-transduced controls (mean
reduction of colony counts by 87.30% ± 5.27%, n=4, p<0.0001 for clone #4, and 73.30%
± 5.51%, n=4, p<0.0001 for clone #5, respectively; see Figure 4.16, B). Of interest,
the colonies formed by YAPshRNA knockdown cells were not only less numerous but
also smaller in size as compared to their mock-transduced counterparts, reflecting the
extend of YAP-knockdown as well as reduced in vitro net cell growth as already observed
previously in MTS assays.
105
4. Results & Discussion
4.2.3. Renal Cell Carcinoma
Downregulation of YAP diminishes growth of ccRCC-cell lines
Three ccRCC cell lines with high basal YAP expression levels - A498, ACHN and MZ1774
- were picked and dysfunctional Hippo-signaling and aberrant YAP activity was abrogated
by shRNA-mediated knockdown. Consistent stable knockdown of endogenous YAP was
confirmed by Western blot analysis (Figure 4.17).
Figure 4.17.: shRNA-mediated YAP-knockdown in ccRCC cells. Stable knockdown
was confirmed by Western blot analysis in A498 (A), ACHN(B), and MZ1774(C) cells.
In all of the three cell lines examined, YAP-knockdown led to a significant time-
dependent reduction of net cell growth as compared to mock-transduced cells (p<0.001,
Figure 4.18). Cell viability as determined by the MTS-assay was used as a surrogate
parameter for cell proliferation.
Figure 4.18.: YAP-knockdown decreases proliferation of ccRCC cell lines. Stable
YAP-knockdown resulted in significantly reduced cell viability as determined by MTS-assay, a
surrogate marker for cell proliferation, in A498 (A), ACHN (B), and MZ1774 cells (C). * p <
0.05, ** p < 0.01, *** p < 0.001
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YAP-knockdown significantly impairs migration of ccRCC-cell lines
Next, effects of YAP-knockdown on in vitro cell migration was assessed by Boyden Cham-
ber assays. A considerable reduction of ccRCC migration was observed in response to
YAP-knockdown in all three cell lines examined (p < 0.001; Figure 4.19 on page 108),
consistent with the observation that high YAP expression levels are associated with in-
vasive properties in vivo (as observed in patient tumor tissue samples, see section 4.1.3,
page 90). All experiments were done in triplicates and repeated twice.
YAP-knockdown decreases colony formation in ccRCC cell lines
To determine potential effects of YAP-knockdown on the ability to form colonies from
single cells and expand clonally, replating efficiency assays were performed using dilute,
single cell suspensions. The ability of ACHN-YAPshRNA#4 cells to form colonies from
single cells in this setting was significantly reduced as compared to mock-transduced
ACHN controls (mean reduction of colony counts by 66.3% ± 6.04%, n=6, p<0.0001,
Figure 4.20, A). Interestingly, the colonies formed by YAP-knockdown cells were not only
less numerous but also smaller in size, reflecting reduced in vitro net cell growth as already
observed previously in MTS assays.
Figure 4.20.: shRNA-mediated YAP-knockdown reduces colony formation and
abates anchorage-independent growth of ccRCC cells. Downregulation of YAP sig-
nificantly reduced the number of colonies formed in replating efficiency assays (A) as well as
anchorage-independent growth in soft agar of the ccRCC cell line ACHN (B). Representative
images and combined colony counts of three independent experiments are shown.
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Figure 4.19.: YAP-knockdown impairs migratory potential of ccRCC cell lines. YAP
downregulation resulted in marked inhibition of ccRCC migration in Boyden chamber assays.
Transwell migration through 8 µm pore filters was assessed after 48 and 72 hours in the cell lines
A498 (A), ACHN (B) and MZ1774(C). A pronounced decrease in cell numbers was found for all
YAP-knockdown mass clones. * p < 0.05, ** p < 0.01, *** p < 0.001 Three randomly selected
microscopic fields of representative experiments were selected and cells were counted. Results
are shown as means ± SD.
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YAP-knockdown potently and reproducibly abrogated anchorage-independent growth
of ACHN cells in soft agar (reduction of colony counts by more than 90.3% ± 2.16%,
n=6, p < 0.0001, Figure 4.20, B). Similar to what was observed in replating assays, the
remaining colonies formed by ACHN-YAPshRNA mass clones were not only less numerous
but also significantly smaller as compared to their mock-transduced counterparts in this
3D culture setting.
YAP-knockdown cells display decreased tumorigenicity in a tumor xenograft
model
The above mentioned results of the in vitro assays suggest that dysfunctional Hippo-
signaling and resulting aberrant YAP-activity contribute to tumor progression and metas-
tasis in ccRCC. The in vivo relevance of these findings was evaluated using a subcutaneous
xenograft model. Male athymic CD1nu/nu nude mice, six to eight weeks of age, were in-
jected subcutaneously with 2.5 × 106 ACHN-YAPshRNA or ACHN-mock cells into both
flanks. Tumor volumes were assessed weekly using digital calipers starting one week post
injection. Xenograft growth of ACHN-YAPshRNA cells was significantly delayed as com-
pared to ACHN-mock controls (p = 0.0182; Figure 4.21, A, left panel & B, see page
110), while at the same time the overall body mass of xenograft-bearing mice was not
significantly altered between the two study arms (Figure 4.21 A, right panel).
At five weeks post injection, mice were sacrificed and tumors were harvested for histo-
pathological and immunohistochemical evaluation, or snap-frozen for mRNA extraction
and subsequent quantitative real-time RT-PCR analysis, respectively. Immunohistochem-
istry of formalin fixed and paraffin embedded xenograft tumor tissue confirmed retained
YAP-knockdown in ACHN-YAPshRNA tumors (Figure 4.21, C).
109
4. Results & Discussion
Figure 4.21.: YAP-knockdown inhibits tumor growth in a subcutaneous xenograft
model. Subcutaneous injection of YAP-knockdown cells into the flanks of CD1nu/nu mice re-
sulted in significantly smaller tumors compared to mock-transduced cells while not affecting the
body mass of the mice (A, B). Immunohistochemistry of formalin fixed and paraffin embedded
xenograft tissue confirmed significant downregulation of YAP in tumors derived from ACHN
YAP-knockdown cells (C). Representative images are shown in × 200, with insets in × 400
magnification.
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4.2.4. Summary and Conclusion
In summary, the experimental data presented here demonstrate that YAP exerts pro-
proliferative functions and enhances colony formation in PDAC, biliary cancer as well as
ccRCC. This is in line with previous findings by others (see [33] for PDAC and [105] for
ccRCC) who reported that YAP enhances tumor formation of PDAC cell lines in nude
mice (see [34], supplemental data).
The finding of a nearly universal phenotype with regard to proliferation and tumor
formation is at the same time remarkable in light of results published by different groups,
who found that YAP functions as a tumor suppressor in breast cancer [179] and reported
that YAP restricts the expansion of intestinal stem cells by repressing uncontrolled sig-
naling via the Wnt-pathway [9]. shRNA-mediated YAP-knockdown in breast cancer cell
lines suppressed anoikis, increased migration, and promoted tumor growth in nude mice
[179], while signaling through the Hippo/ YAP-axis seems to have a balancing effect on
the intestinal stem/ progenitor cell compartment [8]. Uncontrolled YAP activation in in-
testinal stem cells leads to the expansion of multipotent, undifferentiated progenitor cells
which differentiate upon cessation of YAP expression [22]. On the other hand, YAP also
has an unexpected growth-suppressive function restricting Wnt-signals during intestinal
regeneration, and complete loss of the protein is observed in a subset of highly aggressive
and undifferentiated human colorectal carcinomas that are associated with poor survival
and stage IV disease [9].
These findings point towards a crucial context- and tissue-dependency of YAP-signaling
in the adult organism that ties in neatly with the putative manifold upstream signals feed-
ing into the core signaling cassette and influencing the many direct interaction partners
of YAP. It will therefore be very interesting to elucidate potential downstream interaction
partners in order to gain clues for the identification of crucial players that might act as
counterbalance to the pro-proliferative signals of YAP.
With regard to the histology results, that suggest a role of YAP in tumor invasion for all
cancer entities analyzed, it is a little surprising to find that shRNA-mediated knockdown
of the protein impairs in vitro migration of cancer cells only in ccRCC cell lines, while
no phenotype could be observed in pancreatobiliary cancer cell lines. It will therefore
be intriguing to analyze downstream targets and interesting to determine to what degree
those genes are commonly regulated by YAP in different tumor entities.
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4.3. Transcriptomic profiling of YAP-knockdowns –
YAP controls a distinct set of target genes in
different tumor entities
4.3.1. There is little overlap in YAP target gene signatures
The phenotypic characterization of YAP-knockdown cell lines in vitro and in vivo led to
comparable results in PDAC, biliary cancer and ccRCC cell lines and revealed that YAP
functions as a crucial mediator of proliferation and colony formation in all three entities
analyzed. YAP was further identified as a critical promotor of cell migration and invasion
exclusively in ccRCC. In order to gain insight into the mechanism by which YAP exerts
its proproliferative and tumor promoting properties and to identify potential downstream
target genes, transcriptomic profiling of YAP-knockdown mass clones of PK9, G415 and
MZ1774 cells was performed using 100 ng of total RNA extracted from the respective cell
lines as raw material (refer to 3.2.3 on page 67 for details on the experimental procedure).
The striking similarity regarding the phenotypic consequences of YAP knockdown in
PDAC, biliary cancer and ccRCC cell lines suggests a considerable overlap in the target
gene signature of the three tumor entities analyzed with the possible exception of ccRCC,
where a distinct signature regarding genes regulating cell migration and tumor invasion
might be expected. It is therefore very intriguing to observe that the portion of genes
similarly regulated by YAP is very small in PK9, G415 and MZ1774 cells as shown in
figure 4.22.
Figure 4.22.: Heatmap of all cell lines submitted to transcriptomic profiling. The
signals given by the respective probes are aligned to match the pattern of differential expression
observed in PK9 YAP-knockdown as compared to mock-transduced cells. No broad areas of
common genetic regulation can be observed.
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Figure 4.23.: Venn diagram of microarray results.
This impression is further corroborated when the focus is shifted to a more detailed,
single-gene perspective: only a total of six genes were found to be similarly differentially
expressed in all three cell lines analyzed (please see figure 4.4 on page 114 for a list of
those six genes). The overlap between two cell lines at a time was only little higher, with
68 genes being similarly regulated by YAP in PK9 and G415 cells, 36 genes in G415 and
MZ1774 cells and 33 genes in PK9 and MZ1774 cells with a grand total of 32055 genes
analyzed (see Figure 4.23 on page 113).
Rationale for third generation pathway analysis
In a landmark review, Vogelstein and coauthors proposed a model which clarifies our
understanding of oncogenic driver genes. A selective growth advantage is conferred to
a neoplastic cell by either driver gene mutations (this specific variant is termed Mut-
Driver gene) or by epigenetic changes leading to aberrant expression of the driver gene
(Epi-Driver gene) [168]. All known driver genes seem to influence one of three key cellular
functions in order to provide a selective growth advantage to the cell: cell fate, cell survival
and genome maintenance. These functions are affected via roughly twelve core signaling
pathways as graphically depicted in Figure 4.24. This model provides excellent guidance
through the thicket of cancer genomes and the multitude of somatic mutations in any
113
4. Results & Discussion
Table 4.4.: Genes similarly regulated upon YAP-knockdown in all three cell lines
Gene
ID
Symbol Gene name FC
PK9
FC
G415
FC
MZ1774
BH adj.
p Value
4312 MMP1 matrix metallopeptidase 1
(interstitial collagenase)
3,89 2,64 1,55 2,09E-08
3656 IRAK2 interleukin-1
receptor-associated kinase
2
1,83 1,57 1,24 3,45E-07
85463 ZC3H12C zinc finger CCCH-type
containing 12C
1,46 1,65 1,25 5,91E-07
10413 YAP1 Yes-associated protein 1 0,195 0,295 0,395 2,92E-16
2181 ACSL3 acyl-CoA synthetase
long-chain family member
3
0,503 0,645 0,720 1,27E-05
1490 CTGF connective tissue growth
factor
0,503 0,616 0,805 4,44E-05
FC: fold change, BH adj. p Value: Benjamini-Hochberg adjusted p Value
given tumor, because it shifts perspective towards a conceptual, "30,000-feet view" [168].
In full appreciation of this perspective, one has to regard the core signaling pathways
as headlines and concede that the precise mutations influencing a giving pathway are
unlikely to affect the same genes in different tumors.
If applied to the Hippo-YAP axis in cancer, this concept leads to the following consid-
erations:
• Overexpression of YAP does confer a selective growth advantage to cancer cells in
several tumor types, including the three tumor entities examined in this study.
• Since somatic mutations within the YAP gene itself are scarce [64] the observed
widespread aberrant overexpression of the transcriptional coactivator YAP can be
explained either by mutation of an upstream member of the Hippo pathway and
subsequent derepression of YAP (mut-driver gene hypothesis) or epigenetic changes
leading to the observed overexpression (epi-driver gene hypothesis).
• Evidence for the mut-driver gene hypothesis is so far only available in the case of
NF2 in ccRCC. NF2 constitutes the sole member of the upstream Hippo-signaling
network that has been identified as a bona fide tumor suppressor gene and is listed in
the Catalogue Of Somatic Mutations In Cancer (COSMIC) database [64]. Mutations
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Figure 4.24.: Core signaling pathways affected by driver gene mutations in cancer.
Vogelstein et al. demonstrated that all known driver genes can be classified into one or more
of twelve core signaling pathways that confer a selective growth advantage to the affected cell.
Figure from [168]. Reprinted with permission from AAAS.
of other pathway members have been described, but are low in frequency and don’t
qualify as driver gene mutations. This lends plausibility to the hypothesis, that in
the majority of cases, YAP might function as an epi-driver gene.
• Aberrant YAP activation will result in transduction of growth-promoting signals
downstream of growth promoting pathways, putatively involved in cell survival and
cell fate. Transcriptomic profiling and pathway analysis of differentially expressed
genes of YAP-deficient vs. YAP-intact mass clones should therefore provide clues
towards the downstream mechanism of oncogenic signaling via YAP.
• Although individual differentially expressed genes may vary considerably, affected
pathways might still overlap and reveal a common mechanism, when assuming the
"30,000 feet"-perspective.
Pathway analysis is an analytical tool that helps to contextualize gene expression data
collected by microarray experiments and shifts focus from the single-gene perspective to-
wards a conceptual view. This approach was therefore also used for the data presented
in this dissertation. Methodologically, a third generation-approach to pathway analysis
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was chosen and Signaling Pathway Impact Analysis (SPIA) was performed as previously
described [159]. Classical signaling pathway analyses identify affected pathways either by
the number of differentially expressed genes (overrepresentation or enrichment analyses
with arbitrarily determined cutoffs regarding false discovery rate (FDR) and fold-change
(FC) thresholds; also termed first generation methods) or by application of the hypoth-
esis that although large changes in individual genes can have significant effects on path-
ways, weaker but coordinated changes in sets of functionally related genes (i.e., pathways)
can also have significant effects (functional class scoring or second generation methods)
[79]. Third generation methods expand this view by including topological information
and therefore taking into account the hierarchy of gene products inside a given pathway.
SPIA combines evidence obtained from enrichment analyses with topological information
arriving at information about the actual perturbation of a pathway under a given con-
dition. A global pathway significance p-value (pG) is calculated by the combination of
individually determined enrichment (pNDE) and perturbation (pPERT) p-values. pG is
then corrected by two statistical methods: false discovery rate (pGFDR) and familywise
error rate (pGFWER) [159]. For the purpose of this study, results were deemed significant
if either pGFDR or pGFWER was ≤ 0.05.
Limitations The most obvious limitation of a pathway topology based approach is that it
relies on the quality and accuracy of the pathway annotation and gene ontology databases.
However, this problem is inherent to analytical approaches of all generations and consti-
tutes an uncertainty that might be minimized but never completely abolished. For the
purpose of the bioinformatical analysis at hand, the Kyoto Encyclopedia of Genes and
Genomes (KEGG) PATHWAY database was used. A graphic overview of the observed
pathway perturbation can be accessed by following the link in the last column of the re-
spective results tables in the appendix (see tables B.1, B.2 and B.3 on pages 151 through
158).
Evaluation and presentation of results for the respective tumor entities In the
subsequent section, prominent differentially expressed genes as well as the results of the
pathway analyses are presented and discussed for each tumor entity separately, starting
with PK9 YAP-knockdown cells. Comprehensive tables of differentially expressed genes
(fold change-cutoff at 2, unless otherwise indicated) as well as the results of SPIA are
printed in the appendix to this dissertation (see pages 140 through 158).
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4.3.2. Transcriptional regulation by YAP in PDAC
Differentially expressed genes in YAP-knockdown cells
Tables A.1 and Table A.2 on page 140 ff. provide an overview of those genes found
to be twofold up- or downregulated in PK9 YAP-knockdown cells. Among the most
prominently differentially expressed genes were several genes that had previously been
identified to play a role in carcinogenesis or were found to be overexpressed in PDAC (see
Table 4.5 on 118). Some of these genes were picked to validate the microarray results by
RT-qPCR. All genes reported to be downregulated by the expression array analysis were
also highly significantly downregulated if analyzed by RT-qPCR (see figure 4.25). Some
of the most interesting "hits" will be discussed in more detail in the following part.
Figure 4.25.: Validation of putative YAP target genes by RT-qPCR. Eleven differen-
tially expressed genes identified by microarray analysis were picked and differential expression
was confirmed by RT-qPCR.
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Table 4.5.: Differentially expressed genes previously described to be overexpressed in PDAC
Gene name Symbol FC Annotation Ref.
Yes associated pro-
tein
YAP 0,195 Confirms validity of assay
Connective tissue
growth factor
CTGF 0,451 bona fide target gene of YAP; impor-
tant regulator of ECM construction
and tumor-stroma cross-talk; promotes
growth, migration and angiogenesis
[10, 116, 173]
Vestigial like 1
(drosophila)
VGLL1 0,290 Co-transcription factor and interaction
partner of TEAD; competitor of YAP
[128, 129]
Sorting nexin 4 SNX4 0,498 implied in endosomal sorting; interacts
with Hippo pathway member KIBRA
[150, 162]
Insulin-like growth
factor binding pro-
tein 3
IGFBP3 0,368 expression lost in PanIN, IPMN, MCN
and PDAC; expression correlates in-
versely with poor survival
[66]
Insulin-like growth
factor binding pro-
tein 5
IGFBP5 0,361 mediator of cell growth in pancre-
atic cancer cell lines; overexpressed in
chronic pancreatitis, IPMN and PDAC
[74]
Transgelin TGLN 0,203 cross-links actin; target of TGF-β sig-
naling; overexpressed in PDAC
[4, 185]
Folate receptor 1
(adult)
FOLR1 0,296 overexpressed in various cancer tissues;
antibody Farletuzumab is currently in
clinical evaluation
[124, 169]
Major histocom-
patibility complex,
class II invariant
chain
CD74 0,415 overexpressed in PanIN and PDAC; ex-
pression is associated with perineural
invasion and poor prognosis
[85, 181]
Placenta specific 8 PLAC8 0,475 inhibits differentiation of AML-cells by
PMA and ATRA; overexpression in
PanIN, IPMN and PDAC
[19, 96]
S100 calcium bind-
ing protein P
S100P 0,426 overexpressed in PanIN, IPMN, MCN
and PDAC
[19]
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Connective tissue growth factor (CTGF)
CTGF (CCN2), a cysteine-rich, secreted matricellular protein and member of the CCN
family of proteins was consistently downregulated upon YAP knockdown in PK9 (fold
change YAPshRNA#5 0.33 ± 0.01, p < 0.0001) as well as Panc 10.05 cells (fold change
YAPshRNA#5 0.46 ± 0.01, p = 0.001; see figure 4.26 A on page 122). CCN proteins are
synthesized in response to mitogenic signals such as serum, growth factors or oncogenes.
They bind to heparan-sulphate proteoglycans in the extracellular matrix (ECM) as well
as on the cell surface. They are further binding partners of integrins and engage with
cell surface receptors such as low density lipoprotein receptor-related protein 1 (LRP1)
and neurotrophic tyrosine kinase, receptor, type1 (TrkA) [23]. CCN proteins observe a
regulatory role within the complex network of the extracellular space and modulate the
interaction of the plethora of cell types that reside in, communicate across, or produce
matricellular components. Consequently, they have been described to influence a variety
of cellular functions and biological properties, such as cell migration, proliferation and
survival, as well as angiogenesis, fibrosis and wound healing. Furthermore, members of
the CCN family reportedly influence other signaling pathways, among those TGF-β, bone
morphogenic protein (BMP), and VEGF-regulated pathways. Recent work has led to the
conclusion that CCN proteins form a functionally integral part of the ECM while their
structural contribution to tissue architecture is limited [23].
CTGF in pancreatic development and disease CTGF is involved in pancreatic devel-
opment (regulation of islet morphogenesis and function) and functions as one of the key
cytokines in the pathogenesis of pancreatic fibrosis following pancreatitis. In this scenario,
production of the CTGF-protein by both acinar cells and fibroblasts including activated
pancreatic stellate cells at the site of injury, is induced following the over-expression of
TGF-β [23]. Chronic pancreatitis is a well-known risk factor for the development of pan-
creatic cancer and it is therefore no surprise, that CTGF expression is evident in the
mutated ductal cells of PanINs and PDAC [10, 23, 173]. There are indications that the
extent of CTGF-overexpression is proportional to the intensity of the desmoplastic reac-
tion and the cytokine is likewise expressed by stromal cells within the pancreatic tumor
tissue [10, 23]. CTGF is therefore a candidate master-regulator of molecular cross-talk
between tumor and stroma in pancreatic cancer and experimental therapies targeting
CTGF have been successfully employed in a mouse model of pancreatic cancer [116].
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CTGF as a direct target of YAP signaling in pancreatic cancer cells CTGF and
another member of the CCN family of proteins cysteine-rich, angiogenic inducer 61
(CYR61 ) are bona fide target genes of the transcriptional coactivator YAP and CTGF
was markedly downregulated upon YAP-knockdown in PK9 as well as Panc10.05 cells (see
figure 4.26 A on page 122). CTGF was among the first genes discovered to be regulated
by the YAP/TEAD complex and serves as a positive control for YAP/TEAD-regulated
gene expression in many studies [183]. Dysfunctional Hippo-signaling and subsequent
YAP-overexpression in PDAC might be the missing link to explain the observed CTGF-
hyperactivity in pancreatic cancer. Strong YAP immunoreactivity was observed in neo-
plastic as well as stromal cells in tissue samples of patients with PDAC (see 4.1 on page
82), conclusive with the model of CTGF as a dynamic auto- and paracrine regulator of
tumor-stroma cross-talk. Targeting YAP in PDAC would therefore mean to target tumor
and stromal cells alike, which presents a promising therapeutic concept for pancreatic
cancer patients.
CD74
Major histocompatibility complex, class II invariant chain (CD74) is involved in the pro-
duction, processing and transport of the MHC class II protein functioning as a cleft-like
placeholder and blocking the antigen-binding site until the MHC class II-complex is fully
assembled, stable and present on the cell surface [29]. Its expression by human pancre-
atic cancer cells has been studied and seems to be linked to particularly invasive cancers,
resulting in a poor prognosis [85, 181]. Koide and colleagues found overexpression of the
CD74 protein in the tumor tissue of 52/67 of PDAC patients (analysis by immunohis-
tochemistry) [85]. Staining intensity was particularly high in patients with perineural
invasion or liver metastasis and this was prognostically relevant. These results were con-
firmed by Zhang et al. in 2014 who found that high CD74 expression severely worsened
the prognosis for PDAC patients who had their tumors resected [181].
CD74 was initially identified to be associated with perineural invasion by means of gene
expression studies performed on neoplastic cells from a mouse model of perineural invasion
in PDAC [85]. In the same gene expression analysis, elevated expression levels of vestigial
like 1 (VGLL1) were likewise associated with an invasive phenotype. Interestingly, VGLL1
was also prominently downregulated upon YAP-knockdown in PK9 as well as Panc 10.05
cells (see figure 4.26 A on page 122).
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Vestigial like 1 (VGLL1)
Vestigial like 1 (VGLL1) was consistently downregulated upon YAP knockdown in PK9
(fold change YAPshRNA#5 0.17 ± 0.003, p < 0.0001) as well as Panc 10.05 cells (fold
change YAPshRNA#5 0.15 ± 0.003, p < 0.0001; see figure 4.26 A on page 122).
VGLL1 codes for the protein VGLL1, a transcriptional co-activator evolutionary related
to the drosophila protein vestigial (vg), a master regulator of wing development. VGLL1
and vg, however, only share a short, 25 amino acids-long motif ("tondu"-domain) while
all other sequence stretches do not display any similarity [129]. Drosophila vg interacts
with scalloped (sd), which constitutes the drosophila counterpart of mammalian TEAD
[59, 149] and also mammalian VGLL proteins were recently identified as transcriptional
coactivators of TEAD1-4 [129]. Despite a highly different primary sequence, the VGLL1-
TEAD and the YAP-TEAD complex are structurally very similar and VGLL1 and YAP
are competing for TEAD-binding [129]. Although this structural similarity is mirrored
to some degree by a functional similarity - VGLL1-TEAD4 upregulates pro-proliferative
genes in prostate cancer cell lines - both complexes recruit a distinct set of target genes
[129]. While VGLL1-TEAD results in upregulation of genes associated with myogenesis
and proliferation like MYHC, VEGFA and IGFBP5, YAP-TEAD recruits CTGF, CYR61,
IGFBP3 and CMYC in order to maintain organ size and a stem-like phenotype [128].
This is consistent with observations in the fruit fly, where vg can alter target selectivity
of sd, putatively by recruitment of a distinct set of transcriptional regulatory factors
[57]. As of now, information about the regulation of VGLL1 has been scarce except for
the conjecture that phosphorylation by the Hippo signaling cascade is unlikely because
VGLL1 lacks the lats-recognition motif [129]. The data presented here is the first report,
that YAP-TEAD actively regulates the expression of its own competitor.
In order to further evaluate the possibility of YAP-VGLL1 competition in PDAC, ex-
pression analysis of VGLL1 mRNA was performed using RT-qPCR in a panel of PDAC
cell lines (see figure 4.26 B on page 122). Transcripts were present in 8/14 cell lines an-
alyzed, although correlation with YAP protein expression was sketchy underscoring the
need for further elucidation of the YAP-VGLL1 relationship in PDAC (e.g. L3.6pl; see
figure 4.2 on page 84).
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Figure 4.26.: Crossvalidation of putative YAP target genes in PK9 and Panc10.05
cells. Crossvalidation of putative YAP target genes CTGF, VGLL1 and IGFBP5 in PK9 and
Panc 10.05 YAP-knockdown cells (A). mRNA expression of VGLL1 transcripts in a panel of
PDAC cell lines (B).
Insulin-like growth factor binding proteins (IGFBPs)
Two insulin-like growth factor binding proteins (IGFBPs) were downregulated upon YAP
knockdown in PK9 cells. The proteins IGFBP3 (fold change 0.43 ± 0.05, p < 0.0001)
and IGFBP5 (fold change 0.34 ± 0.03, p < 0.0001) are members of the IGF-signaling axis
which is involved in the maintenance of tissue homeostasis by regulation of cellular prolif-
eration, differentiation and migration [35]. Insulin-like growth factors (IGF-1 and IGF-2)
are single chain polypeptides that are produced by almost any cell in the body and inter-
act with the cell membrane-bound receptor IGF-1R which in turn activates intracellular
signaling pathways like the Ras/MAPK/ERK as well as the PI3K/AKT/mTOR cascades.
Activation of the IGF-axis therefore results in pro-proliferative and anti-apoptotic cellu-
lar cues and contributes to tumorigenesis [35, 113]. IGF-signaling further contributes to
tumor-stroma crosstalk in pancreatic cancer with stromal cells producing IGF-1 that binds
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to IGF-1R on cancer cells [66]. IGF-1 and IGF-2 circulate in 1000-fold higher concentra-
tions than most other peptide hormones and their action is modified by binding proteins
which function as major determinants of IGF bioavailability [113]. About 99% of IGF
is bound to one of six different IGFBPs at any given moment. Among those, IGFBP1-5
share high sequence similarity as well as a high affinity for IGF-1, while IGFBP6 displays
a higher affinity for IGF-2 [113].
IGFBP expression is regulated by a wide array of growth enhancing signals that are cell
type-specific and include hormones (steroid hormones, growth hormone, follicle-stimulating
hormone etc.), growth factors (IGFs, platelet-derived growth factor, epithelial growth fac-
tor, fibroblast growth factor etc.) and other mediators (vitamin D, retinoic acid, p53 etc.)
[113]. In pancreatic cancer, at least part of the IGFBP3 and IGFBP5 expression ap-
pears to be triggered by YAP. Cross validation in Panc 10.05 YAP knockdown cell lines,
however, could not wholeheartedly confirm this chain of command due to very low con-
centration of IGFBP3 and IGFBP5 mRNA and resulting high quantification cycles (see
figure 4.26 A on page 122, data for IGFBP3 not shown).
Binding of IGFs to specific IGFBPs may result in distinct consequences: IGFBP3 de-
creases the bioavailability of IGF-1 and 2 whereas IGFBP5 leads to an increased biologi-
cal activity, putatively by regulating their relative distance to the receptor IGF-1R [35].
Consistent with this observation, overexpression of IGFBP3 in pancreatic cancer has been
reported to be inversely correlated with venous invasion while tumors positive for IGF1R
and negative for IGFBP3 were associated with significantly shorter overall survival [66].
IGFBP5 on the other hand functions as a mediator of cell growth in PDAC cell lines, an
action dependent on MAPK and PI3K signaling [74]. Their conflicting functions in cell
growth and tissue homeostasis tie in with the observation that YAP induces transcription
of its own competitor for its main interaction partner TEAD. Pobbati et al. reported
IGFBP5 to be a target gene of the VGLL1-TEAD complex while the YAP/TAZ-TEAD
complex induced IGFBP3 expression in PC-3 cells [129], which suggests that IGFPB5
might be an indirect target of YAP in PDAC. YAP and its putative counterpart VGLL1
might be required for maintenance of tissue homeostasis in PDAC.
Pathways affected by YAP-knockdown in PK9 cells
SPIA returned 26 pathways that were significantly affected by YAP-knockdown in PK9
cells (see figure 4.27 and table B.1 on page 151 ff.). At first glance there appears to be a lot
of seemingly unspecific perturbation of immune-pathways. However this is not surprising
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when considering the relatively high number of soluble cytokines and mediators that
were differentially expressed upon YAP-knockdown in PK9 cells, such as IL-1 and IL-6,
GM-CSF as well as MMP1, which were curiously upregulated (see table A.2 on page 142
ff.). This lends support to the hypothesis that YAP modifies the tumor microenvironment,
shaping local humoral immunity into a tumor-permissive state to facilitate immune evasion
by the neoplastic cells.
One of the most interesting charts is provided by entry number five "Pathways in Can-
cer" (KEGG ID 5200) which agglomerates the key pathways contributing to the hallmark
features of cancerous transformation. This is a true example of the usefulness of path-
way analyses of microarray data, as most of the genes that lead to significant pathway
perturbation are individually not markedly affected. Coordinated, smaller changes lead
to significant consequences in case of the Wnt signaling pathway, cell cycle regulation as
well as the ErbB-signaling pathway.
Wnt-signaling Wnt signaling has previously been connected to the Hippo-YAP axis in
epidermal stem cells as well as intestinal crypts [9, 137]. YAP has been shown to act
downstream of α-catenin to control epidermal proliferation. Activation of YAP-induced
transcription results in an expansion of the epidermal stem cell compartment that can
eventually progress to squamous cell carcinoma-like tumors, while loss of YAP leads to
failure of skin expansion and is embryonically lethal [137]. In the intestine on the other
hand, YAP oversees a surprising growth-suppressive function by restricting Wnt-signals
during intestinal regeneration. Not unlike its paralogue TAZ which functions as a nega-
tive regulator of Wnt/β-catenin signaling in mammalian kidney development [166], YAP
restricts nuclear translocation of the transducer protein Dishevelled (dvl) and therefore
prohibits elevated Wnt-signaling [9]. This once more underlines the tissue-context de-
pendency of the Hippo-YAP axis which can lead to growth-promotion in one setting and
growth-restriction in the next, even through interaction with the same signaling pathways.
In PK9 cells, YAP knockdown seems to modulate Wnt-signaling mainly by downregula-
tion of the membrane-bound receptor Frizzled (Fz) and interference with the homeostasis
of individual members of the Wnt-gene family as well as upregulation of the planar-cell
polarity protein Prickle-like 1.
Cell cycle regulation YAP knockdown led to downregulation of Neuregulin 4 (NRG4)
and subsequent upregulation of Cyclin-dependent kinase inhibitor 1A (p21; fold change
1,74, p = 1,00E-05), directing the cellular program towards growth arrest and upregulation
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of apoptosis. This is in line with the observed inhibition of cell growth in different PDAC
cell lines as described in the results section on functional in vitro data.
ErbB signaling Input into the ErbB signaling pathway was enhanced in PK9 YAP
knockdown cells by means of upregulation of Transforming growth factor, α (TGF-α),
Heparin-binding EGF-like growth factor (Hb-EGF) as well as Neuregulins 1 (NRG1).
Protein kinase C (PKC), an activator of oncogenic transcription and target of experimen-
tal therapies in pancreatic cancer [38] was downregulated upon YAP knockdown in PK9
cells, consistent with the observed decreased tumorigenicity.
ECM receptor interaction Interestingly, especially in light of the presence of stromal
cells that are highly positive for YAP in the tumor surrounding stroma in PDAC patients,
YAP knockdown increased expression of Integrin α and activated the ECM receptor in-
teraction pathway. This once more indicates a role for the Hippo-YAP axis in the orga-
nization of tumor-stroma crosstalk and metastasis and compliments the observation that
nodal involvement was significantly higher in patients with high YAP-immunoreactivity
(see section 4.1.1 on page 81).
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Figure 4.27.: SPIA two-way evidence plot of pathways affected by YAP-knockdown
in PK9 cells. Each point represents a biological pathway affected by YAP-knockdown in PK9
cells. The coordinates of the point are a measure of two aspects of pathway perturbation that form
the two components of the global pathway significance p-value (pG): the enrichment (pNDE)
p-value is a measure for the number of affected genes, whereas the perturbation (pPERT) p-
value takes into account the position of those genes within a given pathway. All pathways are
represented by their KEGG-ID number. Please refer to table B.1 on page 151 ff. and follow the
hyperlink in the last column for a graphic representation of the affected genes and their position
within the pathway topology.
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4.3.3. Transcriptomic landscape in G415 cells
Transcriptomic profiling of G415 YAP-knockdown cells by cDNA microarray analysis
identified 36 genes that were upregulated more than twofold (Table A.4 on page 145
presents the top 49 upregulated genes), and another 42 genes that were downregulated
by more than 50% as compared to mock-transfected G415 cells (Table A.3 on page 143).
Although at first glance the genes represented in the toplists seem interesting, pointing
towards involvement of the Wnt-signaling pathway (DKK1) and modification of tumor-
stroma interaction (ITGB2, FGFBP1, ECM2), the signaling pathway impact analysis only
returned one pathway significantly affected by YAP-knockdown in G415 cells: "Cytokine-
cytokine receptor interaction" (KEGG ID 4060, see figure 4.28). However, this pathway
merely constitutes of an aggregation of receptor-ligand pairs that are not interconnected
and therefore does not provide an interesting lead towards the biologic mechanism of YAP
action in biliary cancer.
A potential way forward would be to repeat the gene expression analysis and include
both a comparison of two mass clones generated by two different shRNA sequences tar-
geting YAP as well as a second biliary cancer cell line.
Figure 4.28.: SPIA two-way evidence plot of pathways affected by YAP-knockdown
in G415 cells. Each point represents a biological pathway affected by YAP-knockdown in G415
cells. All pathways are represented by their KEGG-ID number. Please refer to table B.2 on page
156 ff. and follow the hyperlink in the last column for a graphic representation of the affected
genes and their position within the pathway topology.
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4.3.4. Transcriptomic profile of YAP in MZ1774 cells
Transcriptomic profiling of MZ1774 YAP-knockdown cells by cDNA microarray analy-
sis returned 14 genes that were upregulated more than twofold (Table A.6 on page 149
presents the top 20 upregulated genes), and another 42 genes that were downregulated by
more than 50% as compared to mock-transfected MZ1774 cells (Table A.5 on page 147).
Of these, 8 targets were picked for validation by quantitative real-time PCR. All eight
targets found to be downregulated by microarray analysis were confirmed to be down-
regulated using RT–qPCR. CDH6 is an example of a target found to be overexpressed
in the microarray analysis was also found to be upregulated using RT–qPCR (Figure
4.29). Some of the most interesting genes, which were selected based on their pathophys-
iological relevance as deduced from previously published literature and their mechanistic
implications will be discussed in more detail below.
Figure 4.29.: Validation of putative YAP target genes by RT-qPCR. Nine differentially
expressed genes identified by microarray analysis were picked and differential expression was
confirmed by RT-qPCR.
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Endothelin axis
Among the most prominently downregulated genes were two members of the endothe-
lin family, Endothelin-1 and -2. Cross-validation of mRNA expression of these genes
in MZ1774, A498 and ACHN YAP-knockdown cells confirmed significant Endothelin-1
downregulation in MZ1774 and A498 upon YAP-knockdown (fold changes for MZ1774
0.41 ± 0.009, p < 0.0001 and 0.41 ± 0.019, p = 0.0001 for A498, respectively; see Figure
4.30 on page 130). Endothelin-2 expression was significantly reduced in all three cell lines
examined (fold changes 0.06 ± 0.003, p < 0.0001, for MZ1774, 0.62 ± 0.025, p = 0.001
for A498, and 0.17 ± 0.0067, p < 0.0001 for ACHN, respectively).
Immunohistochemistry and quantitative real-time RT-PCR confirmed consistent knock-
down of YAP as well as downregulation of Endothelin-2, both at the mRNA- and protein-
level in murine xenografts of human ccRCCs (Figure 4.31 on page 129).
Figure 4.31.: The putative YAP target EDN2 is downregulated in ACHN YAP
knockdown xenografts. RT-qPCR of freshly frozen xenograft tissue confirmed significant
downregulation of EDN2 mRNA in tumors derived from ACHN YAP knockdown cells (A). Hema-
toxylin and eosin stainings and immunohistochemistry of EDN2 in ACHN mock and ACHN YAP
knockdown xenograft tissues illustrate downregulation on the protein level (B). Representative
images are shown in ×20, with insets in ×40 magnification.
Endothelins are important regulators of kidney function and endogenous endothelin
is involved in the regulation of renal cell growth and proliferation, as well as fluid and
electrolyte excretion. Production of endothelins in the kidney is increased in numerous
renal diseases [84] and ccRCC tumors have been reported to express Endothelin-1 and
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Figure 4.30.: Crossvalidation of putative YAP target genes in two other RCC cell lines. Cross-validation in two other
YAPshRNA-transfected ccRCC cell lines revealed uniform EDN2, CYR61, and THBS1 downregulation as well as EDN1 and cMYC
downregulation in two tested cell lines.
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its receptor ETA with ccRCC cell lines secreting endothelin-1 [36, 127]. The selective
endothelin-A-receptor antagonist Atrasentan has been used in combination with IFN-
alpha in a phase I study in metastatic RCC, albeit with moderate clinical anti-tumor
effects [52]. The impact of YAP-knockdown on Endothelin-2 expression was most pro-
nounced and present in all three cell lines tested, whereas Endothelin-1 downregulation
could be cross-validated in A498 but not in ACHN YAP-knockdown cells. As ACHN
YAP-knockdown cells displayed the same phenotype in respect to reduced cancer cell
proliferation and migration and did form smaller xenograft tumors in vivo, Endothelin-2
seems to be one of the main effectors responsible for these effects. In line with this hypoth-
esis, we found that Endothelin-2 expression significantly correlates with YAP positivity in
clinical tumor specimen of ccRCC patients as assessed by immunohistochemistry (see fig-
ure 4.32 on page 131 and table 4.6 on page 132). Chromatin immunoprecipitation (ChIP)
confirmed the presence of the YAP-TEAD complex in the promotor regions of the EDN2
and EDN1 genes in MZ1774 cells and established those genes as direct transcriptional
targets of YAP in ccRCC (see figure 4.33 on page 134).
Figure 4.32.: EDN2 expression correlates with YAP positivity in RCC patient tis-
sue. Immunohistochemistry of tumor tissues of 30 patients with ccRCC confirmed that EDN2
expression correlates with YAP positivity. Double positivity for YAP and EDN2 was frequently
observed (A, B), whereas loss of YAP expression often results in minimal to absent EDN2 ex-
pression (C, D).
131
4. Results & Discussion
Table 4.6.: EDN2 expression correlates YAP positivity in ccRCC.
YAP expression
positive weak or negative total
EDN2 positive 20 3 23
weak or negative 2 5 7
total 22 8 30
Fisher’s exact test P = 0,0067
Endothelins in cancer Research on the endothelin axis in cancer has focused mainly
on Endothelin-1 and results have largely been extrapolated to Endothelin-2. It has
been assumed that Endothelin-2 would mimic the actions of its more abundant coun-
terpart Endothelin-1, but recent findings in vitro and in knockout mice underscore that
Endothelin-2 does not simply amplify or duplicate Endothelin-1 action and imply a dis-
tinct function of Endothelin-2 in physiological and pathophysiological processes [100].
Furthermore, Endothelin-2 and not the more abundant Endothelin-1, was first isolated
from RCC cell lines [120]. A recent paper reported Endothelin-2 expression to be a
common and early event in patients with localized ccRCC undergoing nephrectomy and
proposed a potential role in ccRCC progression [15]. An association of higher tumor ex-
pression of Endothelin-2 with longer progression-free survival could not be confirmed after
adjustment for known clinicopathological factors and it would be interesting to compare
expression levels with tumors of patients with advanced, metastatic disease.
Grimshaw et al. reported an important influence of Endothelin-2 on the invasive poten-
tial of breast cancer cells and proposed a mechanism where Endothelin-2 secreting tumor
cells provide chemotactic cues to tumor infiltrating macrophages, which in turn secrete
MMP-2 and MMP-9 to facilitate tumor cell invasion and metastasis [51]. The observed
effect was dependent on both endothelin receptor B and MAPK-signaling, and expression
of Endothelin-2 and its receptor was stronger at the invasive margin of the tumor tissue.
Of note, we observed inhibition of the MAPK-signaling pathway upon YAP-knockdown
in MZ1774 cells. Overexpression of Endothelin-2 increases the invasive potential of breast
cancer cell lines in vitro but is not sufficient to induce an invasive phenotype in benign
cells, indicating the cooperation with other signaling networks [56]. Concordantly, Said
et al. reported an instrumental role of Endothelin-1 signaling via endothelin receptor A
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in the development of metastatic bladder cancer and delineated a proinvasive network
governed by members of the endothelin-family. This involves direct actions like the acti-
vation of proinflammatory transcription factors such as AP-1 and NF-kappaB in human
monocytes and cancer cells and the stimulation of the production of a range of proinvasive
cytokines like interleukin-6, COX2, CCL2, MMP2 and MMP9 as well as indirect modula-
tion of the tumor-microenvironment by influencing tumor-stroma-interactions as well as
tumor-associated immune cells [135]. These endothelin functions were instrumental in the
process of metastatic colonization, the first step of the establishment of a filial tumor at
a distant site. Pharmacologic blockade of endothelin receptor signaling inhibited metas-
tasis significantly in an experimental animal model, despite having only modest effects
on primary tumor growth. We observed that these reported target genes of Endothelin-1
signaling, namely interleukin-6, COX2, VEGFA and CCL2 were also moderately, but sig-
nificantly downregulated in MZ1774 YAP-knockdown cells as determined by microarray
or RT-PCR analysis (fold changes were 0.74, p < 0.0008 for interleukin-6, 0.60, p = 0.002
for COX2, 0.67, p = 0.0065 for VEGFA and 0.82, p = 0.032 for CCL2, respectively).
c-Myc
Cross-validation of differential mRNA expression in MZ1774, A498 and ACHN YAP
knockdown cells confirmed significant c-Myc downregulation in MZ1774 and A498 upon
YAP-knockdown (fold change MZ1774 0.34 ± 0.006, p < 0.0001; fold change A498 0.79
± 0.026, p = 0.0085; see figure 4.30 on page 130). Differential expression could not
be confirmed in ACHN cells. However there was no information available regarding the
mutational status of the c-Myc protein in this cell line and constitutive activation or am-
plification of the protein would provide one possible explanation. Upregulation of c-Myc
expression has been reported to occur in a majority of ccRCC cases [42, 157], although
amplification of the MYC gene is only found in a small subset of cases [89, 157] leading
to the assumption that c-Myc is activated by other mechanisms in addition to amplifica-
tion. We observed strong c-Myc downregulation upon YAP-knockdown in MZ1774 cells.
c-Myc knockdown by siRNA in ccRCC cell lines leads to a phenotype that resembles that
of YAP-knockdown with marked inhibition of proliferation and anchorage-independent
growth [157]. c-Myc expression is stimulated by Endothelin-1 via MAPK signaling in
neoplastic cells [80, 117] and our data show inhibition of the MAPK signaling pathway
along with Endothelin-1 and concomitant c-Myc downregulation upon YAP-knockdown in
MZ1774 and A498 cells whereas mRNA expression levels of these genes were not affected
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Figure 4.33.: The YAP-TEAD1 complex is present in the promotor regions of pu-
tative YAP target genes. Potential TEAD binding sites were picked by identification of con-
sensus sequences in the promotor regions of putative YAP target genes in ccRCC and primers
flanking these regions were designed. A well-characterized YAP/TEAD1-binding site in the pro-
motor region of the bona fide YAP target gene CTGF was selected as a positive control. We
found YAP and TEAD to be simultaneously present on the promotor regions of the MYC, EDN1
as well as EDN2 genes in MZ1774.
in ACHN cells, indicating that c-Myc might be an indirect target of YAP, downstream of
endothelin-1 in ccRCC. However, the MYC-promoter region features GT-IIC consensus
sequences as potential binding sites for the YAP/TEAD complex and the YAP/TEAD
complex is indeed present on those binding sites in MZ1774 cells (see figure 4.33 on page
134), providing evidence that c-Myc functions as a direct transcriptional target of YAP
in ccRCC.
CYR61 We observed consistent downregulation of the bona-fide YAP target gene CYR61
upon YAP-knockdown in all cell lines examined. CYR61 is a positive regulator of cell
growth [126] and has been implicated as a proangiogenic factor in highly vascularized RCC,
acting alongside VEGF and exerting additive, non-overlapping functions [25]. CYR61
upregulation correlated with loss of von Hippel-Lindau protein expression, although its
expression was only partly dependent on HIF-2α function, suggesting additional mecha-
nisms that contribute to CYR61 upregulation in RCC [25]. Furthermore, recent reports
linked CYR61 with integrin-mediated cell migration and invasion in prostate cancer cell
lines, hinting at a potential role in metastasis [138].
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THBS1 Thrombospondin-1 is one of the most potent physiological antiangiogenic fac-
tors and its expression has been reported as an independent prognostic factor in ccRCC
with retained expression being associated with increased survival [186]. It is therefore
somewhat surprising to observe downregulation of THBS1-mRNA upon YAP-knockdown
in all cell lines analyzed. YAP might interfere with the network of pro- and antiangiogenic
factors, such as CYR61 and THBS1, in ccRCC, tipping the balance towards a homeostasis
that favors the proliferation and survival of the tumor cells.
CDH6 Cadherin 6-mRNA expression was found to be upregulated in MZ1774 YAP-
knockdown cells. Normal renal epithelium and RCC express multiple members of the
cadherin family in a distinct pattern with E-cadherin being expressed in Bowman’s cap-
sule and all tubular segments except the proximal convoluted and straight tubules [145].
Consequently, E-cadherin expression frequency in RCC is lower than in other cancers and
even low-grade tumors infrequently express E-cadherin [77]. Conversely, cadherin-6 is
expressed in proximal renal tubules and renal cell carcinoma, especially when E-cadherin
is absent, and seems partly to take over E-cadherin function [146]. Detectable cadherin-
6-mRNA from circulating tumor cells in the peripheral blood of RCC patients has been
proposed as a prognostic marker associated with increased risk of metastasis [97, 146]
hinting not necessarily at an active role of the cadherin-6-protein in metastasis but rather
highlighting the inadequate ability of cadherin-6 to replace E-cadherin in cell adhesion.
Upregulation of the cell adhesion molecule cadherin-6 in response to YAP-knockdown is
therefore not contradictory to a less invasive phenotype.
miR-21 In light of the most recent report published by the Cancer Genome Research
Atlas Network [28], which found frequently altered promoter methylation of miR-21 with
subsequent high miR-21 expression in high stage ccRCCs that inversely correlated with
outcome, it is intriguing to note the significant downregulation of miR-21 upon YAP-
knockdown. Recent work from Dey et al. showed that miR-21 targets PTEN protein
expression and promotes ccRCC survival and invasion via Akt/TORC1 signaling [32].
Pathway analysis
The top three pathways found to be affected were the p53-, MAP kinase as well as cell cycle
progression pathways, all of which have long been well-established as centrally involved
in carcinogenesis and maintenance of a malignant phenotype across several tumor entities
(see Figure 4.34 on page 136 and Table B.3 on 158). Consistent with the phenotypic
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Figure 4.34.: SPIA two-way evidence plot of pathways affected by YAP-knockdown
in MZ1774 cells. Each point represents a biological pathway affected by YAP-knockdown in
MZ1774 cells. The coordinates of the point are a measure of two aspects of pathway perturbation
that form the two components of the global pathway significance p-value (pG): the enrichment
(pNDE) p-value is a measure for the number of affected genes, whereas the perturbation (pPERT)
p-value takes into account the position of those genes within a given pathway . All pathways are
represented by their KEGG-ID number. Please refer to table B.3 on page 158 ff. and follow the
hyperlink in the last column for a graphic representation of the affected genes and their position
within the pathway topology.
observations, the p53-signaling pathway was activated by YAP knockdown, while the
MAP kinase pathway was inhibited. Curiously, the cell cycle machinery was activated,
which might counterbalance the activation of the pro-apoptotic p53-pathway.
On the whole the presented data provides strong evidence that the transcriptional
co-activator YAP plays an important role in regulating proliferation, invasiveness and
metastatic potential of ccRCC and might serve as a target for therapeutic intervention
in the future. Disrupted Hippo signaling and consecutive derepression and activation of
YAP leads to increased production of the YAP target genes Endothelin-1, Endothelin-2
and c-Myc. Increased endothelin-signaling in turn results in increased production of pro-
proliferative and proinvasive mediators by ccRCC cells and might thus enhance metastatic
colonization. Figure 4.35 on page 137 provides a graphic overview of the putative mech-
anistic consequences of YAP-hyperactivity for ccRCC tumor progression. Future studies
aimed at developing specific inhibitory drugs of the Hippo signaling pathway or its down-
stream effectors described here seem warranted in order to generate novel therapeutic
regimens against ccRCC.
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Figure 4.35.: Putative interaction of YAP with the endothelin axis in ccRCC.
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5.1. The transcriptional output of the Hippo-YAP axis
is functionally related but highly tissue
context-dependent in PDAC, biliary cancer and
RCC
Hippo pathway perturbation and consecutive YAP-hyperactivity frequently occur in neo-
plasia of many tissues, including PDAC, biliary cancers and ccRCC. This contributes
to tumorigenicity and YAP knockdown in cancer cell lines impairs proliferation, as well
as anchorage-dependent and independent colony formation in PDAC, biliary cancer and
RCC cell lines, while an influence on in vitro-migration was only observed in RCC cell
lines.
This phenotypic uniformity was however not mirrored by a direct, uniform downstream
expression pathway in the different cancers studied in this work. This apparently high
level of genetic complexity could only be partially resolved when shifting from a single-
gene towards pathway-based analysis models. In fact, certain pathways were activated
by YAP knockdown in one cell line while they were inhibited in another (e.g. MAPK in
PK9 vs. MZ1774 cells).
This confirms the general observation of the enormously high tissue-context dependency
of the transcriptional output of the Hippo-YAP-axis [64].
One common feature identified was the involvement of stromal compartments and the
discovery of single, highly YAP-positive, fibroblast-like cells residing in the tumor-adjacent
stroma which were present in all tumor entities analyzed. Mechanistically, transcriptomic
profiling returned candidates for the regulation of tumor-stroma interaction in all cases,
albeit different individual genes.
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5.2. Future directions
The investigation of the role of the Hippo-YAP signaling axis in the formation of the neo-
plastic stroma as well as tissue homeostasis and tumor-stroma interaction is surely one of
the most interesting avenue for future research. Especially in cancers that elicit an intense
desmoplastic reaction such as PDAC as well as biliary cancers, a better understanding
of the tumor microenvironment could lead to novel and innovative therapeutic concepts.
Potential starting points could be co-expression studies with YAP and markers for acti-
vated fibroblasts in patient tissues (e.g. α-smooth muscle actin) and in vitro co-culture
models [102].
Another interesting line of investigation is further the role of the YAP-paralogue TAZ as
well as the determination of YAP-TEAD initiated transcription in relation to transcription
initiated by YAP in association with other transcription factors like SMADs. This is
potentially interesting in PDAC as SMAD4 and deregulated TGF-β signaling play a
major role during pathogenesis.
139
Appendix A.
Raw data of DNA transcriptomic
profiling
A.1. Differentially expressed genes in PK9
YAP-knockdown cells
Table A.1.: Downregulated genes in PK9 YAP-knockdown cells
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
10413 YAP1 Yes-associated protein 1 NM_001130145.2 0,20 2,23E-14
6876 TAGLN transgelin NM_001001522.1 0,20 4,43E-09
51442 VGLL1 vestigial like 1 (Drosophila) NM_016267.3 0,29 2,92E-14
2348 FOLR1 folate receptor 1 (adult) NM_000802.3 0,30 3,11E-08
3488 IGFBP5 insulin-like growth factor binding
protein 5
NM_000599.3 0,34 3,62E-09
3488 IGFBP5 insulin-like growth factor binding
protein 5
NM_000599.3 0,36 2,44E-10
2348 FOLR1 folate receptor 1 (adult) NM_000802.3 0,37 5,69E-07
3486 IGFBP3 insulin-like growth factor binding
protein 3
NM_001013398.1 0,37 4,59E-05
92747 BPIFB1 BPI fold containing family B, member
1
NM_033197.2 0,38 6,61E-10
3122 HLA-DRA major histocompatibility complex,
class II, DR alpha
NM_019111.4 0,39 2,05E-05
629 CFB complement factor B NM_001710.5 0,40 2,39E-05
1591 CYP24A1 cytochrome P450, family 24, subfamily
A, polypeptide 1
NM_000782.4 0,40 1,26E-08
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Table A.1.: Downregulated genes in PK9 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
2628 GATM glycine amidinotransferase
(L-arginine:glycine amidinotransferase)
NM_001482.2 0,40 3,28E-07
6876 TAGLN transgelin NM_001001522.1 0,41 4,64E-07
56983 POGLUT1 protein O-glucosyltransferase 1 NM_152305.2 0,41 2,41E-09
523 ATP6V1A ATPase, H+ transporting, lysosomal
70kDa, V1 subunit A
NM_001690.3 0,41 4,08E-12
972 CD74 CD74 molecule, major
histocompatibility complex, class II
invariant chain
NM_001025159.2 0,42 2,87E-06
284018 C17orf58 chromosome 17 open reading frame 58 NM_181655.2 0,42 2,54E-11
972 CD74 CD74 molecule, major
histocompatibility complex, class II
invariant chain
NM_001025159.2 0,42 2,72E-05
3486 IGFBP3 insulin-like growth factor binding
protein 3
NM_001013398.1 0,42 7,72E-05
6286 S100P S100 calcium binding protein P NM_005980.2 0,43 3,37E-05
3128 HLA-
DRB6
major histocompatibility complex,
class II, DR beta 6 (pseudogene)
NG_002432.1 0,43 6,41E-06
27063 ANKRD1 ankyrin repeat domain 1 (cardiac
muscle)
NM_014391.2 0,43 1,17E-07
27032 ATP2C1 ATPase, Ca2+ transporting, type 2C,
member 1
NM_001001485.2 0,44 1,08E-07
3122 HLA-DRA major histocompatibility complex,
class II, DR alpha
NM_019111.4 0,45 7,76E-08
1490 CTGF connective tissue growth factor NM_001901.2 0,45 2,05E-04
11167 FSTL1 follistatin-like 1 NM_007085.4 0,46 7,40E-08
284018 C17orf58 chromosome 17 open reading frame 58 NM_181655.2 0,47 5,77E-09
619279 ZNF704 zinc finger protein 704 NM_001033723.2 0,47 5,65E-08
NA NA NA NA 0,47 7,25E-07
54575 UGT1A10 UDP glucuronosyltransferase 1 family,
polypeptide A10
NM_019075.2 0,47 1,21E-04
284018 C17orf58 chromosome 17 open reading frame 58 NM_181655.2 0,47 5,10E-10
525 ATP6V1B1 ATPase, H+ transporting, lysosomal
56/58kDa, V1 subunit B1
NM_001692.3 0,47 1,59E-07
51316 PLAC8 placenta-specific 8 NM_001130716.1 0,47 6,00E-06
1955 MEGF9 multiple EGF-like-domains 9 NM_001080497.2 0,48 6,17E-07
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Table A.1.: Downregulated genes in PK9 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
89846 FGD3 FYVE, RhoGEF and PH domain
containing 3
NM_001083536.1 0,48 2,36E-06
8723 SNX4 sorting nexin 4 NM_003794.3 0,50 6,25E-11
Table A.2.: Upregulated genes in PK9 YAP-knockdown cells
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
4312 MMP1 matrix metallopeptidase 1 (interstitial
collagenase)
NM_001145938.1 3,89 4,46E-08
10468 FST follistatin NM_006350.3 3,29 5,39E-08
5055 SERPINB2 serpin peptidase inhibitor, clade B
(ovalbumin), member 2
NM_001143818.1 3,18 8,55E-07
6947 TCN1 transcobalamin I (vitamin B12 binding
protein, R binder family)
NM_001062.3 3,12 1,44E-10
6364 CCL20 chemokine (C-C motif) ligand 20 NM_001130046.1 3,07 1,00E-06
5055 SERPINB2 serpin peptidase inhibitor, clade B
(ovalbumin), member 2
NM_001143818.1 2,82 6,19E-06
7857 SCG2 secretogranin II NM_003469.4 2,67 3,75E-08
3553 IL1B interleukin 1, beta NM_000576.2 2,60 2,88E-07
NA NA NA NA 2,53 1,37E-08
1437 CSF2 colony stimulating factor 2
(granulocyte-macrophage)
NM_000758.3 2,52 2,31E-05
794 CALB2 calbindin 2 NM_001740.4 2,47 1,23E-09
3552 IL1A interleukin 1, alpha NM_000575.3 2,43 1,55E-08
7431 VIM vimentin NM_003380.3 2,33 1,25E-09
118429 ANTXR2 anthrax toxin receptor 2 NM_001145794.1 2,32 6,12E-08
794 CALB2 calbindin 2 NM_001740.4 2,30 1,09E-10
9638 FEZ1 fasciculation and elongation protein
zeta 1 (zygin I)
NM_005103.4 2,24 3,17E-09
10013-
2240
LOC100-
132240
hypothetical LOC100132240 NC_000001.10 2,22 8,74E-08
5744 PTHLH parathyroid hormone-like hormone NM_198965.1 2,21 2,03E-04
6698 SPRR1A small proline-rich protein 1A NM_001199828.1 2,19 4,32E-08
389336 C5orf46 chromosome 5 open reading frame 46 NM_206966.2 2,19 3,02E-07
3956 LGALS1 lectin, galactoside-binding, soluble, 1 NM_002305.3 2,15 4,12E-07
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Table A.2.: Upregulated genes in PK9 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
207107 SFTA1P surfactant associated 1, pseudogene NR_027082.1 2,11 2,62E-11
7424 VEGFC vascular endothelial growth factor C NM_005429.2 2,09 5,32E-07
1839 HBEGF heparin-binding EGF-like growth
factor
NM_001945.2 2,07 5,91E-05
4319 MMP10 matrix metallopeptidase 10
(stromelysin 2)
NM_002425.2 2,07 6,85E-04
2533 FYB FYN binding protein NM_001243093.1 2,03 1,87E-10
6699 SPRR1B small proline-rich protein 1B NM_003125.2 2,03 7,97E-09
1848 DUSP6 dual specificity phosphatase 6 NM_001946.2 2,02 2,67E-05
A.2. Differentially expressed genes in G415
YAP-knockdown cells
Table A.3.: Downregulated genes in G415 YAP-knockdown cells
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
1455 CSNK1G2 casein kinase 1, gamma 2 NM_001319.6 0,25 1,82E-18
3689 ITGB2 integrin, beta 2 (complement
component 3 receptor 3 and 4 subunit)
NM_000211.3 0,25 3,10E-14
55643 BTBD2 BTB (POZ) domain containing 2 NM_017797.3 0,26 7,66E-17
83729 INHBE inhibin, beta E NM_031479.3 0,29 3,49E-11
10413 YAP1 Yes-associated protein 1 NM_001130145.2 0,30 5,72E-13
11082 ESM1 endothelial cell-specific molecule 1 NM_007036.4 0,32 2,03E-10
2872 MKNK2 MAP kinase interacting
serine/threonine kinase 2
NM_199054.2 0,33 6,93E-10
619383 SCARNA9 small Cajal body-specific RNA 9 NR_002569.2 0,33 9,08E-10
3689 ITGB2 integrin, beta 2 (complement
component 3 receptor 3 and 4 subunit)
NM_000211.3 0,34 1,66E-13
11082 ESM1 endothelial cell-specific molecule 1 NM_007036.4 0,34 2,96E-13
9982 FGFBP1 fibroblast growth factor binding
protein 1
NM_005130.4 0,35 8,93E-12
5673 PSG5 pregnancy specific beta-1-glycoprotein
5
NM_002781.3 0,35 1,89E-10
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Table A.3.: Downregulated genes in G415 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
11170 FAM107A family with sequence similarity 107,
member A
NM_001076778.2 0,35 2,53E-15
1958 EGR1 early growth response 1 NM_001964.2 0,37 2,90E-05
6876 TAGLN transgelin NM_001001522.1 0,37 6,27E-09
115948 CCDC151 coiled-coil domain containing 151 NM_145045.4 0,40 1,82E-09
3936 LCP1 lymphocyte cytosolic protein 1
(L-plastin)
NM_002298.4 0,41 4,33E-08
440 ASNS asparagine synthetase
(glutamine-hydrolyzing)
NM_001178075.1 0,41 6,72E-06
51754 TMEM8B transmembrane protein 8B NM_001042589.2 0,42 8,95E-10
79974 CPED1 cadherin-like and PC-esterase domain
containing 1
NM_024913.4 0,42 9,91E-12
23108 RAP1GAP2 RAP1 GTPase activating protein 2 NM_015085.4 0,43 2,65E-09
5678 PSG5 pregnancy specific beta-1-glycoprotein
9
NM_002781.3 0,43 3,27E-08
8943 AP3D1 adaptor-related protein complex 3,
delta 1 subunit
NM_001261826.1 0,43 8,62E-11
10761 PLAC1 placenta-specific 1 NM_021796.3 0,44 1,17E-10
6023 RMRP RNA component of mitochondrial
RNA processing endoribonuclease
NR_003051.3 0,45 4,27E-09
6876 TAGLN transgelin NM_001001522.1 0,45 2,87E-05
8076 MFAP5 microfibrillar associated protein 5 NM_003480.2 0,45 3,11E-11
11009 IL24 interleukin 24 NM_001185156.1 0,45 2,07E-09
3224 HOXC8 homeobox C8 NM_022658.3 0,45 3,19E-10
221416 C6orf223 chromosome 6 open reading frame 223 NM_001171992.1 0,46 7,91E-08
55902 ACSS2 acyl-CoA synthetase short-chain
family member 2
NM_001076552.2 0,46 2,10E-07
375061 FAM89A family with sequence similarity 89,
member A
NM_198552.2 0,46 1,97E-09
54541 DDIT4 DNA-damage-inducible transcript 4 NM_019058.2 0,46 1,86E-04
284415 VSTM1 V-set and transmembrane domain
containing 1
NM_001288791.1 0,47 1,31E-10
8943 AP3D1 adaptor-related protein complex 3,
delta 1 subunit
NM_001261826.1 0,47 7,94E-09
59277 NTN4 netrin 4 NM_021229.3 0,47 1,40E-08
55902 ACSS2 acyl-CoA synthetase short-chain
family member 2
NM_001076552.2 0,47 7,01E-07
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Table A.3.: Downregulated genes in G415 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
59277 NTN4 netrin 4 NM_021229.3 0,47 8,83E-09
11009 IL24 interleukin 24 NM_001185156.1 0,47 2,89E-06
1843 DUSP1 dual specificity phosphatase 1 NM_004417.3 0,48 1,08E-04
375061 FAM89A family with sequence similarity 89,
member A
NM_198552.2 0,48 1,85E-09
87769 GGACT gamma-glutamylamine
cyclotransferase
NM_001195087.1 0,49 1,26E-07
677800 SNORA12 small nucleolar RNA, H/ACA box 12 NR_002954.1 0,49 1,29E-08
2172 FABP6 fatty acid binding protein 6, ileal NM_001040442.1 0,49 1,29E-06
6303 SAT1 spermidine/spermine
N1-acetyltransferase 1
NM_002970.2 0,49 8,78E-10
440 ASNS asparagine synthetase
(glutamine-hydrolyzing)
NM_001178075.1 0,49 1,14E-05
27147 DENND2A DENN/MADD domain containing 2A NM_015689.3 0,50 9,31E-12
1842 ECM2 extracellular matrix protein 2, female
organ and adipocyte specific
NM_001197295.1 0,50 6,88E-10
9699 RIMS2 regulating synaptic membrane
exocytosis 2
NM_001100117.2 0,50 9,22E-10
Table A.4.: Upregulated genes in G415 YAP-knockdown cells
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
58538 MPP4 membrane protein, palmitoylated 4
(MAGUK p55 subfamily member 4)
NM_033066.2 8,27 2,50E-23
57214 CEMIP cell migration inducing protein,
hyaluronan binding
NM_018689.1 4,57 7,40E-16
22943 DKK1 dickkopf WNT signaling pathway
inhibitor 1
NM_012242.2 3,88 5,20E-09
6288 SAA1 serum amyloid A1 NM_000331.4 3,67 9,54E-09
163071 ZNF114 zinc finger protein 114 NM_153608.1 3,16 1,21E-09
219736 STOX1 storkhead box 1 NM_152709.4 2,85 8,22E-10
4982 TNFRSF11B tumor necrosis factor receptor
superfamily, member 11b
NM_002546.3 2,66 5,49E-11
5055 SERPINB2 serpin peptidase inhibitor, clade B
(ovalbumin), member 2
NM_001143818.1 2,65 1,68E-06
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Table A.4.: Upregulated genes in G415 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
4312 MMP1 matrix metallopeptidase 1 (interstitial
collagenase)
NM_002421.3 2,64 1,09E-06
5055 SERPINB2 serpin peptidase inhibitor, clade B
(ovalbumin), member 2
NM_001143818.1 2,63 1,40E-06
5801 PTPRR protein tyrosine phosphatase, receptor
type, R
NM_002849.3 2,62 3,84E-11
22943 DKK1 dickkopf WNT signaling pathway
inhibitor 1
NM_012242.2 2,58 1,21E-07
7008 TEF thyrotrophic embryonic factor NM_003216.3 2,55 3,65E-08
3575 IL7R interleukin 7 receptor NM_002185 2,51 2,84E-10
4496 MT1H metallothionein 1H NM_005951.2 2,51 2,55E-08
10526 IPO8 importin 8 NM_006390.3 2,50 1,94E-13
8347 HIST1H2BC histone cluster 1, H2bc NM_003526.2 2,39 3,32E-08
8638 OASL 2’-5’-oligoadenylate synthetase-like NM_003733.3 2,27 2,15E-07
440498 HSBP1L1 heat shock factor binding protein
1-like 1
XM_006722476.1 2,18 5,84E-09
10468 FST follistatin NM_013409.2 2,18 4,91E-06
389816 LRRCC26 leucine rich repeat containing 26 NM_001013653.2 2,17 4,88E-11
114907 FBXO32 F-box protein 32 NM_058229.3 2,17 1,81E-07
1583 CYP11A1 cytochrome P450, family 11, subfamily
A, polypeptide 1
NM_000781.2 2,10 3,60E-06
6000 RGS7 regulator of G-protein signaling 7 NM_002924.5 2,10 8,72E-07
6275 S100A4 S100 calcium binding protein A4 NM_019554.2 2,10 9,27E-09
3321 IGSF3 immunoglobulin superfamily, member
3
NM_001542.3 2,09 3,55E-07
57535 KIAA1324 KIAA1324 NM_020775.4 2,05 5,41E-08
23643 LY96 lymphocyte antigen 96 NM_015364.4 2,05 1,42E-09
348093 RBPMS2 RNA binding protein with multiple
splicing 2
NM_194272.1 2,05 8,54E-09
6296 ACSM3 acyl-CoA synthetase medium-chain
family member 3
NM_005622.3 2,04 1,38E-07
3321 IGSF3 immunoglobulin superfamily, member
3
NM_001542.3 2,04 6,77E-10
4494 MT1F metallothionein 1F NM_005949.3 2,02 2,66E-09
2202 EFEMP1 EGF containing fibulin-like
extracellular matrix protein 1
NM_001039348.2 2,01 7,86E-09
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Table A.4.: Upregulated genes in G415 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
4352 MPL myeloproliferative leukemia virus
oncogene
NM_005373.2 2,01 5,72E-08
4973 OLR1 oxidized low density lipoprotein
(lectin-like) receptor 1
NM_002543.3 2,01 2,18E-08
389816 LRRC26 leucine rich repeat containing 26 NM_001013653.2 2,00 1,70E-12
A.3. Differentially expressed genes in MZ1774
YAP-knockdown cells
Table A.5.: Downregulated genes in MZ1774 YAP-knockdown cells
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
1907 EDN2 endothelin 2 NM_001956.3 0,24 1,16E-11
1906 EDN1 endothelin 1 NM_001955.4 0,31 8,57E-06
7057 THBS1 thrombospondin 1 NM_003246.2 0,33 2,34E-05
4616 GADD45B growth arrest and
DNA-damage-inducible, beta
NM_015675.3 0,34 7,53E-05
3491 CYR61 cysteine-rich, angiogenic inducer, 61 NM_001554.4 0,36 1,73E-04
10175 CNIH cornichon homolog (Drosophila) NM_005776.2 0,37 3,02E-06
1646 AKR1C2 aldo-keto reductase family 1, member
C2 (dihydrodiol dehydrogenase 2, bile
acid binding protein, 3-alpha
hydroxysteroid dehydrogenase, type
III)
NM_001354.5 0,37 4,71E-06
4609 MYC v-myc myelocytomatosis viral
oncogene homolog (avian)
NM_002467.4 0,37 1,05E-06
523 ATP6V1A ATPase, H+ transporting, lysosomal
70kDa, V1 subunit A
NM_001690.3 0,38 4,44E-12
4609 MYC v-myc myelocytomatosis viral
oncogene homolog (avian)
NM_002467.4 0,38 2,34E-06
6520 SLC3A2 solute carrier family 3 (activators of
dibasic and neutral amino acid
transport), member 2
NM_001012662.2 0,39 3,40E-06
284018 C17orf58 chromosome 17 open reading frame 58 NM_181655.2 0,39 7,44E-10
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Table A.5.: Downregulated genes in MZ1774 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
10413 YAP1 Yes-associated protein 1 NM_001130145.2 0,40 2,42E-08
81788 NUAK2 NUAK family, SNF1-like kinase, 2 NM_030952.1 0,40 4,10E-05
1316 KLF6 Kruppel-like factor 6 NM_001160124.1 0,40 4,23E-04
586 BCAT1 branched chain amino-acid
transaminase 1, cytosolic
NM_001178091.1 0,41 7,35E-08
81788 NUAK2 NUAK family, SNF1-like kinase, 2 NM_030952.1 0,41 5,60E-06
6526 SLC5A3 solute carrier family 5
(sodium/myo-inositol cotransporter),
member 3
NM_006933.4 0,41 1,85E-07
59345 GNB4 guanine nucleotide binding protein (G
protein), beta polypeptide 4
NM_021629.3 0,42 2,34E-08
54206 ERRFI1 ERBB receptor feedback inhibitor 1 NM_018948.3 0,42 4,98E-09
27032 ATP2C1 ATPase, Ca2+ transporting, type 2C,
member 1
NM_001199180.1 0,42 2,63E-07
84706 GPT2 glutamic pyruvate transaminase
(alanine aminotransferase) 2
NM_001142466.1 0,44 4,04E-08
9518 GDF15 growth differentiation factor 15 NM_004864.2 0,44 8,31E-05
406991 MIR21 microRNA 21 NR_029493.1 0,44 4,12E-07
59272 ACE2 angiotensin I converting enzyme
(peptidyl-dipeptidase A) 2
NM_021804.2 0,44 2,76E-07
8140 SLC7A5 solute carrier family 7 (amino acid
transporter light chain, L system),
member 5
NM_003486.5 0,44 9,39E-07
51125 GOLGA7 golgin A7 NM_001002296.1 0,44 1,41E-11
4703 NEB nebulin NM_001164507.1 0,44 2,93E-05
79660 PPP1R3B protein phosphatase 1, regulatory
(inhibitor) subunit 3B
NM_001201329.1 0,44 4,58E-06
10175 CNIH cornichon homolog (Drosophila) NM_005776.2 0,45 2,71E-05
57761 TRIB3 tribbles homolog 3 (Drosophila) NM_021158.3 0,46 8,68E-06
388272 C16orf87 chromosome 16 open reading frame 87 NM_001001436.2 0,46 1,76E-06
6185 RPN2 ribophorin II NM_002951.3 0,46 1,28E-07
27063 ANKRD1 ankyrin repeat domain 1 (cardiac
muscle)
NM_014391.2 0,47 2,80E-06
29968 PSAT1 phosphoserine aminotransferase 1 NM_021154.3 0,47 1,45E-04
2152 F3 coagulation factor III (thromboplastin,
tissue factor)
NM_001993.4 0,47 4,45E-06
81539 SLC38A1 solute carrier family 38, member 1 NM_001077484.1 0,48 1,17E-04
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Table A.5.: Downregulated genes in MZ1774 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
6397 SEC14L1 SEC14-like 1 (S. cerevisiae) NM_001039573.2 0,48 3,67E-08
10397 NDRG1 N-myc downstream regulated 1 NM_001135242.1 0,48 5,34E-06
5638 PRRG1 proline rich Gla (G-carboxyglutamic
acid) 1
NM_000950.2 0,48 5,42E-08
10797 MTHFD2 methylenetetrahydrofolate
dehydrogenase (NADP+ dependent) 2,
methenyltetrahydrofolate
cyclohydrolase
NM_006636.3 0,49 7,56E-08
2530 FUT8 fucosyltransferase 8 (alpha (1,6)
fucosyltransferase)
NM_178155.2 0,49 3,76E-07
80115 BAIAP2L2 BAI1-associated protein 2-like 2 NM_025045.4 0,49 1,06E-05
5209 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase
3
NM_004566.3 0,49 3,49E-05
10175 CNIH cornichon homolog (Drosophila) NM_005776.2 0,50 2,86E-05
Table A.6.: Upregulated genes in MZ1774 YAP-knockdown cells
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
84952 CGNL1 cingulin-like 1 NM_001252335.1 2,97 2,23E-11
5265 SERPINA1 serpin peptidase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin),
member 1
NM_000295.4 2,49 6,10E-07
80117 ARL14 ADP-ribosylation factor-like 14 NM_025047.2 2,49 1,91E-07
10344 CCL26 chemokine (C-C motif) ligand 26 NM_006072.4 2,47 2,00E-05
1004 CDH6 cadherin 6, type 2, K-cadherin (fetal
kidney)
NM_004932.3 2,27 7,61E-10
266977 GPR110 G protein-coupled receptor 110 NM_153840.2 2,22 5,90E-07
283460 HNF1A-
AS1
HNF1A antisense RNA 1 (non-protein
coding)
NR_024345.1 2,11 2,20E-04
55195 C14orf105 chromosome 14 open reading frame
105
NM_018168.2 2,07 4,97E-03
266977 GPR110 G protein-coupled receptor 110 NM_153840.2 2,06 1,09E-06
11074 TRIM31 tripartite motif containing 31 NM_007028.3 2,04 1,00E-05
55775 TDP1 tyrosyl-DNA phosphodiesterase 1 NM_001008744.1 2,03 7,20E-04
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Table A.6.: Upregulated genes in MZ1774 YAP-knockdown cells (continued)
Gene
ID
Symbol Gene name Accession
number
Fold
change
p Value
283209 PGM2L1 phosphoglucomutase 2-like 1 NM_173582.3 2,02 5,00E-05
5265 SERPINA1 serpin peptidase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin),
member 1
NM_000295.4 2,02 1,30E-04
11221 DUSP10 dual specificity phosphatase 10 NM_007207.4 2,01 1,00E-04
3767 KCNJ11 potassium inwardly-rectifying channel,
subfamily J, member 16
NM_000525.3 1,97 1,00E-05
2353 FOS FBJ murine osteosarcoma viral
oncogene homolog B
NM_005252.3 1,97 5,91E-02
56829 ZC3HAV1 zinc finger CCCH-type, antiviral 1 NM_020119.3 1,97 1,50E-04
158295 MGC24103 hypothetical MGC24103 XR_108934.3 1,96 4,91E-03
7327 UBE2G2 ubiquitin-conjugating enzyme E2G 2 NM_003343.5 1,95 8,77E-03
56664 VTRNA1-1 vault RNA 1-1 NR_026703.1 1,94 1,20E-04
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Appendix B.
Raw data of Signaling Pathway
Impact Analysis
Table B.1.: Signaling Pathway Impact Analysis of PK9 YAP-knockdown cells
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
1 Rheumatoid
arthritis
5323 5,3E-
10
1,0E+00 1,2E-
08
1,3E-
06
1,3E-06 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05323+3552+
3553+3569+1437+4312+4314+
3108+3113+3122+155066+523+
525+6364
2 Cytokine-
cytokine receptor
interaction
4060 4,3E-
04
5,0E-
06
4,5E-
08
2,4E-
06
4,8E-06 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04060+3553+
3552+268+3604+3460+7424+
1437+3569+6367+6364+58191
3 Graft-versus-host
disease
5332 4,2E-
06
1,0E+00 5,7E-
05
2,0E-
03
6,1E-03 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05332+3108+
3113+3122+3569+3552+3553
4 Type I diabetes
mellitus
4940 1,3E-
05
1,0E+00 1,5E-
04
4,2E-
03
1,7E-02 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04940+1363+
3108+3113+3122+3552+3553
5 Pathways in
cancer
5200 2,0E-
05
8,8E-
01
2,1E-
04
4,6E-
03
2,3E-02 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05200+54361+
7476+80326+3914+3918+3655+
2535+7039+8313+5578+1488+
6256+1026+330+7424+4312+3569
6 Calcium
signaling
pathway
4020 9,5E-
03
3,0E-
03
3,3E-
04
5,9E-
03
3,5E-02 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04020+5578+
147+1909+4923+488+154+493
7 Osteoclast
differentiation
4380 4,1E-
02
1,0E-
03
4,6E-
04
7,0E-
03
4,9E-02 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04380+3552+
3553+3460+5971+4688
8 ErbB signaling
pathway
4012 5,2E-
04
1,1E-
01
6,2E-
04
7,6E-
03
6,7E-02 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04012+1026+
5058+7039+5578+1839+3084+
145957
9 MAPK signaling
pathway
4010 2,1E-
02
3,0E-
03
6,8E-
04
7,6E-
03
7,3E-02 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04010+1848+
5495+5971+5578+10912+3552+
3553+5058+2318
10 Toxoplasmosis 5145 1,2E-
04
5,8E-
01
7,3E-
04
7,6E-
03
7,9E-02 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05145+330+
3108+3113+3122+240+3655+
3914+3918+3460
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Table B.1.: Signaling Pathway Impact Analysis of PK9 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
11 Leishmaniasis 5140 7,3E-
05
1,0E+00 7,7E-
04
7,6E-
03
8,3E-02 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05140+3108+
3113+3122+3552+3553+3460+
4688
12 Influenza A 5164 2,1E-
04
4,4E-
01
9,5E-
04
8,5E-
03
1,0E-01 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05164+5644+
3553+3108+3113+3122+3552+
3569+6041+5578+3460
13 Staphylococcus
aureus infection
5150 4,6E-
04
2,5E-
01
1,2E-
03
9,6E-
03
1,3E-01 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05150+629+
715+3108+3113+3122
14 Salivary secretion 4970 7,9E-
03
1,6E-
02
1,3E-
03
9,7E-
03
1,4E-01 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04970+154+
147+493+5578+1469
15 Amoebiasis 5146 1,9E-
04
7,4E-
01
1,4E-
03
9,8E-
03
1,5E-01 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05146+3553+
3914+3918+3569+1437+5578+
1992+5055
16 Complement and
coagulation
cascades
4610 2,1E-
04
8,0E-
01
1,6E-
03
1,1E-
02
1,7E-01 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04610+5329+
5328+5327+629+725+715
17 HTLV-I infection 5166 2,8E-
04
6,5E-
01
1,8E-
03
1,1E-
02
1,9E-01 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05166+1026+
8881+3569+1437+5971+330+
54361+7476+80326+2535+3108+
3113+3122
18 Tuberculosis 5152 1,1E-
03
1,8E-
01
1,9E-
03
1,1E-
02
2,0E-01 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05152+3460+
972+3108+3113+3122+3552+
3553+3569+3656
19 Intestinal
immune network
for IgA
production
4672 2,3E-
04
1,0E+00 2,2E-
03
1,2E-
02
2,3E-01 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04672+3569+
3108+3113+3122+5284
20 Systemic lupus
erythematosus
5322 3,4E-
03
7,1E-
02
2,3E-
03
1,2E-
02
2,5E-01 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05322+715+
3108+3113+3122+8344+8365
21 Asthma 5310 2,8E-
03
NA 2,8E-
03
1,5E-
02
3,1E-01 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05310+3108+
3113+3122
22 Vibrio cholerae
infection
5110 1,8E-
03
3,8E-
01
5,6E-
03
2,7E-
02
6,1E-01 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05110+155066+
523+525+9414+5578
23 Focal adhesion 4510 9,6E-
04
7,4E-
01
5,8E-
03
2,7E-
02
6,3E-01 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04510+3655+
2318+4659+5578+3914+3918+
6696+330+7424+5058
24 Wnt signaling
pathway
4310 2,4E-
03
3,4E-
01
6,8E-
03
3,1E-
02
7,3E-01 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04310+5578+
2535+144165+1488+8313+54361+
7476+80326
25 Epithelial cell
signaling in
Helicobacter
pylori infection
5120 5,1E-
03
1,8E-
01
7,4E-
03
3,2E-
02
8,0E-01 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05120+155066+
523+525+5058+1839
26 Basal cell
carcinoma
5217 0,00 0,80 0,01 0,04 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05217+54361+
7476+80326+8313+2535
27 Pertussis 5133 0,01 0,33 0,01 0,06 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05133+3552+
3553+3569+715+725
28 Salmonella
infection
5132 0,00 0,87 0,01 0,06 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05132+2318+
3553+3460+3552+3569+1437
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Table B.1.: Signaling Pathway Impact Analysis of PK9 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
29 Neuroactive
ligand-receptor
interaction
4080 0,02 0,10 0,02 0,06 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04080+5644+
2568+7433+4923+1909+147+154
30 Small cell lung
cancer
5222 0,01 0,25 0,02 0,08 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05222+3655+
6256+3914+3918+330
31 Notch signaling
pathway
4330 0,01 0,61 0,02 0,08 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04330+1488+
8650+182+28514
32 Antigen
processing and
presentation
4612 0,01 0,28 0,03 0,08 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04612+972+
3108+3113+3122
33 Apoptosis 4210 0,05 0,09 0,03 0,09 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04210+330+
3656+3552+3553
34 Pathogenic
Escherichia coli
infection
5130 0,06 0,08 0,03 0,10 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05130+79861+
5578+9181
35 Herpes simplex
infection
5168 0,01 1 0,03 0,10 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05168+3553+
3569+6041+3460+972+3108+
3113+3122
36 ECM-receptor
interaction
4512 0,01 0,98 0,03 0,10 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04512+3914+
3918+6696+3655+6385
37 p53 signaling
pathway
4115 0,03 0,27 0,04 0,12 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04115+3486+
10912+55240+1026
38 Allograft
rejection
5330 0,01 1 0,05 0,14 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05330+3108+
3113+3122
39 Autoimmune
thyroid disease
5320 0,01 1 0,05 0,15 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05320+3108+
3113+3122
40 NOD-like
receptor signaling
pathway
4621 0,07 0,15 0,06 0,16 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04621+330+
3553+3569
41 Prion diseases 5020 0,01 1 0,06 0,16 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05020+3552+
3553+3569
42 Pancreatic
secretion
4972 0,01 1 0,06 0,16 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04972+493+
5578+9635+5644+488
43 Chagas disease
(American
trypanosomiasis)
5142 0,06 0,18 0,06 0,16 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05142+3553+
3460+5521+3569
44 GnRH signaling
pathway
4912 0,44 0,03 0,07 0,18 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04912+5578+
1839
45 Legionellosis 5134 0,06 0,25 0,08 0,19 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05134+3553+
1917+3569
46 PPAR signaling
pathway
3320 0,08 0,19 0,08 0,19 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa03320+6256+
2181+4312
47 African
trypanosomiasis
5143 0,02 1 0,08 0,19 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05143+3553+
3569+5578
48 Melanogenesis 4916 0,02 0,87 0,08 0,19 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04916+2535+
5578+54361+7476+80326
49 Malaria 5144 0,02 1 0,11 0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05144+6385+
3569+3553
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Table B.1.: Signaling Pathway Impact Analysis of PK9 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
50 Vascular smooth
muscle
contraction
4270 0,09 0,31 0,12 0,27 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04270+4659+
5578+147+1909
51 Bladder cancer 5219 0,03 1 0,13 0,28 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05219+4312+
7424+1026
52 Tight junction 4530 0,33 0,10 0,14 0,29 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04530+5578+
5521+9414
53 Pancreatic cancer 5212 0,33 0,11 0,15 0,31 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05212+7039+
7424
54 Chemokine
signaling
pathway
4062 0,29 0,14 0,17 0,34 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04062+58191+
6364+6367+5058
55 Non-small cell
lung cancer
5223 0,07 0,71 0,19 0,37 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05223+5578+
7039+6256
56 Cytosolic
DNA-sensing
pathway
4623 0,05 1 0,19 0,37 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04623+3553+
3569+10622
57 Hedgehog
signaling
pathway
4340 0,05 1 0,20 0,37 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04340+54361+
7476+80326
58 Glioma 5214 0,09 0,75 0,24 0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05214+7039+
5578+1026
59 Viral myocarditis 5416 0,07 1 0,25 0,46 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05416+3108+
3113+3122
60 Hepatitis C 5160 0,15 0,50 0,27 0,48 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05160+5521+
6041+1026+6256
61 Chronic myeloid
leukemia
5220 0,34 0,23 0,28 0,50 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05220+1488+
1026
62 Natural killer cell
mediated
cytotoxicity
4650 0,10 0,87 0,30 0,51 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04650+3460+
1437+5578+5058
63 Arrhythmogenic
right ventricular
cardiomyopathy
(ARVC)
5412 0,09 1 0,31 0,53 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05412+488+
1832+3655
64 Toll-like receptor
signaling
pathway
4620 0,17 0,58 0,32 0,54 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04620+6696+
3553+3569
65 Gastric acid
secretion
4971 0,27 0,36 0,32 0,54 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04971+5578+
3776
66 Prostate cancer 5215 0,44 0,24 0,34 0,55 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05215+1026+
7039
67 Renal cell
carcinoma
5211 0,10 1 0,34 0,55 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05211+7424+
7039+5058
68 Measles 5162 0,11 1 0,35 0,56 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05162+3460+
3552+3553+3569
69 GABAergic
synapse
4727 0,12 1 0,36 0,57 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04727+2568+
18+5578
70 SNARE
interactions in
vesicular
transport
4130 0,12 1 0,38 0,58 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04130+55014+
10228
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Table B.1.: Signaling Pathway Impact Analysis of PK9 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
71 Mineral
absorption
4978 0,14 1 0,42 0,64 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04978+30061+
261729
72 Long-term
potentiation
4720 0,27 0,53 0,43 0,64 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04720+5578+
4659
73 Jak-STAT
signaling
pathway
4630 0,15 1 0,44 0,65 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04630+10252+
3460+3569+1437
74 RIG-I-like
receptor signaling
pathway
4622 0,26 0,62 0,46 0,65 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04622+54941+
80143
75 Regulation of
actin
cytoskeleton
4810 0,22 0,72 0,46 0,65 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04810+5305+
4659+5058+89846+3655
76 Cell cycle 4110 0,35 0,46 0,46 0,65 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04110+8881+
1026+10912
77 Endocrine and
other
factor-regulated
calcium
reabsorption
4961 0,51 0,35 0,49 0,68 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04961+5578
78 Glutamatergic
synapse
4724 0,51 0,36 0,49 0,68 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04724+5578+
9455
79 VEGF signaling
pathway
4370 0,69 0,27 0,50 0,69 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04370+5578
80 Neurotrophin
signaling
pathway
4722 0,62 0,34 0,54 0,73 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04722+10019+
3656
81 TGF-beta
signaling
pathway
4350 0,35 0,75 0,61 0,82 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04350+10468+
268
82 Leukocyte
transendothelial
migration
4670 0,51 0,55 0,64 0,84 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04670+5578+
4688
83 Adipocytokine
signaling
pathway
4920 0,30 1 0,66 0,85 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04920+2181+
6256
84 Axon guidance 4360 0,31 1 0,67 0,85 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04360+59277+
5058+9037
85 Fc gamma
R-mediated
phagocytosis
4666 0,45 0,68 0,67 0,85 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04666+5058+
5578
86 Lysosome 4142 0,32 1 0,69 0,85 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04142+1075+
9374+7805
87 Melanoma 5218 0,66 0,50 0,69 0,85 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05218+1026
88 RNA degradation 3018 0,33 1 0,70 0,85 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa03018+5073+
10950
89 Fc epsilon RI
signaling
pathway
4664 0,33 1 0,70 0,85 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04664+1437+
5578
90 Dilated
cardiomyopathy
5414 0,37 1 0,74 0,88 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05414+488+
3655
91 Oocyte meiosis 4114 0,52 0,71 0,74 0,88 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04114+8881+
9985
92 Gap junction 4540 0,39 1 0,75 0,88 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04540+5578+
79861
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Table B.1.: Signaling Pathway Impact Analysis of PK9 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
93 Thyroid cancer 5216 0,39 1 0,76 0,88 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05216+6256
94 T cell receptor
signaling
pathway
4660 0,46 1 0,82 0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04660+1437+
5058
95 Aldosterone-
regulated sodium
reabsorption
4960 0,46 1 0,82 0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04960+5578
96 Dopaminergic
synapse
4728 0,58 0,84 0,84 0,95 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04728+5578+
5521
97 mTOR signaling
pathway
4150 0,56 1 0,89 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04150+7424
98 Endometrial
cancer
5213 0,58 1 0,90 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05213+8313
99 Long-term
depression
4730 0,62 1 0,92 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04730+5578
100 Insulin signaling
pathway
4910 0,63 1 0,92 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04910+5834+
10211
101 Bile secretion 4976 0,63 1 0,92 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04976+6256
102 Colorectal cancer 5210 0,64 1 0,93 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05210+8313
103 RNA transport 3013 0,72 1 0,96 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa03013+1917+
10799
104 B cell receptor
signaling
pathway
4662 0,72 1 0,96 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04662+8519
105 Alzheimer’s
disease
5010 0,73 1 0,96 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05010+488+
3553
106 Progesterone-
mediated oocyte
maturation
4914 0,74 1 0,96 0,98 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04914+8881
107 Cholinergic
synapse
4725 0,80 1 0,98 0,99 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04725+5578
108 Olfactory
transduction
4740 0,93 1 1,00 1,00 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04740+9635
Table B.2.: Signaling Pathway Impact Analysis of G415 YAP-knockdown cells
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
1 Cytokine-
cytokine receptor
interaction
4060 0,0002 0,20 0,0004 0,0119 0,01 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04060+83729+
11009+4352+3575+4982
2 Amoebiasis 5146 0,0258 0,02 0,0046 0,0515 0,15 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05146+3689+
5055
3 PPAR signaling
pathway
3320 0,0006 1 0,0047 0,0515 0,15 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa03320+2172+
4973+4312
4 Hedgehog
signaling
pathway
4340 0,1218 0,01 0,0110 0,0908 0,36 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04340+1455
5 TGF-beta
signaling
pathway
4350 0,0163 0,15 0,0175 0,1062 0,58 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04350+83729+
10468
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Table B.2.: Signaling Pathway Impact Analysis of G415 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
6 Regulation of
actin
cytoskeleton
4810 0,4013 0,01 0,0193 0,1062 0,64 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04810+3689
7 Jak-STAT
signaling
pathway
4630 0,0043 1 0,0279 0,1168 0,92 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04630+3575+
4352+11009
8 Mineral
absorption
4978 0,0050 1 0,0315 0,1168 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04978+4494+
4496
9 Natural killer cell
mediated
cytotoxicity
4650 0,2415 0,02 0,0319 0,1168 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04650+3689
10 Osteoclast
differentiation
4380 0,2578 0,03 0,0415 0,1371 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04380+4982
11 Leukocyte
transendothelial
migration
4670 0,2374 0,03 0,0470 0,1409 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04670+3689
12 Pertussis 5133 0,0142 1 0,0746 0,2000 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05133+3689+
23643
13 Rheumatoid
arthritis
5323 0,0180 1 0,0904 0,2000 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05323+4312+
3689
14 Prion diseases 5020 0,0705 0,26 0,0905 0,2000 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05020+1958
15 Leishmaniasis 5140 0,1499 0,12 0,0909 0,2000 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05140+3689
16 MAPK signaling
pathway
4010 0,0261 0,76 0,0972 0,2004 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04010+1843+
5801+2872
17 Wnt signaling
pathway
4310 0,3084 0,12 0,1610 0,3126 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04310+22943
18 Malaria 5144 0,0904 1 0,3076 0,5229 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05144+3689
19 Staphylococcus
aureus infection
5150 0,0977 1 0,3250 0,5229 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05150+3689
20 Bladder cancer 5219 0,1002 1 0,3307 0,5229 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05219+4312
21 Insulin signaling
pathway
4910 0,2835 0,41 0,3634 0,5229 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04910+2872
22 mTOR signaling
pathway
4150 0,1218 1 0,3783 0,5229 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04150+54541
23 Pathogenic
Escherichia coli
infection
5130 0,1313 1 0,3979 0,5229 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05130+23643
24 Legionellosis 5134 0,1313 1 0,3979 0,5229 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05134+3689
25 HTLV-I infection 5166 0,1373 1 0,4099 0,5229 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05166+3689+
1958
26 Viral myocarditis 5416 0,1383 1 0,4120 0,5229 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05416+3689
27 Toll-like receptor
signaling
pathway
4620 0,1992 1 0,5206 0,6257 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04620+23643
28 Systemic lupus
erythematosus
5322 0,2057 1 0,5309 0,6257 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05322+8347
29 Toxoplasmosis 5145 0,2578 1 0,6072 0,6662 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05145+23643
30 Axon guidance 4360 0,2638 1 0,6153 0,6662 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04360+59277
31 Lysosome 4142 0,2718 1 0,6258 0,6662 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04142+8943
32 Tuberculosis 5152 0,3306 1 0,6965 0,7183 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05152+3689
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Table B.2.: Signaling Pathway Impact Analysis of G415 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
33 Pathways in
cancer
5200 0,5590 1 0,8841 0,8841 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05200+4312
Table B.3.: Signaling Pathway Impact Analysis of MZ1774 YAP-knockdown cells
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
1 p53 signaling
pathway
4115 1,5E-
06
0,13 3,2E-
06
0,00 0,000 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04115+3486+
1647+4616+7057+8795+54205+
1021+27244
2 MAPK signaling
pathway
4010 1,8E-
04
0,32 6,2E-
04
0,02 0,067 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04010+11221+
2247+627+9261+1649+51776+
1647+4616+3554+4609+2872
3 Cell cycle 4110 6,5E-
02
0,00 6,9E-
04
0,02 0,074 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04110+1647+
4616+1021+4609
4 Insulin signaling
pathway
4910 8,6E-
04
0,95 6,6E-
03
0,16 0,713 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04910+2872+
5501+5507+79660+5295+5590+
8660
5 Tuberculosis 5152 1,0E-
02
0,09 7,3E-
03
0,16 0,793 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05152+1051+
1054+7096+54205+3592+3456
6 HTLV-I infection 5166 1,0E-
02
0,15 1,1E-
02
0,21 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05166+6513+
821+4609+115+3554+5295+
64784+94241
7 Regulation of
actin
cytoskeleton
4810 9,3E-
03
0,23 1,5E-
02
0,21 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04810+26999+
85477+7414+4659+5501+5295+
2247
8 Cholinergic
synapse
4725 6,2E-
03
0,37 1,6E-
02
0,21 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04725+115+
3710+59345+9586+5295
9 Type II diabetes
mellitus
4930 1,1E-
02
0,25 1,9E-
02
0,21 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04930+5295+
8660+5590
10 Colorectal cancer 5210 3,6E-
02
0,09 2,1E-
02
0,21 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05210+5295+
4609+54205
11 Neurotrophin
signaling
pathway
4722 6,3E-
02
0,05 2,1E-
02
0,21 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04722+627+
5295+8660+9261
12 Vascular smooth
muscle
contraction
4270 7,1E-
03
0,55 2,5E-
02
0,22 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04270+4659+
5501+3710+136+115
13 Complement and
coagulation
cascades
4610 2,4E-
02
0,17 2,7E-
02
0,22 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04610+2152+
5265+5328
14 Cytokine-
cytokine receptor
interaction
4060 9,0E-
03
0,61 3,4E-
02
0,23 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04060+3554+
3456+3592+10344+27242+51330+
8795
15 Influenza A 5164 9,4E-
03
0,63 3,6E-
02
0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05164+5295+
3456+3592+8795+54205+10625
16 Long-term
potentiation
4720 3,8E-
02
0,17 3,9E-
02
0,23 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04720+4659+
5501+3710
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Table B.3.: Signaling Pathway Impact Analysis of MZ1774 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
17 Apoptosis 4210 1,7E-
02
0,42 4,2E-
02
0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04210+54205+
5295+3554+8795
18 Measles 5162 1,0E-
02
0,69 4,2E-
02
0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05162+3456+
5295+3592+8795+1021
19 Amoebiasis 5146 2,7E-
02
0,28 4,4E-
02
0,23 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05146+3554+
3592+5295+7414
20 Pathways in
cancer
5200 3,4E-
02
0,23 4,6E-
02
0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05200+5295+
4609+7428+54205+1488+1021+
6513+2247
21 Adipocytokine
signaling
pathway
4920 8,1E-
03
1 4,7E-
02
0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04920+2182+
51703+6513+8660
22 Renal cell
carcinoma
5211 9,0E-
03
0,95 4,9E-
02
0,23 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05211+6513+
7428+201163+5295
23 Glutamatergic
synapse
4724 3,6E-
02
0,25 5,1E-
02
0,23 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04724+115+
81539+3710+59345
24 Malaria 5144 9,1E-
03
1 5,2E-
02
0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05144+6383+
3592+7057
25 GABAergic
synapse
4727 5,4E-
02
0,18 5,4E-
02
0,23 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04727+115+
59345+81539
26 Small cell lung
cancer
5222 1,9E-
02
0,52 5,5E-
02
0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05222+4609+
5295+54205+1021
27 Toll-like receptor
signaling
pathway
4620 1,9E-
02
0,55 5,8E-
02
0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04620+3456+
7096+5295+3592
28 Chronic myeloid
leukemia
5220 1,2E-
02
0,91 5,9E-
02
0,23 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05220+1488+
4609+1021+5295
29 Huntington’s
disease
5016 3,4E-
01
0,04 7,4E-
02
0,28 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05016+627+
54205+9586
30 ECM-receptor
interaction
4512 1,9E-
01
0,11 9,9E-
02
0,36 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04512+7057+
6383
31 Melanoma 5218 4,3E-
02
0,51 1,1E-
01
0,37 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05218+2247+
1021+5295
32 Notch signaling
pathway
4330 9,5E-
02
0,26 1,1E-
01
0,39 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04330+1488+
8650
33 Toxoplasmosis 5145 1,6E-
01
0,17 1,2E-
01
0,39 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05145+3592+
54205+5295
34 Aldosterone-
regulated sodium
reabsorption
4960 7,3E-
02
0,37 1,2E-
01
0,39 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04960+8660+
5295
35 TGF-beta
signaling
pathway
4350 2,2E-
01
0,13 1,3E-
01
0,40 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04350+7057+
4609
36 Chemokine
signaling
pathway
4062 4,7E-
02
0,66 1,4E-
01
0,40 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04062+10344+
5295+59345+115+5590
37 Bacterial
invasion of
epithelial cells
5100 1,9E-
01
0,16 1,4E-
01
0,40 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05100+5295+
7414
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Table B.3.: Signaling Pathway Impact Analysis of MZ1774 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
38 Legionellosis 5134 1,3E-
01
0,27 1,6E-
01
0,41 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05134+54205+
3592
39 Leukocyte
transendothelial
migration
4670 3,5E-
01
0,10 1,6E-
01
0,41 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04670+5295+
7414
40 PPAR signaling
pathway
3320 3,6E-
02
1 1,6E-
01
0,41 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa03320+2182+
51703+51129
41 Gastric acid
secretion
4971 3,6E-
02
1 1,6E-
01
0,41 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04971+115+
3710+3773
42 Viral myocarditis 5416 5,0E-
01
0,08 1,6E-
01
0,41 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05416+54205
43 Herpes simplex
infection
5168 1,2E-
01
0,36 1,8E-
01
0,45 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05168+3592+
5501+3456+54205
44 Dopaminergic
synapse
4728 5,3E-
02
0,86 1,9E-
01
0,45 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04728+3710+
59345+9586+5501
45 Protein
processing in
endoplasmic
reticulum
4141 1,4E-
01
0,35 1,9E-
01
0,45 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04141+1649+
821+6185+55432
46 Focal adhesion 4510 6,8E-
02
0,72 2,0E-
01
0,45 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04510+4659+
5501+7414+5295+7057
47 Hepatitis C 5160 4,3E-
01
0,11 2,0E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05160+3456+
5295
48 Vasopressin-
regulated water
reabsorption
4962 9,1E-
02
0,56 2,0E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04962+115+
9586
49 Oocyte meiosis 4114 1,3E-
01
0,39 2,0E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04114+3710+
115+5501
50 Pathogenic
Escherichia coli
infection
5130 4,8E-
01
0,11 2,1E-
01
0,45 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa05130+113457
51 Taste
transduction
4742 6,2E-
02
0,91 2,2E-
01
0,45 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04742+5136+
3710
52 Lysosome 4142 5,7E-
02
1 2,2E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04142+3423+
427+1497+3482
53 Natural killer cell
mediated
cytotoxicity
4650 1,3E-
01
0,46 2,3E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04650+3456+
8795+5295
54 Jak-STAT
signaling
pathway
4630 6,3E-
02
1 2,4E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04630+4609+
5295+3592+3456
55 Amyotrophic
lateral sclerosis
(ALS)
5014 4,5E-
01
0,14 2,4E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05014+54205
56 Chagas disease
(American
trypanosomiasis)
5142 9,5E-
02
0,69 2,4E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05142+3592+
3456+5295
57 SNARE
interactions in
vesicular
transport
4130 6,9E-
02
1 2,5E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04130+55014+
8676
58 Carbohydrate
digestion and
absorption
4973 6,9E-
02
1 2,5E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04973+280+
5295
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Table B.3.: Signaling Pathway Impact Analysis of MZ1774 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
59 Wnt signaling
pathway
4310 5,0E-
01
0,14 2,6E-
01
0,45 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04310+4609+
1488
60 Gap junction 4540 7,2E-
02
0,98 2,6E-
01
0,45 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04540+115+
113457+3710
61 Pancreatic
secretion
4972 7,2E-
02
1 2,6E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04972+3710+
280+115
62 Tight junction 4530 1,8E-
01
0,40 2,6E-
01
0,45 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04530+2035+
5590+51776
63 Alzheimer’s
disease
5010 5,5E-
01
0,13 2,6E-
01
0,45 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05010+54205+
3710
64 Axon guidance 4360 4,1E-
01
0,19 2,7E-
01
0,46 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04360+285220+
9901
65 Calcium
signaling
pathway
4020 9,0E-
02
0,87 2,8E-
01
0,46 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04020+5136+
3710+115+136
66 Melanogenesis 4916 3,0E-
01
0,27 2,8E-
01
0,46 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04916+115+
1906
67 Bladder cancer 5219 8,4E-
02
1 2,9E-
01
0,47 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05219+7057+
4609
68 Parkinson’s
disease
5012 7,5E-
01
0,11 2,9E-
01
0,47 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05012+54205
69 Fc epsilon RI
signaling
pathway
4664 5,8E-
01
0,16 3,1E-
01
0,49 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04664+5295
70 Osteoclast
differentiation
4380 1,6E-
01
0,61 3,2E-
01
0,49 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04380+3456+
5295+3554
71 VEGF signaling
pathway
4370 2,0E-
01
0,54 3,5E-
01
0,53 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04370+9261+
5295
72 Non-small cell
lung cancer
5223 1,4E-
01
0,79 3,6E-
01
0,54 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05223+5295+
1021
73 Endometrial
cancer
5213 1,3E-
01
1 3,9E-
01
0,57 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05213+4609+
5295
74 Vibrio cholerae
infection
5110 1,3E-
01
1 4,0E-
01
0,58 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05110+523+115
75 Pancreatic cancer 5212 2,0E-
01
0,67 4,1E-
01
0,59 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05212+5295+
1021
76 Acute myeloid
leukemia
5221 1,5E-
01
1 4,4E-
01
0,62 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05221+4609+
5295
77 Fc gamma
R-mediated
phagocytosis
4666 3,0E-
01
0,51 4,4E-
01
0,62 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04666+5295+
85477
78 Bile secretion 4976 1,6E-
01
1 4,5E-
01
0,62 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04976+115+
6513
79 RIG-I-like
receptor signaling
pathway
4622 1,6E-
01
1 4,5E-
01
0,62 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04622+3456+
3592
80 Glioma 5214 1,7E-
01
0,94 4,6E-
01
0,62 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05214+5295+
1021
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Table B.3.: Signaling Pathway Impact Analysis of MZ1774 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
81 Maturity onset
diabetes of the
young
4950 1,7E-
01
1 4,7E-
01
0,63 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04950+6928
82 Salivary secretion 4970 2,2E-
01
1 5,6E-
01
0,73 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04970+115+
3710
83 Progesterone-
mediated oocyte
maturation
4914 2,5E-
01
1 6,0E-
01
0,78 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04914+115+
5295
84 ErbB signaling
pathway
4012 2,7E-
01
0,99 6,2E-
01
0,78 1 Activated http://www.genome.jp/dbget-bin/
show_pathway?hsa04012+5295+
4609
85 Prostate cancer 5215 2,9E-
01
0,93 6,2E-
01
0,78 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05215+9586+
5295
86 Allograft
rejection
5330 2,7E-
01
1 6,2E-
01
0,78 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05330+3592
87 RNA transport 3013 2,7E-
01
1 6,3E-
01
0,78 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa03013+11260+
10605+26999
88 GnRH signaling
pathway
4912 2,9E-
01
1 6,5E-
01
0,79 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04912+115+
3710
89 Thyroid cancer 5216 3,0E-
01
1 6,6E-
01
0,81 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05216+4609
90 Type I diabetes
mellitus
4940 3,2E-
01
1 6,8E-
01
0,81 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04940+3592
91 African
trypanosomiasis
5143 3,2E-
01
1 6,8E-
01
0,81 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05143+3592
92 Neuroactive
ligand-receptor
interaction
4080 3,2E-
01
1 6,9E-
01
0,81 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04080+2743+
1903+136
93 Endocrine and
other
factor-regulated
calcium
reabsorption
4961 4,0E-
01
1 7,7E-
01
0,89 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04961+115
94 Fanconi anemia
pathway
3460 4,4E-
01
1 8,0E-
01
0,91 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa03460+2067
95 Cytosolic
DNA-sensing
pathway
4623 4,4E-
01
1 8,0E-
01
0,91 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04623+3456
96 mTOR signaling
pathway
4150 4,5E-
01
1 8,1E-
01
0,91 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04150+5295
97 Antigen
processing and
presentation
4612 4,9E-
01
1 8,4E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04612+821
98 Long-term
depression
4730 5,0E-
01
1 8,5E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04730+3710
99 Shigellosis 5131 5,2E-
01
1 8,6E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05131+7414
100 Leishmaniasis 5140 5,3E-
01
1 8,6E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05140+3592
101 Epithelial cell
signaling in
Helicobacter
pylori infection
5120 5,5E-
01
1 8,8E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05120+523
102 Pertussis 5133 5,7E-
01
1 8,9E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05133+3592
103 RNA degradation 3018 5,8E-
01
1 8,9E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa03018+167227
104 B cell receptor
signaling
pathway
4662 6,0E-
01
1 9,1E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04662+5295
105 Dilated
cardiomyopathy
5414 6,1E-
01
1 9,1E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05414+115
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Table B.3.: Signaling Pathway Impact Analysis of MZ1774 YAP-knockdown cells (continued)
KEGG
pathway
ID pNDE pPERT pG pGFDR pGFWER Status KEGG-link
106 Rheumatoid
arthritis
5323 6,1E-
01
1 9,1E-
01
0,93 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05323+523
107 Systemic lupus
erythematosus
5322 6,5E-
01
1 9,3E-
01
0,94 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa05322+3014
108 T cell receptor
signaling
pathway
4660 6,7E-
01
1 9,4E-
01
0,94 1 Inhibited http://www.genome.jp/dbget-bin/
show_pathway?hsa04660+5295
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